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SUMMARY
Minor components of the gentamicin series were isolated 
from commercial samples of gentamicin sulphate. Mass spectrometry 
and nuclear magnetic resonance (NMR) were applied to elucidate 
structures. Total identification was not achieved for all compon­
ents though evidence for novel central sub-units was presented.
An unusual site for N-methylation was discovered at the 3-position 
on gentamicin •
Reversed phase high performance chromatography (HPLC) with
pre-column derivatisation was used to quantitate gentamicin
component levels in commercial samples from various sources.
A method for the measurement of gentamicin in blood plasma by
HPLC was developed. Methods for extraction of gentamicin from
plasma constituents were evaluated and a chosen method used to
determine levels in over fifty patient samples. These values
were compared with those found by microbiological assay and a
close relationship was observed. Pharmacokinetic parameters
were estimated for the individual gentamicin components (C^,
C_ and C ). Gentamicin C was found to possess a longer la Z la
plasma half life than the other two components.
The fluorometric reaction of ortho-phthalaldehyde (OPA) 
with the gentamicin components was studied using ^H and 
NMR. The reactive intermediate was shown to be a. i dihydro- 
isobenzofuran and a reaction pathway proposed. The OPA reagent 
was found to react with all the primary amino functions on the
lii.
gentamicin components. Ninhydrin was used to confirm this result.
The retention characteristics of the gentamicin-OPA deriva­
tives in the HPLC system used were investigated and an explanation 
of the factors governing the observed behaviour, proposed. 
Differences in the order of elution of the components, reported 
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The aminoglycoside aminocyclitols are a group of antibiotics
1 2which are still clinically very important ' . The first member.
Streptomycin, was isolated from Streptomyces griseus in 1944^.
Thereafter other structurally related antibiotics such as the
neomycins^, the kanamycins^, paramomycins^ and lividomycins^'^
were isolated from other Streptomyces species after an intensive
search of cultures of organisms similar to fungi. In 1963
gentamicin, a complex of three components, was discovered in
9 10two species of Micromonospora ' ; M. purpurea (N.R.R.L. 2953)
and M, echinospora (N.R.R.L. 2985). It was the first antibiotic
to be found in this genus and subsequent investigation led to
■ ' 11 ■the isolation of the sisomicins from M. inyoensis in 1970 I
Both of these genera, Micromonospora and Streptomyces, belong
12to a group of organisms called the Actinomycetes which are
thought to be related to gram positive bacteria^^. Tobramycin,
one of the most recent natural aminoglycosides in clinical use,
was discovered in 1967^^ as nebramycin factor 6 from S. tenebrarius^^.
Sagamicin, introduced into clinical practice in Japan recently,
has been identified as gentamicin Research has also been
directed towards developing semi-synthetic aminoglycosides.
17 18Amikacin and Butakacin have both been derived from Kanamycin-
19A, whilst Dibekacin is from Kanamycin B. A more recent synthesis 
was Netilmicin from Sisomicin^^.
Chemistry of the Aminoglycosides
The aminoglycoside family of antibiotics is characterised by
an aminocyclitol subunit; either a streptamine (I) or a 2-deoxy-
1 21 22 streptamine(II) ring ' '
u m A — rA^NHz HzN-^ A-NH’ HO2*/  ■■ %
(I)
(II)
23 1 3The streptamine ring was isolated from Streptomycin as a N N -
diamidino derivative. Neomycin was the first antibiotic found
to contain the deoxystreptamine^^'^^ moiety which was isolated by
acid hydrolysis. Since then most aminoglycosides discovered
have had (II) as part of the structure. The configuration of
2-deoxystreptamine was found to be all trans by the size of the
coupling constants measured by Nuclear Magnetic Resonance (N.M.R.)^^,,
The deoxystreptamine molecule is seen to possess two pairs of
enantiotrgpic centres with the numbering starting at the nitrogen
22bearing carbon which has the R-configuration . The aminoglycosides 
can be further subdivided by the position of attachment of the 
two glycosidic bonds to the 2-deoxystreptamine. It is known that 
the neomycins, lividomycins and paramomycins are 4,5 substituted
whilst the kanamycins and gentamicins are 4,6 substituted. The amino- 
sugar attached to the 4-position receives primed numbers whilst 
that attached to the 5 or 6-carbon receives double primed numbers.
Streptomycin has the structure illustrated in FigurellA with 
a streptidine ring linked to L-methylglucosamine by a sugar 
moiety called streptose. Dihydrostreptomycin has the reduced 
streptose ring present as shown in Figure
Neomycin is a complex of three major components as shown in
Figure Neomycin B is the major component and differs
from Neomycin C only in the stereochemistry of the aminomethyl
group attached to C-5'''. Neamine is a degradation product of
25Neomycins B and C as well as a fermentation product . Other
minor components have been found to be co-produced but they
28 29possess little biological activity ' ' . I n  the United Kingdom
a limit of 2% w/v of neamine in neomycin sulphate is set but
there is no limit on the proportion of neomycin C present^^.
However, Framycetin is classified as being ngomycin B and limits
30of 3% w/v neomycin C and 1% w/v neamine are defined 
Neomycin C present is measured by ion-exclusion chromatography 
with ninhydrin monitoring whilst the neamine level is controlled 
ty Thin-Layer Chromatography (TLC) using a reference standard.
The FDA in the United States requires only a potency determination 
and no assessment of component composition^^. This is because 
neomycin is not administered parenterally, and so less strict limits
Figure 1.1. Structure of Streptomycin.
NH
H
(lA) R = CHO Streptomycin
(IB) R = CH^OH Dihydrostreptomycin







Neomycin B OH NH2 H H CH2NH2
Neomycin C OH NH^ H CH2NH2 H
Paromomycin I OH OH H H CH2NH2
Paromomycin II OH OH H CH^NH^ H
Lividomycin A H OH Mannose H
Lividomycin B H OH H H CHNH
6,
are required. Other methods have been devised to separate and
_ . 32-41^assess component composition
The paromomycins and lividomycins are very similar to the 
neomycins with the main difference being the degree of hydroxylation 
in the 'A' ring (Figure12).
Kanamycin also consists of three components (A, B and C)
1 21(Figurel-S) ' , Unlike the neomycins it is a 4,6 substituted
aminoglycoside and only consists of three rings. Kanamycin A
is the major component and is the least toxic^. Kanamycin C
is the least active whilst kanamycin B has twice the activity
as well as twice the toxicity of kanamycin A. In the United
Kingdom the amount of kanamycin B present in kanamycin sulphate
BP is restricted to less than 3% w/v using the same ion-exclusion
method as for framycetin sulphate BP but no limit is set
for kanamycin In the United States there is also no limit
on kanamycin C but a 5% w/v limit set on kanamycin B^^, as
measured by a selective bioassay. Other methods have been reported
42-44for kanamycin ratio determination
Tobramycin (Figurel-3), a member of the nebramycin complex,
is 3'-deoxykanamycin B. Its purity is assessed by TLC and by 
30-1its potency
Amikacin (FigureU) , a commercially available semi-synthetic
Figure 1.3. Structure of the Kanamycins.
RH
R *̂ 2
Kanamycin A H OH OH OH NH2
Kanamycin B H NH2 OH OH NH2
Kanamycin C H NH2 OH OH OH
Tobramycin H NH2 H OH NH2
Dibekacin H NH2 H H NH2
Amikacin HABA OH OH OH NH2
Butakacin HAB OH OH OH NH2
aminoglycoside is based on kanamycin A, having an L (-)-y-amino-a-
hydroxybutyric acid (L-AHBA) side chain attached to the C-1 carbon
atom. This was synthesised because studies showed that the
naturally occurring Butirosins were resistant to many inactivating
enzymes, with the L-AHBA side chain present in that group of
45antibiotics being the probable protecting factor . Butakacin
and Dibekacin (Figurel*3) have also been synthesised to improve
.  ̂  ̂ 1,22,46,47resistance to inactivating enzymes
The sisomicins are a relatively recent family of amino- 
11 21 22glycosides ' ' , with a novel structure (Figurel-4) and show
an antimicrobial spectrum similar to g e n t a m i c i n ^ S i s o m i c i n
49is the 4',5' dehydro derivative of gentamicin and
21verdamicin exhibits a similar relationship to gentamicin
By selective N-ethylation of the C-1 amino group under controlled
20pH conditions netilmicin (Figurel4) was produced . It shows
a similar potency to gentamicin but the N-ethyl group protects
SO-lit against various important inactivating enzymes . Other 
recently discovered aminoglycosides of importance include the 
seldomycins and the mutamicins"^^'^^, both of which show beneficial 
characteristics.
One of the largest families of aminoglycosides are the 
1 9 22 52gentamicins ' ' ' . I n  the culture broth are produced many
antibiotics. The gentamicin C complex is separated from other 
related compounds by use of a cation exchange resin to extract 
the antibiotics, followed by selective precipitation of the c-















21 53complex using dodecyl sulphonate ' . Co-produced antibiotics
1 52related to the c-complex are shown in Figurel5 ' . They tend
to be more polar and have quite extensive alterations in
54-61functional group substitution . Gentamicin A components have
an aminopentose ring instead of the aminohexose (garosamine) sub­
unit present in most other g e n t a m i c i n s ^ ^ T h e  'A'-ring is 
the main site for the variation in structure of these polar 
components in respect to gentamicin C, with hydroxylation 
primarily at the 3' and 4' position increasing the polarity.
Although they show lower toxicity than gentamicin C there is
46also a corresponding, .reduction in activity
The gentamicin C complex is shown in Figure 1-6̂  ̂ . There
are three main components C^, C^^ and C^ 69,70 which two
additional isomers, C^^ and C ĵ̂  also exist^^'^^ . Ring C
which is common for all five components is called the garosamine
ring^^'^^ and ring A,the purpurosamine ring^^. The variations
in the latter arise from the number and position of methyl groups
present. Gentamicin has no methyl groups; and
each have one methyl group and gentamicin'C^ has two methyl groups
in the A-ring^^,65^ This, is readily illustrated by proton NMR
64—68and mass ^ectrometry of these compounds . The isomer
72
gentamicin is thought to be an enanticmer of gentamicin
whilst gentamicin is N-methylated instead of being C-methylated^^,
A further component having the L-manno configuration has also 
.71been reported
Figure 1.5. Structure of Gentamicin Polar Components,
11,
R1 ^2 ^3 "4
Gentamicin A NH2 OH OH H OH H
Gentamicin B OH OH OH H NH2 (==3
Gentamicin OH OH OH CH3 NH2 CH3
Gentamicin X NH2 OH OH H OH “ 3
12







Gentamicin Cla H H H
Gentamicin CH3 H H
Gentamicin H ^=3 H
Gentamicin H H CH3
Gentamicin CH3 H CH3
13.
Numerous minor components of the gentamicin series have been
discovered with the majority belonging to the polar type
compounds. These unfortunately show lower antimicrobial activity
than the gentamicin C components and are susceptible to 3'-
22phosphorylating enzymes . Other components of novel structure
were discovered and interest has arisen as to the antimicrobial
74-77action and possible resistance to bacterial enzymes
The proportion of the gentamicin C components and levels
of minor components is difficult to control in the commercial
material. A wide range of geographical sources of the antibiotic 
has led to marketed samples showing significant compositional 
differences^^ The desirability for a standard of the
47,78-9antibiotic is obvious and would restrict potential inequivalences
In the United States, limits are set on all three of the major
^ 31 components :-
25 < gentamicin C]_ < 50%
15 < gentamicin 40%
20 < gentamicin < 50%
The analysis of component ratio is achieved by paper chromatography 
to separate the components followed by a microbiological assay 
to quantitate levels. Thus the component composition is 
determined by potency estimation and has been criticised as 
being prone to inter-laboratory variation^^'^^. The sample is 
also required to pass a potency and specific rotation test but 
it is apparent that mixtures with widely differing clinical
14,
properties can be deemed suitable.
In the United Kingdom the component composition is not set 
as precisely as in the USA but is controlled within broad limits 
by a nuclear magnetic resonance (NMR) measurement of the sulphate 
salt in deuterium oxide^^'^^. Quantification is by peak height 
measurement of the signals for methyl protons at different 
resonances. The mixture exhibits resonances due to two N-methyl 
groups, and two C-methyl groups and it is two ratios of these 
signals which define the limits. Only gentamicin concentration 
can be measured directly by this technique with the other two 
components expressed as ratios. This has been used successfully 
with commercial samples^^'^^'^^ but is fraught with potential 
errors. Gentamicin is not measured directly and the presence
of a component like gentamicin could lead to errors in 
gentamicin estimation. Minor components can interfere in the 
assay, and the total gentamicin C content is not measured.
A more specific and accurate analysis method for gentamicin
is required especially to cope with the gentamicin isomers
which have been reported in significant concentrations in gentamicin
s a m p l e C o n v e n t i o n a l  thin-layer chromatography has
84-88been unable to identify these components . High-performance
liquid chromatography (HPLC) has been used in various studies
in determinations of composition of material of varying geographical 
78 79 82 89source ' ' ' . It has the advantages of speed, accuracy and
15
79 82the ability to quantitate the gentamicin levels ' . Another
useful method of component determination is field desorption 
90mass spectrometry , but this requires specialised instrumentation 
which is not generally available.





(III) Requirements for activity in 4,6 substituted glycosides
Due to the large number of aminoglycoside compounds discovered
an extensive investigation into the influence of the structure of
46the antibiotic on its activity is possible (III) . It is known 
that the basic 2-deoxystreptamine subunit is inactive.
Substitutions at the 5 and 6 position produces compounds with 
only weak activity whilst substitution at the 4 position also
16,







Thus highly active antibiotics in the main can only be obtained
when 2-deoxystreptamine is disubstituted at the 4,5 or the 4,6 
46positions. Price has discussed the requirements for activity 
in each of the subunits. The presence of amino functions has been 
found to be essential and for 4,5 substituted aminoglycosides 
the activity is increased by increasing the numbers of amino 
groups,in the molecule. For 4,6 glycosides,at least in respect 
to the C-4 substituent,the activity is increased by an increase 
in amino groups present. Mono-N-alkylation with a small alkyl 
group like methyl has minimal effect on activity whilst N-acylation 
at any position except the amine at C-1 will reduce the activity.
An amino group is required in the C-4 substituent but not in 
the C-5 substituent of deoxystreptamine. A primary or secondary 
amine is needed at C-3 and a basic function is required at C-1 
in deoxystreptamine (III) . In the C-6 substituent the location
17
of the amino group is essential in determining effectiveness in 
antimicrobial action. Information on hydroxyl contribution is 
less dependable and varies for different compounds. All 
hydroxyls can be modified in some manner yet retain activity,but 
various structural changes seen especially in the kanamycins can 
have a large influence on potency.
Therapeutic Aspects of Aminoglycosides
The aminoglycosides are active against gram positive and gram
negative organisms as well as Mycobacteria^'^'^^'^^'^^. They are
not against anaerobic bacteria or fungi. Some compounds (paramomycin
46and hygromycin B) possess antiprotozoal and anthelmintic activity
but these properties are not common to other aminoglycosides.
Bacteria susceptible to aminoglycosides include Escherichia coli.
Pseudomonas aeruginosa, Proteus sp.,Serrâtia sp., Klebsiella sp.,
2and Staphylococcus aureus . They do not possess significant
activity against streptococci or meningococci. Gentamicin is
the principal antibiotic for the treatment of many life-
threatening infections such as septicaemia, neonatal infections,
91 93-95endocarditis, infected burns and peritonitis . Tobramycin
is also used in a similar manner to gentamicin but amikacin is 
withheld for use against resistant organisms.
18
Mechanism of Action
The aminoglycosides.are bactericidal but cell death is
96-98preceded by a marked inhibition of protein biosynthesis
This activity is seen to occur at the 70s ribosomes but is
incompletely understood. Streptomycin is known to bind to
protein S12 of the 30s subunit involving at least four other
96ribosomal proteins and possibly 16s RNA . This binding is
thought to induce conformational changes which disturb the
97normal functions of the acceptor and donor site . This is
observed as misreading of the genetic code at the ribosome,
inhibition of initiation of peptide chains on the complex,
slowing of elongation of partly completed chains and increased
96unusual messenger activity . Gentamicin, neomycin and kanamycin
show three separate concentration dependent effects on isolated
96 97ribosomes which suggest multiple binding sites for these drugs '
These observations do not satisfactorily explain the lethal effect
96which may also involve damage to the cytoplasmic membrane . It
is known that aminoglycoside uptake into bacterial cells occurs 
99,100in three phases . There is an initial energy independent
binding of the compounds to the exterior of the cell. Thisiis 
followed by energy-dependent phase 1 in which aminoglycosides 
associate with membrane transporters by virtue of their positive 
charge and are driven across the membrane by the existing 
potential gradient. A faster rate of aminoglycoside uptake 
occurs after ribosomal binding. This is called energy dependent
19.
phase II and the rationale behind it is not certain. It could
96
either be due to synthesis of a polyamine permease induced
by the aminoglycoside itself or it could be due to an increased
membrane potential associated with loss of potassium ions^^^.
Phase II is essential for the lethal action of the aminoglycosides 
100
to be realised , as is the ribosomal binding.
Resistance to Aminoglycosides
The build-up of resistance to the aminoglycosides is a
problem especially associated with inappropriate drug use. It
increased dramatically against streptomycin and kanamycin and
was forseen when gentamicin was introduced^^^. The frequency
of resistant organisms to gentamicin in the United Kingdom has
been comparatively low^'^^^ and careful antibiotic policy in
hospitals has controlled outbreaks^^^, There have been three
possible mechanisms of resistance to aminoglycosides discovered^^
mutational change in ribosomal protein, reduced cell permeability
and inactivating enzymes. The mutational change in the genes
coding for ribosomal protein leads to the drug being unable to
attach to ribosomes^^. This has arisen for streptomycin where
replacement of a single amino acid in the S12 protein of the 30s
99ribosomal subunit can cause resistance . This type of resistance 
has not been shown to be clinically i m p o r t a n t . A second 
resistance mechanism, of gram negative bacteria, is a reduced
20.
uptake of the aminoglycoside^^^. Opinion has differed as to
whether this is due to a change in the cytoplasmic membrane or
due to enzyme production, as inactivated aminoglycosides do not
96accumulate in bacterial cells . A compositional change could
involve replacement of magnesium ions by a protein H, preventing
99penetration of the membrane by aminoglycosides . This has
been shown to be a clinically important type of resistance
especially for Pseudomonas species and a major type of resistance 
50
to amikacin . The third and most important form of resistance
is due to aminoglycoside inactivating enzymes. The enzymes are
classified by type of reaction they catalyze into aminoglycoside
0-phosphotransferases (APH), 0-nucleotidyltransferases, (ANT),
100and N-acetyltransferases (AAC) . Enzymes show specific action
at defined sites and can be further classified for affinity for
different substrates. Thus, AAC (3) I acetylates gentamicin readily
at the C-3 amino group, but tobramycin only slightly, whilst
AAC (3) II acetylates both gentamicin and tobramycin easily at 
47the same site . Up to twenty one enzymes which modify amino-
47glycosides have been reported . Of these,about half act on 
gentamicin with different outcomes. The group of enzymes which 
act on gentamicin include AAC(3), AAC(2'), AAC(6'), APH(2") 
and ANT(2") . Acétylation is a major route to inactivation due 
mainly to the deoxygenated nature of the gentamicin C complex.
A similar number of enzymes inactivate tobramycin but act at 
different sites^^^. The N-ethyl side chain of netilmicin is 
thought to offer protection against ANT(2"), APH (2") and AAC(3)
21
22 51enzymes ' . Similarly for amikacin the aminobutyric acid
side chain protects the molecule from all enzymes except AAC(6 ')^^,
47in contrast to kanamycin A from which it is derived . Bacteria 
show variation in the type and number of inactivating enzymes 
they possess and this is reflected in the relative susceptibilities 
of these bacteria to the different aminoglycosides^^
In gram positive and gram negative bacteria genes coding
95for these enzymes are carried on R-plasmids . It is these plasmids
which have been responsible for the rapid growth in resistant
bacteria, due to the ease of gene transfer by transduction 
97and conjugation . The origin of R-factor resistant genes
may have been in antibiotic producing organisms and even more
information for aminoglycoside resistance could arise from that 
106source
Pharmacokinetics
The aminoglycosides are poorly absorbed by the gastro­
intestinal tract and thus are administered parenterally for
1 2 92 107systemic infections • • • . Following intra-muscular injection
of an aminoglycoside, peak serum levels are reached in thirty 
to ninety minutes depending on circulation and muscle mass^^^ 
Administration by intravenous injection as a bolus produces 
immediate high peak plasma levels which soon r e c e d e ^ B y
22
administering by iv. infusion over twenty to thirty minutes serum
levels comparable to those obtained by intra-muscular injection 
2are achieved . The half life of the aminoglycosides shows wide 
interpatient response but is about two
A secondary half life has been calculated since it was observed
that after treatment has finished, gentamicin continues to be
excreted in the urine^^^. The existence of a slower elimination
pathway is supported by the lack of complete recovery of the 
118dose in urine , which should be possible since the aminoglycosides
are uhmetabolised. This secondary half life has been calculated
to be about one hundred hours and may be due to release of drug
118from the renal cortex . in renal failure the primary half life
109of two hours can extend to up to forty hours , since glomerular
118filtration is the major elimination mechanism
119Haemodialysis removes the aminoglycoside and shortens 
the extended half-life considerably, in such compromised patients, 
and thus, care has to be taken to ensure adequate drug levels^^^'^^^.
Protein binding of aminoglycosides is not appreciable with 
values of O - 25% reported^^^'^^^'^^^. The volume of distribution 




The dosage interval of aminoglycosides is eight hours due 
principally to the two hour half life. The dosages for gentamicin, 
tobramycin and netilmicin are similar but amikacin requires much 
higher doses because of its lower potency^. In children and 
infants a proportionally higher dose is required since amino­
glycosides are well tolerated^^^. This may be due to the higher
percentage extracellular fluid volume which occurs in the very 
121 122young ' . For gentamicin a dose of 2 - 5 mg/kg daily in
three doses is recommended for an adult with normal kidney 
123function . For children aged two weeks to twelve years a
dose of 2 mg/kg is given every eight hours, whilst for infants
less than two weeks old a dose of 3 mg/kg every twelve hours
is recommended. In neonates the half life tends to be longer due
to the lower glomerular filtration rate. In the presence of
renal failure the dosage interval is usually lengthened in
relation to the creatinine clearance^^'^^^'^^^'^^^. Various
nomograms, relating body weight and creatinine clearance to an
appropriate dose, have been proposed and used in clinical
practice^^^'^^^'^^^ They are useful for estimating a dose
bat plasma monitoring should be undertaken to ascertain the 
119.attained levels
For gentamicin and tobramycin a peak of 5 - 12 yg/ml and a 
trough of 1 - 2  yg/ml is desired for efficient treatment. For
24
amikacin the target peak concentration is 20 - 30 yg/ml and
92trough of 5 - 10 yg/ml . Peak serum levels of less than 4 yg/ml 
of gentamicin or tobramycin and less than 14 yg/ml for amikacin
92 94are unlikely to be effective and could create resistant bacteria '
Therapy with other antibiotics can increase the effectiveness
of the aminoglycosides. Indeed synergy with penicillins is well 
127 128reported ' ,such as the combination of gentamicin with
129carbenicillin in Pseudomonas infections . It is thought to
arise from penicillin attack on the cell wall,increasing the
penetration of the aminoglycoside. A secondary effect of the
combined use of these antibiotics is that chemical inactivation
can occur in vivo and in vitro^^^ ^ . This is especially
135prevalent in intravenous infusion bottles , and when a high
131concentration of penicillin is present . The reaction is
thought to involve opening of the beta-lactam ring and
132 135subsequent reaction with the aminoglycoside '
Toxicity
The major disadvantage of the aminoglycosides is the low
therapeutic index, with overdosage leading to severe side
effects^^^. It is known that the amino groups contribute
46significantly to the toxicity of aminoglycosides . Examples 
of this are found in the kanamycins. Kanamycin B has one more amino
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group than kanamycin A and is twice as toxic. N-acetylation of
any of the amino groups decreases the toxicity of the compound.
The gentamicins A, X and B are thought to be less toxic than the
gentamicin C components because they are hydroxylated at the 3'
46position. Price related toxicity to antimicrobial activity and 
concluded that toxicity to,micro-organisms could not be fully 
separated from the toxicity to mammals.
Toxicity is thought to be related to plasma levels although
disagreement exists as to ascribing it to peak or trough levels,
137or frequency of dosing . Some studies have shown a significant 
correlation of trough levels greater than 4 yg/ml with a rising 
creatinine level^^^'^^^. Another proposal is that susceptible
people retain the drug in a three times higher concentration in
  . - - - 118the tissues than average . For gentamicin it has been 
recommended for peak levels to be below 10 - 12 yg/ml and trough 
levels below 2 yg/ml.
The main adverse effects of aminoglycosides are nephro-
1 2 92toxicity, ototoxicity and neuromuscular blockade ' ' . The
nephrotoxic and neuromuscular effects are usually reversible 
but the ototoxic effects are frequently irreversible^^^'^^^.
Aminoglycosides are concentrated in the renal cortex with 
accumulation by reabsorption from the proximal tubule^^^'^^^'^^^. 
This may arise by pinocytosis as this method is used by the brush
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142border cells for other compounds . Alternatively they might
be transported across the membrane by an active transport 
118system or by binding to the charged anionic polyphospho- 
143inositidies . These phospholipids are present in a relatively
high concentration in the plasma membrane of renal cells and
143-4are believed to be involved in calcium transport
Complexation with these molecules could disrupt the membrane and
increase the permeation of the gentamicin into the cell. It is
suggested that 5 - 10% of the population show early and rapid
tissue accumulation of the aminoglycosides, although the mechanism
118of this more rapid uptake has not been defined
Nephrotoxicity is gauged by a necrosis of proximal tubular
cells associated with leakage of enzymes and proteins prior to
an increase in serum creatinine^^^ The onset of renal damage
reduces the glomerular filtration rate^^^ and thus leads to an
accumulation of the aminoglycoside. The various aminoglycosides
show differing toxic potentials with neomycin the most nephro- 
46toxic . This may arise from the particular cellular toxicity
146of the drug rather than the extent of uptake . It may explain
why netilmicin is considered to be less nephrotoxic than gentamicin
146even though rates of uptake are similar . The gentamicin C 
components are believed to have different toxicities although 
opinion.is not agreed on which is the most n e p h r o t o x i c ^ .
Other factors which can precipitate acute renal failure are
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dose and duration of therapy, state of hydration and underlying 
153-4renal failure . Lack of standards of definition of nephro-
51,118toxicity restricts accurate estimation of occurrence. . It
148is believed to occur in 2 - 10% of patients
Ototoxicity, the other serious side effect of aminoglycoside
treatment again is dependent on the particular drug but usually
results in loss of inner ear function^^^ ^ The accumulation
of aminoglycosides in the inner ear with slow elimination precipi-
92tates the toxicity . Netilmicin is thought to be virtually 
non-ototoxic^^ whereas gentamicin is significantly toxic^^. 
Gentamicin has been reported to be less ototoxic than the 
gentamicin C complex used as a whole^^^. A theory of interaction
with the phospholipids of the cellular membrane has been proposed
]_41 157 —for the toxic effect ' . Vestibular function can also
92become disturbed and is associated with ototoxicity
Neuromuscular blockade has been shown to be reversible with
calcium ions and to be similar to that produced by conventional 
98blocking agents . This can induce weakness of skeletal muscle 
and respiratory depression.
To minimise toxic effects, careful use in clinical practice, 
especially in susceptible patients, is required. Monitoring of
plasma levels is required in these patients to prevent onset
 ̂  ̂ 119,137of toxicity
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Plasma Analysis of Gentamicin
The assessment of plasma levels of gentamicin to optimise 
treatment^^^ has traditionally fallen to the microbiological 
assay; either by diffusion or by dilution^^^'^^^ 164^ The dilution 
method was shown to be highly inaccurate in a quality control 
survey and is little used now^^^'^^^. The plate diffusion method 
can use either well or disc for distribution of antibiotic to 
the medium
The procedure is subject to large variation due to type of 
166-8medium used , concentration of cations, species of organism
tested against, pH^^^ and composition of sample^^^ ^ and
137standard solutions and the length of time of incubation . The
time required for an assay is a major disadvantage with twelve
to eighteen hours required for zone diameters of inhibition to 
137be measured . Clinical signs of inappropriate treatment
may therefore be available before the plasma concentration is
known^^^'^^^. Faster bioassays were developed to achieve a
measurable zone in three to four hours using a heavy inoculum
of a fast growing species of bacterium^^^' Principal
advantages of the bioassay are that it is a cheap and easy
173technique requiring skills readily available in hospitals 
It is also very flexible in adaption to size of workload.
A disadvantage is the poor accuracy which was highlighted 
in quality control surveys carried out in 1973 and 1974.
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Only 21% of those tested achieved a ± 25% accuracy^^^. The
presence of other antibiotics in the sample can interfere^with
results especially when the laboratory is not informed of
them^^^'^^^. Some assay media have also shown a tendency to
169underestimate gentamicin levels in uraemic sera . in
comparison to other assay methods the bioassay was held to be
> 1 7 3 , 1 7 5 - 8 0  ^ . 181clinically acceptable except in one case . They
generally exhibited poorer precision and correlation with other
 ̂ 177,180,182methods was variable
A quick and simple technique utilises gentamicin-sensitised
latex particles which react with anti-gentamicin antiserum to
give an agglutination reaction^^^ It is ideal for low
workloads although performance at plasma concentrations of less
184—5than 2 yg/ml is poor
The radioenzymatic method, a much used technique, involves
the acétylation or adénylation of gentamicin by bacterial
enzymes^^^ 190^ coenzyme in either case (ATP or acetyl CoA)
159is tagged with a radioactive label , which after reaction
produces a labelled gentamicin derivative. This is adsorbed
onto phosphocellulose discs and counted on a liquid scintillation 
137counter . The assay method is quick, requiring two hours 
to perform and is relatively easy to use. However stability 
problems of enzyme, breakdown of ATP by inherent ATPase in serum 
and variations in binding capacity of the phosphocellulose paper
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137have been noted . There were reports that plasma constituents 
191and tetracyclines have decreased gentamicin readings.
Availability of a scintillation counter is essential and expertise
137in the handling of radioactive isotopes is a requisite . In 
clinical studies^^^'^^^'^^^'^^^ the radioenzymatic method was 
satisfactory except on one occasion where the kit was judged to 
be unacceptable
Immunoassays developed for the aminoglycosides use radio­
activity, absorbance and fluorescence as an indicator of extent 
of binding.
193-4In radioimmunoassays gentamicin frcm the sample competes
with standard labelled gentamicin for antibody binding sites
decreasing thé measured bound activity^^^ ^ . The assay is
specific, sensitive and precise and results are obtained in
two hours^^^. The cost of reagents is high^^^ and is comparable
to those used for fluoroimmunoassays^^^'^^^. In three clinical
studies^^^'^^^'^^^ the readings were found to be consistently
high which has been ascribed to significantly inaccurate 
192,198standards . The precision of the assay is, like other
^ ^ I . . .3 176-8,180-2,193,199immunoassays, more than adequate for clinical needs
Similar equipment to that used in the radioenzymatic method is
required.
Enzyme immunoassays^^ ^ generally involve competitive 
binding to antibody, of gentamicin in the sample, with
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gehtamicin-linked enzyme in the standard. The extent of binding 
is revealed as a change in the activity of the enzyme. One of 
these kits, EMIT (Syva Corporation)utilises a gentamicin- 
glucose-6-phosphate-dehydrogenase conjugate (G5PDH) which can 
convert nicotinamide adenine dinucleotide (NAD) to NADH, a change 
which can be monitored by UV spectrophotometry.. The assay 
requires a spectrophotometer with a thermostatted flow cell and 
a timer-printer, as readingsare made after 15 and 45 seconds^^^. 
Cross reactivity is only a problem with other aminoglycosides 
and therefore unlikely to be significant in clinical practice^^^. 
The assay is easy and very fast with only thirty minutes required 
for a calibration^^^. A loss of precision has been noticed at 
the higher end of the concentration range but can be overcome
by diluting the plasma^^^. The EMIT method has been assessed
176-9, 181-2, 192, 199  ̂ ^ ^ .in various papers .and no detrimental
properties were reported. Precision and specificity were high
179although in one paper, recovery was low . The cost of reagents
and equipment was considered to limit the technique to large
, 176,182numbers of samples
Fluoroimmunoassays for aminoglycQsides^^^ mainly depend
209,213 , . 208,212on quenching or polarisation of fluorescence when
gentamicin labelled with fluoroscein is bound by antibody. The
two methods, as well as EMIT, are termed homogenous because no
separation step is required. An increase in polarisation of
fluorescence results when fluorescent ligand binds to the antibody
32.
2o8 212because of an increase in rotational relaxation time '
Thus gentamicin in the sample will cause an increase in fluorescence 
in one assay and a decrease in polarisation in the other.
Standard curves used in these assays were not straight lines 
raising the question of accuracy^^^'^^^. Another fluoroimmunoassay 
uses an enzyme which reacts with a gentamicin-conjugate to
produce a fluorescent species, which is quenched by binding to
... 210-11 antibody
The fluoroimmunoassays, similar in cost to the other immunoe 
asays, were generally less precise than EMIT in most studies^^^ 78,180.2
One paper found apparent gentamicin readings due to penicillin in 
182one kit . Direct correlation of the results with those obtained
by enzyme immunoassay was good but it was not as fast or as easy 
182to use . For both fluorescence and enzyme immunoassays it 
is recommended that calibrations be made each day thus adding to 
the overall cost^^^.
A potential disadvantage of the immunoassays is the possibility
of non-specific binding of substrate labelled drug to plasma
constituents, such as protein^^^. Experience of the clincal use
212of these assays suggests this is of little significance 
Background fluorescence of plasma could interfere with fluorescence 
measurements but again has not been shown to be important^^^ 180
Another method used for aminoglycoside analysis in plasma
X62 215”8is chromatography ' . Gas-liquid chromatography (GLC)
was used, after derivatisation of gentamicin, but the
219components were not separated
High-performance liquid chromatography (HPLC) has been used 
experimentally many times for this analysis with many methods 
d e v e l o p e d ^ T h e  popularity of the technique in relation 
to GLC originates from the different conditions used to effect 
separation. For HPLC, chromatography of non-volatile compounds 
is possible, separations can be varied enormously, sample prep­
aration can be easy and specificity of detectors can isolate
215drugs from the background matrix . The HPLC technique was
178-80compared in three studies with various other assays . In
one study HPLC was found to have the worst precision when copipared
with the three immunoassays but was still thought to be satis-
178 179factory . In another study HPLC showed the best precision
Both these papers noted that the labour intensive nature of
HPLC was a major drawback. The final paper found no specific
advantage for HPLC and indeed precision was poor although the
f luoro immunoassay was equally imprecise^^^. Thus in these
general studies the HPLC method was not found to possess, any
substantial advantages. However they ignore the unique ability
of HPLC to quantitate individual component levels for gentamicin.
This is of potential use if the components are discovered to
differ in pharmacokinetic or toxic properties. The low
comparative cost of the HPLC reagents is counteracted by increased
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staff cost. The latter could be reduced if automation could be 
introduced to the technique.
Thus, there have been many methods developed for the analysis 
of aminoglycosides in plasma reflecting the requirement for fast 
and accurate measurements. None of these techniques shows over­
whelming success and each is satisfactory in some respects.
In the present study it was intended to develop a method 
for the accurate analysis of gentamicin levels in plasma using 
HPLC. It was proposed to adapt the method for the assay of 
gentamicin components in commercial gentamicin sulphate samples 
and pharmaceutical preparations. In pursuing this it was found 
necessary to investigate an existing inconsistency in the current 
literature concerning the HPLC behaviour of gentamicin components.
In addition it was proposed to isolate minor components of 
the gentamicin complex frcm commercial gentamicin samples, to 
characterise these using spectroscopic and chemical techniques 
and to investigate possible antimicrobial activity.
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CHAPTER 2
ISOLATION AND IDENTIFICATION OF MINOR COMPONENTS OF THE 
GENTAMICIN SERIES
2.1 Introduction
The determination of aminoglycoside structure was, in the past,
accomplished by classical chemical techniques of oligosaccharide
analysis^^' * 244^ Recent improvements in instrumental analysis
have enhanced the structural resolution of mixtures of amino- 
49, 62-66, 245glycosides
Carbon-13 nuclear magnetic resonance spectroscopy has proved 
to be particularly useful in this respect^^^ ^. The wide range 
of chemical shifts and use of off-resonance decoupling enable 
individual carbon atoms to be identified. The similarity of the 
chemical shifts of the equivalent rings in different amino­
glycosides has been considered advantageous, and the use of 
protonation shifts for the determination of the stereochemistry
of the sugar groups in relation to the deoxystreptamine ring has
247also proved to be useful . However, the ability of aminoglycosides
to absorb carbon dioxide from the atmosphere can produce erroneous
14. 246 results
Proton nuclear magnetic resonance spectroscopy (NMR) is less 
applicable to the aminoglycosides than carbon-13 NMR because of 
the large number of protons resonating in a smaller shift range. 
Extensive overlap of proton resonance peaks occurs, masking useful 
structural information. Degradation to the single ring moieties
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followed by proton NMR has proved very useful in providing 
conformational information
Mass spectrometry is an ideal method for size and structure
248analysis especially with small amounts of sample . Electron
249impact (E.I.) mass spectrometry has been widely used for the 
aminoglycosides. The various fragmentation pathways of the 
gentamicins were characterised and these have also been applied 
to other aminoglycosides^^' Electron-impact relies on
sample volatisation before ionization by a beam of electrons.
This mechanism produces low ion yields for polar and nonvolatile 
compounds such as the aminoglycosides. Adaptations of the basic 
technique have been attempted to increase ion yield^^^. Apart 
from these methods excessive heating is normally required for 
the aminoglycosides and although stru cturally useful fragments 
are produced the molecular ion yield is very low^^.
249Chemical Ionization (C.I.) is:a "softer" method of 
ionization than E.I., relying on ion-molecule reactions, with 
the ions generated from a reactant gas. The particular gas used 
can produce an individual fragmentation pattern. The initial energy 
content of molecular ions formed by Cl is generally much less 
than for El and this results in less fragmentation and a higher 
yield of molecular ion. For the aminoglycosides fragmentation 
is usually only into the major subunits and a clear indication 
of structure is achieved^^'^^.
37
251Field desorption (F.D.) mass spectrometry also uses a
"soft" ionization, where volatilisation of the sample occurs
after ionization and depends on the electrical field strength and
249 252 253the emitter anode temperature ' ' . Protonated and
cationized pseudo-molecular ions can form and are.msually more
stable than the molecular ion^^^' 254^ Spectra produced by
F.D. show predominantly such pseudo-molecular ions with very
little fragmentation, and the method is thus suitable for
77molecular weight determinations of unknown components . Polarity 
and volatility of the sample, is not as critical as E.I. but 
molecular ion yield is low and transiently produced
More recently other "soft" ionization methods have been
developed. These include plasma desorption^^^' electro-
, _ ; 260-2 - —  ---  7 263 . 264-6hydamic ionization , laser desorption , secondary ion
255"8 287“V2and fast atom bombardment mass spectrometry '  ̂ A
localised hot spot which enhances desorption of ions has been
proposed to occur with these methods and similar spectra can
be observed between them even though particles of vastly differing energies
are used to achieve ionization^^^'^^^.Both positive and negative ion spectra
can be recorded by these methods which can extend their utility.
Fast atom bombardment (FAB) is a development of secondary 
ion mass spectrometry and indeed some suggest there is little 
difference between them^^^ Instead of a beam of ions, a beam
of atoms, of usually xenon or argon, is used to produce secondary 
ions from the sample. The sample is suspended in a liquid, usually
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glycerol, and is bombarded by atoms at about 20° to the horizontal
to give maximal ion yield ' The glycerol phase probably
presents a constantly new surface for bombardment, by diffusion
and thermal currents enabling stable ion production over a
270relatively long period of time . Some compounds are enriched
at the surface, whilst others can be completely masked by the
glycerol^^^. Xenon used as a source gas can increase ion yield
271probably by virtue of its larger molecular size . FAB has
255“6 272been used for numerous non-volatile compounds ' such
as peptides, and even gentamicin sulphate was measured by this 
269method . The combination of high molecular ion yield with 
some fragmentation promises the versatility required for 
analysing minor components of the gentamicin series.
The minor components were isolated from commercial gentamicin 
sulphate of various origins by column chromatography. Characterisation 
of these components was primarily achieved by mass spectrometry 
with NMR used for larger sample sizes.
2.2 Materials and Methods
2.2.1 Materials
Gentamicin sulphate samples from a variety of geo­
graphical sources were donated by Nicholas Laboratories Ltd. 
Netilmicin sulphate was supplied by Kirby-Warrick Pharmaceuticals 
Ltd. Silica gels for column chromatography of different particle 
size were used. Woelm silica gel, less than 63 ym and 100 - 200 ym
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particle size were obtained from Koch Light Laboratories Ltd. 
Silica gel, 15 - 40 ym and silica gel H for thin-layer cliromato- 
graphy were from Merck, supplied by BDH Chemicals Ltd. Glass 
columns with fixed internal glass sinters and dimensions of 
45 X 5^, 40 X 2, 30 X 1*2 and 30 x 1 cm were used. Ninhydrin 
and dimethylamine borane were obtained from Aldrich Chemical 
Company Ltd. Amberlite IRA 400 (Cl) resin was from BDH Chemicals 
Ltd. General purpose grade solvents were redistilled before use.
2.2.2 Methods
Thin-Layer Chromatography (T.L.C.)
Silica gel 60 plates were made as required. They were 
spread on 10 x 20 degreased, glass plates with a layer thickness 
of 0.25 mm. The developing solvent was the lower layer of a 
chloroform/methano1/ammonia (2:1:1 (18 M)) mixture. The tank 
was allowed to equilibrate for at least three hours before use. 
New mobile phase had to be prepared every four days due to 
evaporation of ammonia causing decreased solvent strength.
A sample volume of 5 - 10 y1 was applied for each spot using a 
micro syringe. Development of the plates was continued until 
the solvent had travelled at least 10 cm. Plates were dried 
at 110°c for twenty minutes to remove ammonia. Detection was by 
use of ninhydrin spray, consisting of ninhydrin (1.2 g) dissolved 
in pyridine (50 ml) and acetone (50 ml). After spraying the 
plates were heated at 110°C for five minutes to produce purple- 
red spots on a white background.
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Paper Chromatography
A descending technique using Whatman No. 1 paper and a 
solvent system of the lower phase of a mixture of chloroform/ 
methanol/ammonia (2:1*1 (9M)) was used. Both upper and lower 
phases were allowed to saturate the tank for twelve hours before 
development. The solvent took five hours to reach the end of 
Üie paper during development, after which, the paper was dried 
for twenty minutes at 110°C. Spots were detected with the same 
ninhydrin spray used for TLC.
Preparation of Gentamicin Base
Gentamicin base was generated from the sulphate salt 
by use of an anion exchange resin. Amberlite IRA 400. Resin 
(Cl) (50 g) was converted first to the OH form by passing IM 
sodium hydroxide through the resin. Distilled water was used 
to wash column free of alkali. Gentamicin sulphate (4 g) was 
dissolved in a minimum amount of water, passed ontouthe column 
and eluted with water. Alkaline fractions were collected and 
lyophilised to yield gentamicin free base. This was stored 
(over phosphorous pentoxide) in a desiccator together with 
potassium hydroxide pellets to absorb carbon dioxide.
Column Chromatography of Minor Components 
Various columns, types and weights of silica gel were 
used. In general, silica gel (40 g) was slurried in the mobile
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phase and packed into a column of 40 x 2 cm dimensions, with internal 
volume of 125 ml.. The column was allowed to stand for twenty four 
hours before use to allow trapped air to escape. The initial 
eluent was the lower phase of a chloroform/propan-2-ol/2.25 M 
ammonia (2:1:1) mixture. Gentamicin base (6 g) was dissolved in 
about 10 ml of the eluent and applied directly to the top of the 
column. Elution proceeded at about 0.3 ml min for about three 
colunn volumes when the eluent was changed to the lower phase of 
a (2: 1:1(4.5 M)) mixture of the same solvents. This was continued 
until gentamicin was initially detected (by TLC monitoring of 
fractions). The solvent polarity was then increased to (2:1:1 
(9M)) and continued until gentamicin C^ began to elute. Methanol 
was then used to elute the remaining components.
When the major components were to be collected separately, 
methanol was not used. Instead, the elution was continued with 
a (2:1:1 (18M)) mixture followed by a (1:1:1 (18M)) mixture
after gentamicin C had eluted.
2
Fractions were collected in 5 ml aliquots on a LKB 7000 
fraction collector, which could be adjusted to step at specific 
time intervals as required. Fractions were monitored by 
Thin-Layer Chromatography, comparing with a standard 1% w/v 
gentamicin sulphate solution, and those of similar composition 
were combined and the solvent removed under reduced pressure. 
Residues were redissolved in a small amount of distilled water 
and then lyophilised. Components collected were stored in
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desiccators over silica gel or phosphorus pentoxide and potassium 
hydroxide.
Semi-Preparative High Performance Liquid Chromatography (H.P.L.C.)
A single run on a Jobin Yvon Mini-Prep system was completed.
The mobile phase used was the same as for column chromatography
except that elution was started with the lower phase of a
(2:1:1 (9M)) mixture. Silica gel used for the stationary phase
was Lichroprep Si 60, 15 - 25 ym. To construct a column of
size 37 X 2 cm, required 50 g of silica. Flow rate was 1.8 ml 
-1min at a solvent pressure of 8 bar. Fractions of 3 ml were 
collected on a fraction collector. Monitoring of the eluate 
was performed by TLC.
Hydrolysis:
Hydrolysis^^f major components was accomplished by dissolving 
the sample (100 mg) in 6 N hydrochloric acid (20 ml) and refluxing 
for six hours. The product, 2-deoxystreptamine dihydrochloride 
was isolated by precipitation when the hydrolysate was added, 
dropwise, to dry ether (250 ml). The precipitate, isolated by 
filtration, was purified and converted to its base form by 
passing through an anion exchange column.
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N-Acetylation : Micro-scale N-acetylation was carried out as
follows. Sample (0.5 - 5 mg) was dissolved in methanol (100 yl) 
in a reaction vial. This was placed in ice and acetic anhydride 
(50 yl) was added dropwise to the cooled methanolic solution. 
After stirring with the needle of the syringe the reaction 
was left for three hours at room temperature, Progress of 
reaction was followed by the TLC system. On disappearance of 
ninhydrin positive spots the reaction was judged to be complete. 
The reaction was terminated by adding 18 M ammonia (60 yl).
This solution was passed through a small column (5 g) of 
Amberlite IRA (OH) 400 resin, and the eluate lyophilised.
Mercaptolysis;
65 . - -The procedure of Cooper et ai. of mercaptolysis of
the N-acetylated components was adopted. In this the compound
(10 mg) was dissolved in ethanethiol (100 yl) and concentrated
hydrochloric acid (100 yl). The reaction was left for 24 hours
at room temperature after which, the thiol was evaporated in
vacuum at 40°C. The remaining solution was diluted with
water (10 ml), neutralised by addition of lead carbonate,
filtered and lyophilised. The residue obtained was dissolved
in methanol (100 yl) and acetic anhydride (50 yl) was added
dropwise. After six hours at room temperature, the solvent
was removed by vacuum and the residue dissolved in chloroform.
The solution was filtered to remove N,N-diacetyl-deoxystrept-
amine and chromatographed on a silica gel column (20 g) using
toluene/methanol (4:1) as the mobile phase. The main component
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as determined by TLC was collected and the solvent removed by 
evaporation. Mass spectromety was used to identify the 
fraction as a N-acetylpurpurosamine thioacetal.
Reduction:
The reduction of one of the components suspected of 
containing an imino group was also carried out. The sample 
(20 mg) was dissolved, in a reaction vial, in glacial acetic 
acid (40y1). DImethylamine borane (10 mg) was dissolved in 
glacial acetic acid (60 yl) and 20 y1 of this solution was 
added to the vial, and the mixture stirred with the needle 
of a microsyringe. The reaction was left for two hours at 
room temperature, then 18 M ammonia (60 yl) was added. The 
solution was passed through a small anion exchange column and 
the eluate lyophilised.
Mass Spectrometry:
Field desorption mass spectra were determined by 
Mr. M. Rossiter at the Department of Chemistry, University 
College, Cardiff using a Varian CH-5D.mass spectrometer. 
Chemical Ionization,Electron Impact and Fast Atom Bombardment 
mass spectra were determined by Mr. C. Cryer at the Department 
of Chemistry, University of Bath, using a V.G. 7070 E mass 
spectrometer.
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Nuclear Magnetic Resonance (N.M.R.)
The 100 MHz proton NMR spectra were determined by Mr. D. 
Wood on a JEOL P.S. 100 NMR spectrometer and carbon-13 NMR 
spectra were determined by Mr. H. Hartnell onda JEOL FX 90Q 
Fourier Transform NMR spectrometer at the School of Pharmacy 
and Pharmacology, University of Bath.
2.3 Results and Discussion
2.3.1 HPLC Semi-Preparative Isolation of Minor Components 
The separation obtained from one run of a Jobin-Yvon 
instrument using 1.5 g of gentamicin base was compared to the 
separation of 0.5 g of gentamicin base by a gravity fed column 
in Table 2.1.
With both columns some overlap of major components occurs 
but the resolution of the Jobin-Yvon column was superior to 
that of the ordinary column. The semi-preparative instrument 
also used less mobile phase and was more rapid. This advantage 
in speed was negated to an extent by the TLC method of column 
monitoring which increased the run time of the column consid­
erably and was by nature a retrospective check. The UV 
monitor of the eluent was inappropriate with gentamicin 
because of the poor absorption characteristics. A refractometer 
would have been more suitable but was unavailable.
The semi-preparative instrument coupled with an equally 
matched detection system would prove to be far superior
46,
Table 2.1. Comparison of Semi-Preparative HPLC with Classical 
Column Chromatography





Gentamicin C^ 204-330 414-660
Gentamicin C^ 315-453 576-750
Gentamicin C, la 480-570 720-900
Mobile phase
2:1:1 (9M) 0-390 0-730
2:1:1 (18M) 391-690 731-1380
to the ordinary classical method, yet the TLC used here decreased 
the advantages.
2.3.2 Spectral Characteristics of the Gentamicin C Components
Mass Spectrometry;
Electron impact spectra of all three major components are 
similar to that illustrated in figure 2.1 for gentamicin C^^. 
The fragment ions were identified by Daniels et and
are reproduced here.There is no molecular ion in figure 2.1 but 
the peak at m/z 432 is probably due to loss of ammonia from 
that ion (m/z 449). The peaks at m/z 350 and 322 are highly 
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m/z 350 w/z 322
R = Garosamine
The fragment, m/z 322, can further lose water to give another 
fragment at m/z 304. These three ring fragments are indicative 
of a garosamine-deoxystreptamine combination. The presence of 
2-deoxystreptamine can be further verified by the peaks at m/z 
191, 163 and 145^^. Garosamine is indicated by a fragment of 
m/z 160 which can lose water to give m/z 142. The A-ring of 
the gentamicins which is preferentially cleaved off is shown 
by a peak at m/z 129 in figure 2.1. Gentamicins and 
show corresponding peaks at m/z 157 and 143 respectively, for 
the purpurosamine A and B fragments. More extensive frag­
mentation of these subunits produces prominent peaks at 
m/z 130, 126 and 118. Electron impact spectra can often 
provide comprehensive structural data but often at the loss of 
the molecular ion. This is disadvantageous when investigating 
component of unknown molecular weight.
Chemical ionization spectra show the peaks due to the frag­














The yield of the pseudo-molecular ion [m +hJ"*" is large as shown 
in Figure 2.2 which is the Cl spectrum of gentamicin C^^.
A field desorption spectrum of gentamicin is shown in 
Figure 2 3 and reveals just the pseudo-molecular ion with 
traces of impurity present.
The fast atom bombardment spectrum of gentamicin with 
some gentamicin present is illustrated in Figure 2.4.
This is a positive ion spgictrum because negative ion yield 
was low with the instrument used. The |m+iJ peak is evident
for both of these components in the spectrum. Also present 
is the (M+sodium)^ peak at 472 for gentamicin This is a
common occurrence with FABly and also sometimes with FD, glycerol 
can also form complexes with ions vÆiich can complicate the 
spectrum immensely. There is fairly extensive fragmentation 
in this spectrum comparable to that produced by Cl. As a whole 
the FAB technique is potentially the most versatile of those 
discussed for polar compounds.
To further aid identification, N-acetylation can be used 
to produce FAB spectra similar to that shown for the gentamicin 
components in Figure 2.5. The penta and tetra N-acetyl P r i ­
vatives of each component are present, as are the N-acetyl 
derivatives of the purpurosamines at m/z 241, 227 and 213. 
Garosamine and deoxystreptamine fragments are at m/z 202 and 
247 with a combined fragment at m/z 448. N-acetylation is thus 





































Proton and Carbon Nuclear Magnetic Resonance SpectrosTOpy
Proton NMR of the gentamicin C components does not produce
very distinctive results. A 100 MHz spectrum of gentamicin
is illustrated in Figure 2.6. This shows one secondary methyl
group at 61.04 (J = 6 Hz), one tertiary methyl group at 61.18
and two nitrogen substituted methyl groups at 62.32 and 62.51.
The only other readily identifiable protons are the two
anomeric protons appearing as overlapping doublets (J = 4 Hz
for both) at about 65.1. The other components have spectra
with slightly different patterns of methyl groups but no other
discernible features. Hydrolysis of the gentamicins by acid
produced 2-deoxystreptamine (2.1) which has the 100 MHz proton
spectrum shown in Figure 2.7. The protons of C-2 have a shift
of 61.30 for the axial and 61.96 for the equatorial proton.
The J = 12 Hz, J = 4  Hz and the geminal constant was aa ae
13 Hz. The 1 and 3 hydrogens form a complex multiplet 
at 62.7 and the 4,5 and 6 hydrogens form the complex of 
multiplets at, about 63.1. Further information on the 
spatial relationship of these protons was gained by Lemieux^^ 
who used metihylation and acétylation of the functional groups 
to separate the protons.
Carbon-13 NMR of the major gentamicin C components shows
virtually identical shifts for the garosamine and deoxystrept-
246amine rings in all three . The effect of the varying 
degree of méthylation on the aminomethane sidechain at C-5' 
leads to slight but significant differences in the chemical 
shifts for the C-4' to C-6' carbons. The carbon-13 NMR spectrum
55,
Figure 2.6. loo MHz Proton NMR of Gentamicin C
HDO
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of gentamicin is shown in Figure 2.8 with the chemical shifts
denoted in Table 2.2. The chemical shifts of the carbon atoms
of isolated deoxystreptamine are also given as are the shifts
calculated for each carbon atom by the Lindeman and Adams 
273equation
The chemical shifts reported here are similar to literature 
246-7values . The shifts for the deoxystreptamine moiety are
comparable to those for the free compound and indicate the use­
fulness of spectral data of the individual sub-units. It is 
interesting to note that glycosidic bond formation at the C-4 
and 6 does not have a large effect on the shift values of the 
remaining carbon atcxns contrary to the calculated expectation. 
The calculations used are based on straight chain paraffins 
and extension of their usé to cyclic systems increases the 
error. The shift values calculated for the anomeric carbons 
show significant error which must bear seme relation to the 
glycosidic bond not exerting the expected electronegative pull.
It is noticeable that the C-5' and 5" atoms have shift 
values also considerably less than predicted and this function 
is therefore inaccurately defined by the equation. Neverthe­
less , the use of these equations can prove useful in assigning 









































1 51.91 46.92 51.90 51.92
2 36.92 38.98 37.49 40.98
3 50.82 46.92 51.90 51.92
4 88.59 88.53 79.09 81.53
5 75.73 71.46 77.25 77.46
6 87.63 88.53 79.09 81.53























2.3.3 Isolation of Minor Components
Swiss-Italian Samples:
Swiss (Benzian, BN/G022, GMC-L-8) and Italian
(Pierrel SpA, Lot 064/065) gentamicin sulphate samples were
subjected to coluim chromatography. A total of 9.2 g of
gentamicin base was separated on seven columns with a further
two columns used to purify the isolated minor components. This
second column yielded a fraction (54 - 75 ml) of about 2 mg which
revealed two spots by TLC, with R values of 1.84 and 1.59.
^1
In this system the R_: of gentamicin C and C were 0.79 and2 la.
0.39 respectively. The isobutane Cl spectrum of the minor 
components is shown in Figure 2.9. The peaks at m/z 446 and 
432 are [m +h] signals and the difference of 14 suggests they
are structural homologues. The presence of a garosamine moiety
is suggested hy the peak at m/z 160, but there is no signal at 
m/z 163, 191 or 145. The absence of the characteristic peaks 
of m/z 350, 322 and 304 further verify the lack of a deoxy­
streptamine moiety. These components are thus similar to
77those discovered by Krai sin tu . The prominent peak at m/z 
290 is possibly due to a two ring fragment equivalent to the 
m/z 322 of the gentamicins. This implies a fragment of m/z 131
for the central ring if it behaves similarly to deoxystrept­
amine. The ring shows a large signal at m/z 130 which may corre­
spond to the ring without a proton addition. The B ring is 
thus 32 mass units smaller than 2-deoxystreptamine and various 
structural interpretations can be proposed for this loss.
The 'A ' ring in these components is required to be 157 and 143 




















and C^. These are in fact seen in Figure 2.9 and confirm 
the size of the B-ring. Further characterisation of these 
components was achieved by N-acetylation with the FAB spectrum 
illustrated in Figure 2.10. No clear molecular ions are 
visible, probably due to fragment combination. However,peaks 
corresponding to tri-N-acetylated compounds plus sodium occur at 
m/z 594 and 580 with no greater N-acetylated ions present. 
Garosamine is disclosed by the signal at m/z 202, with the 
purpurosamines at m/z 241 and 227. There is no peak at m/z 130 
or at 172 or 214 (N-acetylated). It is possible that the m/z 
130 fragment of the B ring has become associated with glycerol 
or some other species 1 The peak at m/z 304 is also present 
in the FAB spectrum of the unacetylated minor ccraponents but 
absent in the Cl spectrum (Figure 2.9). It may represent a 
dimer of ring B and sodium (129 + 23). There is a m/z 152
peak present but this is comparatively small (8%) and there 
is a larger peak at m/z 168 which could be ring B plus potassium. 
It is therefore likely that the central moiety is not stable in 
the FAB conditions employed but there is no indication of N- 
acetylation. The uneven molecular weight of the components 
indicates an odd number of nitrogen atoms present. The overall 
evidence is that there are only three amino groups in the 
components and these are distributed in the A and C rings. The 
B ring with a weight of 128 and possible molecular formula of 




















More specific structural assignments would require additional
sample to enable carbon-13, proton NMR and degradative studies to
be performed.The components, however, appear to represent a
family of gentamicins identical to the C-components, but without
the deoxystreptamine ring. The microbiological activity of these
46components would be low according to Price as they lack a basic
77function at the C-1 and 3 positions. However, Kraisintu re­
ported similar activity to the C-components. These minor 
components would be resistant to micro-organisms which produce 
the AAC-3 inactivating enzyme.
Italian Sample
A different batch of Pierrel (BN Genta/121) gentamicin 
base (26 gj was chromatographed on a column to isolate more 
of the 445/431 components. However mass spectral analysis and 
TLC was unable to detect them in appreciable yield. Some of 
the fractions of minor components were N-acetylated in an attempt 
to identify some of those present. The fractions of F551-90 
and F591-630 show peaks at m/z 424 and 410 amongst the numerous 
signals present (Figure 2.11). N-acetylation of these fractions 
revealed peaks at m/z 452/466, 494/508 and 536/550 (Figure 2.12), 
which represent mono, di and tri-acetylated derivatives of the 
423/409 components. Garosamine is again present as shown by 
the m/z 160 and 202 in the separate spectra. The N-acetylated 
spectrum indicates that purpuro samines A and B are present 
because of the sizeable m/z 227 and 241 signals. However the 






























in the fraction and peaks due to purpurosamines may originate 
from them. No other explainable peaks are observed for the 
ring A and if these components do contain the purpurosamines 
the central ring must possess a molecular weight of only 106.
A peak at m/z 108 is present but is small and addition reactions 
may have occurred. Thus analysis of gentamicin sulphate samples 
from the Italian manufacturer yielded small quantities of poten­
tially interesting components with major changes of the central 
sub-unit.
Chinese Sample;
A sample of gentamicin sulphate of undetermined source, but
thought to be Chinese was chromatographed (15.2 g) on four
columns. Unlike the gentamicin samples studied in a) and b)
the minor components eluted as clear distinct zones and were
thus more amenable for isolation. The profile of minor
components eluting before gentamicin C^ was as shown in
Table 2.3 with R values given.
^1
Table 2.3. Minor component profile of Chinese material
Component Weight (mg)
'^1
CMl < 1 3.52





The CMl and CM3 components were not isolated in sufficient 
yield to achieve any identification. The field desorption, 
chemical ionization and FAB spectra all depicted m/z 445 as 
the[M+H]* ion. The El spectrum of CM4 is illustrated in 
Figure 2.13. Peaks at m/z 350, 322, 191, 163 and 160 all imply 
that garosamine and deoxystreptamine are present as the B and 
C rings. The remaining A ring has, by subtraction, to be a 
fragment of m/z 124 and possess an odd number of nitrogen atons. 
There is indeed a peak of m/z 124 present but this is not con­
clusive as garosamine can lose water to produce an ion of this 
mass.However the peak at m/z 286 is indicative of a 124 subs­
tituent joined to deoxystreptamine and it is not usually found 
in gentamicin spectra (Figure 2.2). Berdy isolated a
compound of the same molecular weight and assigned a structure 
(2.V) to it although he offered no supporting evidence.
The 100 MHz proton NMR spectrum of CM4 is presented in 
Figure 2.14 which can be compared with a similar spectrum of 























represents the tertiary methyl at C-4" and compares to 61.18 
for gentamicin C^.
No secondary methyl group is evident but two methyls appear 
in the 62-3 region. The peak at 62.53 is comparable to 62.50 
for gentamicin and represents the amino substituted methyl 
in the garosamine ring. The other peak at 62.16 does not corre­
spond closely with the 62.32 found for the aminomethyl group 
on C-5' in gentamicin . It could plausibly represent a 
methyl group adjacent to an imine function but could also 
fit other groups. One of the anomeric protons is shifted 
to 65.26 and broad peaks appear at 64.35 and 4.51. The latter 
may be the C-2' and C-5' deshielded protons.
The carbon-13 NMR spectrum of this compound is reproduced
in Figure 2.15 and assignments of the shifts are made in
Table 2.4, with a comparison to gentamicin C^. Two peaks
representing carbons 3' and 5' were not detected even after a
duplicate run. Otherwise the resonances were very similar to
77those reported by Krai sin tu . The shifts of the B and C 
rings show a close comparison to those found in gentamicin 
confirming mass spectral analysis. For the A-ring, the 
C-2' is deshielded by 5.5 ppm and the peak of 181.96 is 
the carbon of the imine'function. This is similar to some 
literature values of imines and lies outside the normal 
aldehyde/ketone region^^^ The shift of the methyl group
(C-7') attached to the C-6' is anomalous since the presence of 















Table 2.4. Carbon-13 NMR shifts of CM4 and Gentamicin Cg






















0.3 ppm, especially considering the proposed shift in the proton 
spectrum (Figure 2.14). Thus the spectroscopic data suggests, 
but is not adequate to confirm , structure (2.V) .
In order to confirm the presence of an imine group the
275compound was reduced with dimethyl amine borane . This reagent, 
will reduce an imine to the amine and carbonyl to the alcohol^^^ 
and was chosen so that the product could be easily isolated.
The actual reduction can be judged to occur by comparison of 
the infra-red spectrum of the CM4 component with that of the
reduced product shown in Figure 2.16. A weak band is visible
-1 -1 at 1640 cm on the broader band at 1600 cm due to the N-H
\bending. This is expected for a ^C=N- group and values of
1665-1645 cm ^ of variable bond strength are quoted^^^ for
compounds of the type R-C=N-R. Carbonyl absorption bands tend
—1
to be strong and higher in frequency. This band at 1640 cm 
is absent from the IR spectrum of the reduced component. The 
success of the reduction was confirmed by a FAB spectrum which 
showed a ratio of 4:1 of m/z 447 to 445. A peak at m/z 126, 
with little m/z 124 present confirmed that the site of reduction 
was in the purpurosamine ring and that m/z 124 in Figure 2.13 
was due to this ring and did not arise from loss of water 
from garosamine. It is concluded that the structure (2.V) 
is probably correct and that the amlpiguous NMR data was due 
to an insufficiently large sample size.
The CM2 component, only separated in a very small quantity, 
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spectrum (Figure 2.17). This is fourteen mass units larger 
than CM4 and is possibly a homologue. However the proposed 
structure of the A-ring excludes the normal méthylation wit­
nessed in the C components. Chemical ionization and FAB 
spectra of this component did not produce conclusive grounds 
for structural determination.
The CM5 component was procured in a significant yield.
The field desorption mass spectrum of this compound indicated 
a molecular weight of 477, equivalent to gentamicin C^. The 
proton NMR spectrum of the component showed four methyl groups 
at shifts of 62.53, 2.35, 1.20, l.OB ppm compared to shifts 
of 62.51, 2.32, 1.18 and 1.04 ppm for gentamicin C^. A carbon- 
13 NMR of the component was recorded shown in Figure 2.18, 
although one carbon atom could not be detected and splitting 
of other resonances also occurred. A comparison of chemical 
shift assignments with gentamicin is made in Table 2.5.
There is little evidence of difference except for the splitting 
which mainly occurs in the A-ring. This was thought to be due 
to a mixture of stereo-isomers about the C-5' position. An 
important difference between the spectra is the peak attri­
buted to the C-7' methyl which is deshielded by nearly 4 ppm 
and is of comparable size to the C-7' in gentamicin (18.51). 
This conflicting data was assessed by a Cl spectrum of CM5 
shown in Figure 2.19. The molecular weight is confirmed 
as 477, and garosamine is present. The signal at m/z 143 
suggests that it is purpurosamine B and not A which is a sub­
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Table 2.5. Carbon-13 NMR shifts of CMS and Gentamicin C,
OH
CH-NHCH 




Carbon Gentamicin C^ (p£xn) CMS (ppm)
1 SI.91 SI.76
2 36.92 -
3 SO. 84 SO. 63
4 88.S9 88.03
S 7S.73 7S.94







































absent, but a strong peak at m/z 177 suggests N-methylation 
of deoxystreptamine. A peak at m/z 336 is equivalent to the 
m/z 322 characteristic peak of the gentamicins. Thus the CM5 
component must be N-methylgentamicin . The carbon-13 NMR 
assignments given in Table 2.5 are therefore not accurate, 
as the shift for C-6' has to be switched with either C-1 or 
C-3 depending on the position of N-methylation and C-8' becomes 
C-7. The Cl spectrum of CMS was supported by a FAB spectrum 
of the N-acetyl derivative which had major peaks of m/z 688,
261, 227 and 202 indicating N-acetylated garosamine, purpuro- 
samine B and N methyl deoxystreptamine. To determine the position 
of the N-methylation reference was made to a paper by Wright^^.
A method using high energy El mass spectrometry had been 
developed which related a fragmentation pattern to the site of 
N-alkylation in the deoxystreptamine ring. This pathway 
involved the loss of the amino group adjacent to the glycoside 
bond cleaved to produce two possible ions (2.VI, 2.VII)^^.






R =CHg R=H 1-N-Methylgentamicin C2 m/z 3o3 272
R^=H R=CH2 3-N-Methylgentamicin C^ m/z 289 286
83
Thus depending on which pair of ions is present, the site 
of N-alkylation can be determined. The 70 eV El spectrum of 
CM5 is illustrated in Figure 2.20. The peaks of 289 and 286 
are obvious whilst the alternative pair are not present. Thus 








20The position of N-methylation is important, as Wright 
reported that the synthetic 3-N-ethylgentamicin deri­
vative possessed weak anti-bacterial activity, whilst the 1-N- 
ethyl analogue possessed strong activity. If the CM5 component 
was active it would have an inherent resistance to AAC-3 
enzymes, an important source of gentamipin inactivation.
The identification of CM5 can also be applied to the CM2 
component discussed previously. It is possible that this 
component could bear a similar relationship to CM4 as CM5 
does to gentamicin C ^ . N-methylation of the deoxystreptamine 
would leave the components with the same A-ring and would be 
consistent with the homologue idea.
84.





























The Chinese sample also produced large amounts of a co­
eluting component of gentamicin C^. This was recognised by 
unusual Carbon-13 NMR spectra though TLC or paper chromatography 
could not separate the components. The component, assumed to 
be gentamicin Cg^, was separated analytically by HPLC and 
estimated to be in equal proportions to gentamicin C^ (3.3.1)
Other components were eluted after gentamicin C^^ in large
77quantities but were likely to be two ring fragments . A field
desorption spectrum did reveal components of m/z 450 and 435
which were possibly the same as the demethyl derivatives isolated 
74by Berdy
It is interesting to conclude that the different sources 
of gentamicin sulphate reveal varying minor component profiles, 
due probably to different conditions of incubation medium or 
to different strains of producer organism. These components 
exhibit a wide range of structural modification of the genta­
micin C nucleus, some of which are promising in terms of en­
hancing the aminoglycosides clinical activity. The Chinese 
sample seems to have been produced in a culture medium with 
an unusual biosynthetic pathway as the deoxystreptamine is 
an unorthodox site for N-methylation. Other naturally-occurring 
aminoglycosides have been isolated With such N-methylation 
such as Hygromycin B and Destomycin A but in these compounds
the deoxystreptamine group is not central and only has one
46glycosidic bond attached
86,
2.3.4 Spectroscopic Study of Netilmicin
The observation of two peaks for netilmicin in the 
HPLC system (3.3.1) which rendered it unsuitable as a standard 
was probably due to a column or reaction effect. However, to 
rule out the possibility of a heterogenous compound an investi­
gation of its composition was made. The structure of netilmicin 






A chemical ionization spectrum is shown in Figure 2.21, 
with the [m +1] of m/z 476 agreeing with the molecular formula 
of ^21^41^5^7’ Garosamine is present (m/z 160) as is the 
4',5'-dehydropurpurosamine C at m/z 127. The N-ethyl deoxy­
streptamine is indicated by the signal at m/z 191 and the 
peak at m/z 350 vdiich is the N-ethyl deoxystreptamine attached 
to garosamine. There is no evidence from this spectrum of
an impurity or that the sample is a mixture. The mercaptolysis
49 +of N-acetylated netilmicin , though it provided a [jM+l]
peak of m/z 335 attributable to the 2,6-diacetamido-5-keto-
hexanal, did not exhibit the expected fragmentation pattern.
Hydrolysis and N-acetylation of netilmicin revealed the N,N-
diacetyl, N-ethyldeoxystreptamine by a chemical ionization
87



























spectrum (Figure 2.22). The m/z 275 signal corresponds to the 
[m +3] of this fragment and the large m/z 202 peak is due to 
an impurity of N-acetylgarosamine.
The carbon-13 NMR spectrum of netilmicin is illustrated in
Figure 2.23 with' chemical shifts assigned in Table 2.6, and
conpared to gentamicin The introduction of unsaturation
to the purpurosamine C ring deshields the C-4' and S' by over
70 ppm which is as expected for such a function. The values
for the A-ring are very similar to those reported for siso- 
246micin . The N-ethyl group appears to influence both the B 
and C rings. The N-methyl (C-7") is shielded by 6 ppn although 
a reason for this is unknown. It is unlikely to be the in­
fluence of the unsaturation as sisomicin has been reported to
possess chemical shifts of the C ring the same as the 
246gentamicins . It is most likely caused by a steric factor 
which may also account for netilmicin's unusual resistance 
against bacterial enzymes.
The 100 MHz proton spectrum of netilmicin is shown in 
Figure 2.24. The tertiary methyl (6") exhibits a signal 
at 61.20 and the N-methyl (7") at 62.52 which are similar to 
resonances found in the gentamicins. The methylene group in 
the A ring (6') gives a singlet at 63.16 whilst the 4' proton 
doublet is not distinguishable. The ethyl protons show as a 

























Table 2.6. Carbon-13 NMR shifts of 
to Gentamicin C^^.
netilmicin in comparison

















































Both the carbon-13 and proton NMR spectra show no sign of 
heterogenity. Applying the mass spectral test of position 
of N-alkylation^^ used in (2.3.3) for component CM5 would 
yield ions of m/z 317/256 for 1-N-ethylation or m/z 289/284 
for 3-N-ethylation. The El spectrum. Figure 2.25, has peaks 
at m/z 317 and 256 with no peaks visible at the other positions. 
It thus demonstrates that the sample was indeed 1-N-ethyl- 
sisomicin and no trace of contaminant was detected.
95.
CHAPTER 3
QUANTITATION OF COMPONENT LEVELS OF GENTAMICIN IN COMMERCIAL 
SAMPLES OF GENTAMICIN SULPHATE AND IN BLOOD PLASMA BY HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHY
3.1 Introduction
High-performance liquid chromatography (HPLC) has been used
in various studies to determine the component ratio of gentamicin
78 79 82 89sulphate in commercial samples from a wide range of sources ' ' ' , 
The advantages of this technique are the speed and precision over 
more established chromatographic methods such as paper chroma­
tography^^, thin-layer chromatography^^ and ion-exchange^^'.
Gentamicin does not possess a chromophore and has to be
derivatised before detection is possible. Fortunately the amino
groups present offer a wide choice of suitable derivatisation 
236reactions . The HPLC methods developed for component deter­
mination in commercial samples use ortho-phthalaldehyde (OPA)
237 238as the derivatising agent, which yields a fluorescent product '
OPA can be reacted with the gentamicin either before or after
236passing the sample through the chromatographic column . The 
advantages cited for post-column reaction^^^'^^^ are that 
formation of artefacts is less likely and product stability is 
not important. The pre-column reaction enables greater optimi­
sation of the conditions thus allowing a wider choice of reagents
and the formed products can have superior separation. Methods
78 82 89which utilise pre- ' and post-column reactions with OPA
for gentamicin have been reported and both types show good precision.
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These chromatographic techniques generally separate the
samples into the three major components, gentamicin C , C
82and . However, Freeman developed an OPA pre-column deri­
vatisation technique which could also separate the gentamicin 
component. This was achieved by altering the composition
of the fluorescent reagent and adding an ion-pair compound to
79the mobile phase. White et al. used this method to investigate 
the relative component composition of gentamicin sulphate from 
various geographical sources. The availability of the HPLC 
method enables more stringent analysis of samples of different 
origin and thus the possibility of a greater standardisation 
of the component composition especially in respect to gentamicin
Sa-
The development of methods of plasma analysis of gentamicin
by HPLC has been reported more frequently^^^ 235^ perhaps because
of the more exacting conditions imposed, or because of a more
apparent need. More reagents have been used to derivatise
the amino groups than just OPA,and ultra-violet detection used
228 229as well as fluorescence ' . Reagents used for pre-column
235 220—2derivatisation include fluorescamine , dansyl chloride ,
229 228benzene sulphonyl chloride and fluorodinitrobenzene
For some of these reactions the individual component deri-
 ̂  ̂  ̂  ̂^ , 220,222,228,229vatives were not totally separated by the column
and this could lead to inaccurate results if a mixture of
different composition from that used in the calibrations was
assayed. Only OPA has been used for post-column derivatisation
of gentàmicin^^^  ̂because of the severe constraints imposed
97'
on post-column reactions.
Separation of the gentamicin from the plasma constituents
is an important procedure, as gentamicin is slightly bound to
protein and biogenic amines can readily react with the reagent
and cause interference. Two types of separation can be used;
either adsorption or extraction. The former has been achieved
for gentamicin by use of silicic acid or ion-exchange resins
223"22o 233before reaction with the reagent ' . The other type
of separation used was protein precipitation followed by
220—2 2TJ7~232solvent extraction with a variety of methods developed '
Many published methods rely on external standardisation because 
of the difficulty in obtaining suitable internal standards.
Tobramycin and netilmicin have also been assayed by HPLC using
. _ . . 221,224,230—32—  - .   , ,similar techniques and in some cases can be used
229 233as internal standards in gentamicin assays '
All developed methods claim good precision with values of 
less than 10% coefficient of variation^^^. Another advantage 
of HPLC is the specificity, since no compounds have been re­
ported to overlap with the gentamicin components . The 
quantity of plasma required for a single analysis varied from 
0.02 to 0.5 ml in the reported assays and thus allows sampling 
from infants. The time required for a single assay depends on 
the method, but was in a range of about fifteen to seventy 
minutes. The absolute time limitation is the retention time 
on the column. The sensitivity of the methods extended to 
at least 0.5 yg/ml which is adequate for clinical use.
98,
The aim of the work in this chapter was to develop a pre­
column OPA derivatisation HPLC method for gentamicin component 
analysis and apply it to commercial samples from differing^ 
sources. Also some of the reported methods of HPLC deter­
mination of gentamicin in plasma were investigated. Using a 
developed, plasma method, a comparison with the microbiological 
assay was made and pharmacokinetic parameters of the three 
components calculated.
3.2 Materials and Methods
3.2.1 Materials
Ortho-phthalaldehyde (Sepramar), boric acid, potassium 
hydroxide, mercaptoethanol, trichloroacetic acid and anthracene 
were all supplied by BDH Chemicals Ltd. Ethylenediaminetetra- 
acetic acid (tripotassium salt), tetradecylamine, tridecylamine 
and gnlecylamine were supplied by Fluorochem Ltd.. Nonylamine 
was obtained from Aldrich Chemical Company Ltd., Dodecylamine 
from Eastman Kodak Company and Decylamine from Sigma Chemical 
Company. HPLC grade methanol and diethyl ether were obtained 
from Fisons Scientific Apparatus Ltd. Filters of 0.45 ym and 
prefilters were obtained from Millipore (UK) Ltd. Netilmiciha 
sulphate was a gift from Kirby-Warrick Pharmaceuticals Ltd. 
Gentamicin components (C^, C^^ and C^) had been isolated by 
column chromatography and purity was checked by TLC (2.2.2).
The pump used was a Laboratory Data Control Minipump and the 
detector was a LDC Fluoromonitor III (excitation filter 370 nm, 
emission filter 418 - 700 nm). The injection valve used was
99,
a Rheodyne 7125 with a 100 yl loop and the recorder was a 
Servoscribe RE 541.20. A Hewitt and Packard 3903 integrator 
was also used in some component assays. The column used 
contained Spherisorb ODS, 5 ym, and had dimensions of 150 x 
5 mm.
3.2.2 Methods
3.2.2a General HPLC Method
Chromatographic Conditions :
The mobile phase used was methanol/water (80:20)
-1with 2 g/L EDTA, tripotassium salt. The flow rate was 1.3 ml min 
and the column temperature was maintained at 30°C.
223Derivatising (OPA) Reagent :
Ortho-phthalaldehyde (OPA) (200 mg) and mercapto­
ethanol (0.4 ml) were dissolved in methanol (2 ml). Boric acid 
(1 g) was dissolved in distilled water (38 ml) and the pH was 
adjusted to 10.4 with 45% w/v potassium hydroxide solution.
The entire buffer solution thus prepared was then added to the 
OPA methanolic solution. The reagent was stored under nitrogen 
at 4°C and was stable for at least two weeks.
Reaction Conditions:
The basic reaction consisted of adding OPA reagent 
(0.5 ml) to an aqueous solution of gentamicin (0.01 mg/ml) (0.5 ml)
loo.
and after vortex mixing for one minute, methanol (2 ml) was 
added. The solution was filtered and stored at room temperature, 
in the dark until injection.
The reaction conditions were varied to optimise yield. The 
length of time of reaction was varied up to 120 minutes for 
each of the individual components. The temperature was altered 
up to 50°C and the effect of lowering the pH of the reaction 
mixture was also investigated.
Internal Standards
Arginine, anthracene, nonylamine, decylamine, unde- 
cylamine, dodecylamine, tridecylamine, tetradecylamine and 
netilmicin were all examined as possible internal standards. 
Kappa' (k ') values were calculated for each from
t - t r o
to
where t^ = leading edge of first deflection (unretained)
t^ = centre of peak (retained)
3.2.2.b Gentamicin component ratio determinations in- 
commercial material samples and pharmaceutical 
preparations
Gentamicin Standard Solutions (Raw Material Analysis) 
Each of the three gentamicin C components was dissolved
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in water to produce 2 mg/ml standard solutions. These were 
kurther diluted with water to give a range of solutions of 20, 
30, 40, 50, 60, 70 and 80 yg/ml for each of the components.
Standard Solution for Injection Analysis:
From the 2 mg/ml standard solutions of the components, 
0.27 ml of gentamicin 0.33 ml of gentamicin and 0.40 ml
of gentamicin were taken and diluted to 5 ml to give a 
0.4 mg/ml solution containing all the components though not 
of equal concentration.
Internal Standard Solutions;
Anthracene 0.06 mg/ml in methanol, undecylamine 
and tridecylamine 0.1 mg/ml in methanol, solutions were prepared.
Preparation of Commercial Material Samples : 
Gentamicin sulphate (25 mg) was dissolved in water 
(25 ml). A 1 in 10 dilution of this solution was made and 
used in the assay. Duplicate solutions of each sample were 
prepared.
Preparation of Injectable Formulation 
Gentamicin Injection (80 mg in 2 ml) (0.1 ml) was 
diluted to 10 ml with water to give a 0.4 mg/ml solution.
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Duplicates from the same ampoule were prepared.
Calibration - Gentamicin Commercial Material
Calibration solutions were prepared by adding 0.3 ml
gentamicin C^^ standard solution to 0.36 ml of gentamicin
solution and 0.44 ml of gentamicin C solution, all of the same
1
strength (10 - 80 yg/ml). Undecylamine (0.1 ml) and tridecyl­
amine (O. 1 ml) were added followed by OPA reagent (0.5 ml) 
and methanol (2 ml). The solution was vortex mixed, filtered 
and stored in the dark and injected (lOO yl) 60 minutes after 
the reaction had started. This was the standard procedure 
for the reaction, and kept to unless otherwise stated.
Gentamicin Sulphate Injection: Calibration 
Solutions were prepared by adding varying volumes 
(60 - 140 yl) of the gentamicin, 0.4 mg/ml standard solution, 
to water to produce 0.2 ml. Then undecylamine (0.1 ml), OPA 
reagent (0.5 ml) and methanol (2 ml) were added, and the reaction 
carried out as above. In most cases a five point calibration 
was used.
Gentamicin Commercial Material Assay 
Samples were analysed by the standard method using 
unknown 0.1 mg/ml solution (1.1 ml), undecylamine (0.1 ml), 
tridecylamine (0.1 ml), OPA reagent (0.5 ml) and methanol (2 ml).
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Gentamicin Injection Assay
Samples were assayed by adding the approximately 0.4 mg/ml 
solution of the unknown (0.1 ml) to water (O. 1 ml) and undecyl­
amine (0.1 ml). To this OPA reagent (0.5 ml) and methanol (2 ml) 
were added and the usual procedure followed.
3.2.2.C Assay of Gentamicin Levels in Blood Plasma 
Plasma
Blood plasma used in the development of the method 
and for assay calibration was obtained from the Royal United 
Hospital, Bath. It was from a pool of healthy subjects with no 
drugs present. Plasma was spiked with gentamicin standard 
solution, 0.4 mg/ml, the day before use and stored frozen at 
-20 C.
Gentamicin Extraction from Plasma onto a Silica Gel
^ 1 223Column
A short silica gel column was prepared by blocking a 
pasteur pipette with glass wool and filling the pipette with 150 mg 
of silica gel (lOO - 200 ym). Water was added to plasma (0.5 ml) 
to give a 2 ml volume. This solution was transferred to the 
column and washed in with 1 ml of water. OPA reagent (0.5 ml) 
was added to the column and the OPA derivative of gentamicin 
was eluted with 1.5 ml of ethanol after ten minutes. This 
solution was filtered and injected after fifteen minutes.
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Protein Precipitation with Acetonitrile? Extraction
231with Ethyl Acetate
Plasma, spiked with gentamicin (0.2 ml) was added to 
0.1 M phosphate buffer (pH 11.0) (0.8 ml). To this acetonitrile
(3 ml) was added, vortex mixed, and centrifuged for 10 minutes 
at 3,000 rpm. All of the supernatant was then added to 
methylene chloride (3 ml), mixed gently, then centrifuged for 
5 minutes at 2,000 rpm. Then aqueous phase (0.5 ml) was taken 
and added to OPA reagent (0.5 ml) . This was mixed and left for 
5 minutes before ethyl acetate (0.5 ml) was added. The mixture 
was centrifuged at 1,000 rpm for one minute. Organic layer 
(100 yl) was then injected immediately after separation. For 
some samples isopropanol (0.25 ml) and sodium carbonate (500 mg) 
were used at the final extraction step instead of ethyl acetate.
Protein Precipitation with Trichloroacetic Acid;
Extraction with Diethyl Ether
Trichloroacetic acid (10% w/v in 80:20, methanol: 
water), 0.25 ml, was added to plasma (0.5 ml). This was vortex 
mixed for one minute then centrifuged for ten minutes at 
3,000 rpm. Total supernatant was added to 0.4 M borate buffer 
(pH 10.4) , (0.25 ml) and OPA reagent (1 ml). This was mixed 
and left for twenty minutes in the dark. To the solution 
diethyl ether (5 ml) was added, lightly mixed, then centrifuged 
at 2,000 rpm for 5 minutes. The upper etherial layer was 
separated, evaporated under nitrogen and the residue redissolved 
in 1:1 methanol:water (0.5 ml). This solution (100 yl) was 
injected immediately.
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Protein Precipitation with Trichloroacetic Acid - 
No Extraction
Trichloroacetic acid (10% w/v in 80 :20;methanol;water), 
(0.25 ml), was added to plasma (0.5 ml). This was vortex mixed 
for one minute, then centrifuged for ten minutes at 3,000 rpm.
Total supernatant was added to 0.4 M borate buffer (pH 10.4),
0.25 ml, and OPA reagent (0.5 ml). Methanol (0.8 ml) was added 
and the solution was prefiltered, filtered and injected (lOO yl) 
after sixty minutes.
Plasma Assay Calibration
Blood plasma (2 ml) was spiked with gentamicin 
standard solution, 0.4 mg/ml, to give 1, 2.5, 5, 7.5 and lO yg/ml 
solutions of gentamicin in plasma. These were processed, in 
duplicate, by the method of trichloroacetic acid precipitation 
with no extraction except that 4 yl undecylamine (0.1 mg/ml) 
as internal standard was added after protein precipitation.
Assay of Plasma Samples
The patient samples were prepared in an identical 
fashion to the calibration solutions. To avoid the need for 
daily calibrations, standard solutions were assayed after every 
two unknown sample injections. About nine samples, each in 
duplicate, were analysed every day. In total sixty five samples 
from five patients were used and assayed at random. At the end 
of each day the HPIX̂  column was eluted with methanol to prevent
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build-up of contaminants.
3.3 Results and Discussion
3.3.1 Determination of Component Levels in Commercial Material 
Optimising Conditions;
The HPLC system used, was based on that reported by 
223Maitra et al, with some modifications. The mobile phase 
was a 80:20,methanol-water mixture containing 2 g/L ethylene- 
diaminetetra-acetic acid, tripotassium salt. This gave a 
typical separation such as that illustrated in Figure 3.1.
The retention times of the components were 5, 6 and 12 minutes 
for gentamicins and respectively. No buffer was
used as the salt was found to produce a fairly constant pH of 
8.5 in the mobile phase. Extensive variation of the mobile 
phase is discussed in Chapter 5.
The reaction condi tLons of the derivatising reagent were 
studied to optimise the sensitivity. The peak height of the 
three components was measured against time of incubation at 
room temperature with a graph of the results shown in Figure
3.2. The components showed different reaction kinetics with 
the rate possibly influenced by stereochemical factors. Sixty 
minutes was taken as the optimal time since two components had 
reduced peak height after this juncture. The use of elevated 
temperature (50°C) was examined, but the rate of decomposition 
of the product was also increased and timing was more critical.
The reaction was thus kept at room temperature to minimise
107,
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Figure 3.2. Time Course of Gentamicin-OPA Reaction with 
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variation in reaction yields.
The addition of an alcohol to the aqueous reaction mixture
increased the fluorescence produced. The resolution of the
gentamicin and peaks in a chromatogram was 1.2 in a
90% methanol solution as shown in Figure 3.3. This compares
to a resolution of 1.0 in a 90% (methanol/ethanol (1:1))
mixture and 0.7 for 90% ethanol or isopropanol reaction solutions
For methanolic solutions there is less than a 1% overlap of
peaks, if taken as gausian in shape, which is satisfactory for
241quantitative determinations . The poor resolution in the 
other alcoholic reaction solutions was probably related to the 
increase in solvent strength at the head of the column, on
injection, eluting the derivatives slightly faster and with
- - 241poorer separation
The pH of the reaction mixture was not found to be critical
so long as conditions remained alkaline and thus the OPA reagent
223used was as described by Maitra et al. , with a pH of 10.4.
A pH range of 8 - 12 for the reaction gave peak heights of 
similar magnitude but incubation at an acid pH (0.6) only 
produced 13% peak size. Alteration of the pH thirty minutes 
after reaction was started also showed the derivatives to be 
stable if the pH was kept alkaline. Changing the pH to 3.9 
decreased peak heights by 14%; and to 2.0 by 49% after thirty 
minutes in comparison to the control.
To minimise variation in experimental procedure a set time
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Figure 3.3.. Resolution of and components injected 

















of sixty minutes at room temperature, with the same pH 10.4 
buffer and the same percentage volume of methanol were used in 
the reaction.
Internal Standards:
77 78The standard used by Kraisintu ' , L-arginine was
tested, but found to elute with a retention time of about two 
minutes and overlapped peaks due to the derivatising reagent. 
Various aliphatic and aromatic amines and naturally fluorescing 
compounds were investigated but most were non-retained. Netilmicin 
was also examined but under these conditions it eluted as two 
peaks. This was possibly due to a partial reaction as the 
relative size of the peaks depended on the age of the reagent. 
Other aminoglycosides tried, including neomycin and kanamycin, 
were not retained sufficiently in this system to be of use 
as standards.
Anthracene was discovered to have an ideal retention time 
and have good peak shape in the system used. The chromatogram 
of anthracene with the gentamicin components is shown in Figure 
3.4. However as a standard this only monitors variations due 
to volume of injection. Since it does not react with the deri­
vatising reagent it does not control variations due to quality
82of reagent or reaction conditions. Freeman used nonylamine 
in an assay of gentamicin, but in the conditions used here, 
this overlapped with the gentamicin components. A range of 
straight chain amines were chromatographed to assess suitable
112.










Figure 3.5. Graph of In k ' against number of carbon 








retention times. A plot of In k' (capacity factor) against
number of carbon atoms is shown in Figure 3.5. It is seen
to follow the Martin rule for a series of structural homo-
logues^^^'^^^. The slope of 0.31 which refers to the increment
of added methylene groups is constant for the given system
and column. It is similar in value to the estimated slope
82of 0.40 from a graph presented by Freeman . This illustrates 
the similarity of the two systems in terms of chromatographic 
response in spite of all the differences in conditions employed. 
The amines with retention times different to the gentamicin 
components were undecylamine, tridecylamine and tetradecylamine. 
Tetradecylamine was considered unsuitable because of the long 
retention time (25 minutes) and broader peak shape. The peak 
area ratio of gentamicin C component to that of undecylamine, 
against time of reaction is shown in Figure 3.6. The plot of 
peak height for the same relati^ship resembles that for peak 
area. The onset of an approximately constant ratio is ob­
tained after sixty minutes. At times less than this the 
gentamicin peak heights are increasing whilst that of undecylamine 
is decreasing.
Calibrations and Assay;
Anthracene was initially used alone as an internal 
standard with the slopes and intercepts of calibrations cal­
culated by regression analysis. A calibration graph obtained 
using anthracene is illustrated in Figure 3.7, where peak 
height ratios were used. Peak area calibrations were also
115.
Figure 3.6. Ratio of Gentamicin Component to Undecylamine 
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Figure 3.7. Aqueous Calibration of Gentamicin Components 














simultaneously performed to assess the relative precision of 
the two calibration methods. Four calibrations on consecutive 
days were compared with the height measurement showing a 7% 
variation in the slopes determined whilst the variation was 
13% for the area measurement. Despite this area determinations 
were continued with in case of an alteration in component 
retention. Anthracene, when used in the assay of the genta^ 
micin sulphate commercial material, produced results with 
large standard deviations. This error was thought to arise 
because of the absence of reaction of anthracene with the OPA 
reagent, limiting the compound to a standard of volume but not 
of the reaction. It was therefore apparent that anthracene 
was only partially successful as a standard and that an 
amine which reacted with OPA was required.
Retention data shown in Figure 3.5 suggested that undecyl- 
amine or tridecylamine might be suitable to act as an internal 
standard. Accordingly calibrations were carried out with both 
these amines present to assess their suitability. A chromatogram 
of the two standards with the gentamicin components is shown 
in Figure 3.8, with undecylamine eluting as the third'peak 
and tridecylamine as the last. Results using tridecylamine 
as standard were subject to large coefficients of variation, 
but undecylamine showed higher precision, probably because of 
its narrower peak width. A peak height calibration using undecyl­
amine is shown in Figure 3,9. The mean of four such calibrations 
was taken for both peak height and area, and used in the assay 
of component ratios. The figures used are shown in Table 3.1.
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Figure 3.8. HPLC Chromatogram of Undecylamine and
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Figure 3.9. Aqueous Calibration of Gentamicin Components 
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The larger variation in the gentamicin calibration is probably 
because of the poorer peak shape in relation to the other two 
components.
Table 3.1. Undecylamine Calibration Means (n = 4)
Gent Cla
PEAK HEIGHT 
Gent Cg Gent C^ Gent C, la
PEAK AREA 
Gent Cg Gent C^
Slope 0.01517 0.02016 0.00754 0.01278 0.01810 0.01485
Intercept -0.00761 0.00107 0.04624 -0.00801 0.00871 0.0779
% CV 4.6 2.0 15.2 7.2 7.6 12.4
These calibration figures were used to calculate the levels 
of components by the equation:
Concentration Ratio-intercept a x F x 0.88 100 25= - .......—  X ' " " X   X —of Component slope 1.1 56 wt
here ratio is determined ratio of component to undecylamine 
a is fraction of component present in calibrations 
(C^^ = 0.3, C^ = 0.36, C^ = 0.44)
F is weight factor of component standard solution 
wt is weight of sample in the 25 ml solution 
0.88 refers to proportion of moisture in standard 
100
56 is the conversion of the base to sulphate
The conversion factor of base to sulphate was calculated 
as follows : The sulphate content of the samples was assumed
121
77 78to be 32% w/w from reported results ' . The percentage
moisture content was set at 12% as determined by the supplier 
using the Karl-Fischer titration method^^ and confirmed by loss 
of weight on drying determination^^. Thus 44% of the sample 
was thought to not be gentamicin base. The separate genta­
micin components used to produce the standard solutions were 
also found to contain about 12% moisture. This could not be 
accurately determined because of the low sample weight available 
(50 - 150 mg) and also the melting of the individual components 
at 105°C presented experimental difficulties.
The component composition of six samples of gentamicin 
sulphate powder of two manufacturing sources and one sample of 
possible Chinese origin were determined. The former six 
materials were assayed on three separate days in duplicate by 
peak area and height measurement and all).results combined to 
give the mean value. The Chinese material was only assayed 
by height measurement, repeated five times. The results 
are shown in Table 3.2.
Table 3.2. Component Levels in Gentamicin Sulphate Material
Sample (%) Cg (%) c^ (%) Total C Stand Dev.
A1 26.0 38.9 35.1 100.0 2.4
A2 26.3 40.6 37.3 104.2 3.1
A3 24.3 38.5 35.0 97.8 3.2
B1 27.2 36.2 30.2 93.6 3.8
B2 24.9 40.5 29.3 94.7 4.2
b3 26.9 37.7 28.7 93.3 3.1
Chinese 18.9 37.3 19.7 75.9 2.7
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The standard deviation was greater than expected and 
probably was a combination of the variation in the three separate 
calibrations required for the calculated total, and the interday 
variation. The three samples from manufacturer 'A' are similar 
in composition and show a higher gentamicin content than 
the samples from manufacturer 'B'. The total gentamicin C content 
of the samples from manufacturer A also seem to be higher than 
those from B, though since sulphate levels were not determined 
it cannot be stated categorically. The Chinese material showed 
a marked reduction in the total gentamicin C content, and this 
was confirmed by TLC which revealed very high minor component 
levels. Table 3.2 can be converted to component ratios 
by dividing by the respective gentamicin C totals to give 
Table 3.3.
Table 3.3. Component Ratios of the Commercial Samples
Sample  ̂ ^la % C 2 % C^
A1 26.0 38.9 35.1
A2 25.3 38.9 35.8
A3 24.9 39.3 35.7
B1 29.1 38.7 32.2
B2 26.3 42.8 30.9
B3 28.8 40.5 30.8
Chinese 24.9 49.1 26.0
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The samples of manufacturer A show very similar component 
profiles illustrating low batch variability. The samples from 
manufacturer B do not exhibit such small variation but are 
probably within acceptable limits. There is obviously some 
difference between the two sources but this is unlikely to 
provoke widely differing clinical responses. The Chinese 
material, however, is markedly different from the other two 
sources, with a very high gentamicin C^ content and low C^ 
content. If the toxicity profiles of the components are 
different then the Chinese material would be likely to have 
differing properties to the two other sets of materials.
When a Hypersil column was used instead of a Spherisorb
column, using otherwise identical conditions, the order of
retention was altered with the gentamicin Ĉ  ̂peak eluting
before the C and C_ peaks. An extra peak was also observed la 2
to be partially separated from the gentamicin C^ peak and
this was thought to be due to gentamicin C . This was
82reported to be separated by Freeman who also used a Hypersil 
column. A chromatogram of the retention of the gentamicin 
components on the Hypersil column is given in Figure 3.10.
A full component analysis was not performed on this column 
because no standard for gentamicin C^^ was available and 
also because of the absence of a baseline separation between 
the gentamicin C^^ and C^ components. However an estimation 
of the percentages of gentamicin C^ and C^^ was made by ref­
erence to the component ratios already found for A1 and Bl,
The approximate levels are given in Thble 3.4.
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Figure 3.10. HPLC Chromatogram of Gentamicin Components 
on a Hypersil Column
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Table 3.4. Gentamicin and levels in commercial samples







The relative composition of samples from sources A and B
are similar to each other, but quite different from the other
two sources. The Chinese material had a very high gentamicin
C^^ content especially in comparison to the C^ level. Similar
79values have been reported by White in commercial preparations
though none with the same high ratio of C^^ to C^. The Italian
sample, conversely, has a lower C^^ to C^ ratio than that of the 
A/B sources. This :^stem is thus useful for estimating the 
content of gentamicin C^^ in commercial samples which is 
difficult to achieve using other methods.
Assay of Gentamicin Injection
Two ampoules of the same batch of 40 mg/ml gentamicin 
injection were analysed for gentamicin C component levels.
The calibration figures of the undecylamine peak height ratio 
were used to calculate levels from the equation:
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ratio - intercept ^ a „% component =  :-------------x 0.99 x  ̂ x F.slope 1.1 1
where a has the same value as used previously
F^ is weight factor of the component solutions.
The 0.99 figure in the equation refers to an estimated 
1% water content in the standards because the components were 
lyophilised immediately prior to solution preparation. A total 
of four determinations on each of the ampoules was performed, 
and as no significant difference was detected the results 
were combined. These results are given in Table 3.5 with 
component percentages of total C component given below that 
of the calculated percentage in the injection.
Table 3.5. Component levels in gentamicin injection
Gent C^^ Gent Cg Gent C^ Ctotal Stand. Deviation
% calculated 21.2 49.9 34.5 105.6 2.04
Component i 
ratio 47.3 32.6 100 -
The determination of total component composition for 
injections of gentamicin is by potency test in the and
these limits, related by logarithms, cannot satisfactorily be 
applied to this HPLC assay. The component ratio volumes 
reveal a very high gentamicin content and low gentamicin 
C^^ levels when compared to the values in Table 3.3. It is
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another indication of the potential for variation in the compo­
sition of gentamicin C samples available commercially.
The HPLC assay used in this quantitative determination of
commercial samples proved to be very useful in discovering the
major component ratios, although definition of total gentamicin
C content in the samples was not as satisfactory, primarily
because of the lack of major components in a pure state. The
use of undecylamine as internal standard was successful, although
no clear advantage of peak area measurement was observed which
may be related to the lack of a total baseline separation of
the gentamicin C^^ and C^ components. The levels of major
components calculated were similar to those reported in the
literature and conformed to the FDA regulations^^ regarding
component composition. The disadvantage of the HPLC system
used, in not separating gentamicin C was not felt to be a2&
major drawback. This was because column responses would have 
to be estimated in the absence of a Ĉ ^̂  standard and the lack 
of literature information on the component would signify 
uncertainty as to whether high or low levels were deleterious 
to the sample.
3.3.2 High-performance Liquid Chranatographic Analysis of 
Gentamicin in Blood Plasma
In order to assess HPLC as an assay technique in the 
determination of gentamicin in blood plasma, a suitable separation 
method of the drug from constituents of plasma was required. 
Various methods from the literature as well as developed
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methods were investigated. Certain requirements were set to 
ensure relevant clinical performance. The most important 
aspect of the techniques used was the precision of the method. 
Crude precision tests were performed by comparing peak heights 
for replicate assays to give an indication of the variability 
and this was reinforced by studying the steps involved in each 
method. The sensitivity of the method was also considered to 
be very important, especially since it is related to precision 
at low concentrations where small measurements of peak height 
have to be made. An arbitrary scale of peak heights was 
devised to compare the assay methods investigated with the 
assay method finally chosen, in terms of sensitivity. Specific 
recovery experiments were not performed^because this was con­
sidered a less important aspect of the method. One hundred 
per cent recoveries were not sought but the variability of the 
recovery had to be low, and the sensitivity high. Estimated 
recoveries for each method are given, calculated from the 
recovery experiment on the chosen assay method and the 
sensitivity value with respect to that method. Qualitative 
aspects of the methods were also assessed in terms of ease of 
use, number of transfers and amount of labour required
The three quantitative parameters used to compare:the 
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Extraction onto a Silica Coluipn
This method summarised in Figure 3.11 was used by 
223Maitra et al. to separate gentamicin fron the plasma before 
derivatisation with OPA. Table 3.5 shows that although the 
sensitivity and recovery were good the precision was low.
233This lack of reproducibility was also described by Marples
and may have arisen from differing adsorption of the gentamicin
179to the silica column. Delaney et al. used silicic acid 
as a suspension to extract gentamicin, but this method was 
not examined in this study. A Sephadex column was utilised 
in a similar manner as in Figure 3.11, but even lower precision 
was achieved. The methodology was promising in terms of 
sensitivity and ease of use but the lack of precision appeared 
insurmountable.
Acetonitrile Precipitation and Ethyl Acetate Extraction
231 232The methods of Back and Haughey for isolating
aminoglycosides were assessed for suitability as a clinical
assay. The extraction procedures for each are comparable with
231Back's method shown in Figure 3.12 . Haughey's extraction
procedure differs only in the quantities of solvents used and
the final extraction being into isopropanol instead of ethyl 
232acetate . With ethyl acetate extraction only one peak in 
the position of gentamicin was distinguishable by HPLC, 
though all three components were confirmed to be present, by 
evaporating the ethyl acetate and redissolving in methanol.
It seems most likely that the high solvent strength of the ethyl
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Figure 3.12. Acetonitrile Protein Precipitation, Ethyl Acetate 
Extraction.
PLASMA (0.2 ml)
^  0.1 M PHOSPHATE BUFFER
(pH 11.0)
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1 ml + 3 ml ACETONITRILE
i
CENTRIFUGE 
2,500, rpm 5/10 MIN
PRECIPITATE ^
DISCARDED i












FILTERED AND INJECTED (100 yl)
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acetate eluted the components more rapidly and caused the earlier 
eluting and components to merge with highly fluorescent 
material near the solvent front. The use of isopropanol for 
the final extraction produced peaks for all components, but 
the high salt content of the aqueous solution, required for 
efficient partition, into this solvent, led to excessive 
extraction of other fluorescent material into the organic layer. 
The phosphate buffer used in both assays was precipitated by 
the acetonitrile and may have interfered with the protein pre­
cipitation. Precipitation with acetonitrile did not seem to be 
compjiete because of the cloudy supernatant produced. Extraction 
with methylene chloride was difficult as an emulsion formed 
easily with too much mixing. Spiking of the sample at each 
stage in the procedure showed a significant loss at the methylene 
chloride extraction. This may account for the sensitivity not 
being as high as expected and a high coefficient of variation 
for three samples of 10 yg/ml concentration (Table 3.6). The 
entire method was thought to be too labour intensive and un-n. 
suitable for clinical determinations. The large number of 
transfers suggests that a high precision would be very difficult 
to achieve;;,.
Trichloroacetic Acid Precipitation and Diethyl Ether 
Extraction
Despite the many disadvantages of the extraction 
method it is desirable because of the removal of interfering 
substances and also to protect the HPLC column from irreversibly
134
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bound compounds. Thus a superior protein precipitation tech­
nique was required, coupled with a reproducible extraction method
The developed method is shown in Figure 3.13. Trichloroacetic
217 218acid (TCA) is a well known precipitating agent ' and has
77been used with gentamicin in a previous study by Kraisintu
The TCA was dissolved in 80% v/v methanol because it en­
hanced precipitation over the aqueous analogue and produced a 
clear supernatant. Prior to reaction with OPA, borate buffer 
(pH 10.4) was added to neutralise excess TCA and maintain an 
alkaline pH. The reaction was allowed to continue for only 
twenty minutes in order to restrict total assay time to a 
minimum. The ether added was easily separated from the aqueous 
layer and evaporated by nitrogen within five minutes. Initially 
only 2ml of ether was used to extract the gentamicin derivatives 
but this gave a low recovery and a large coefficient of variation 
at 10 yg/ml (Table 3.6). The reproducibility of ether ex­
traction was monitored using aqueous solutions of gentamicin 
and larger volumes of ether were found to be required. The 5 ml 
of ether finally adopted increased the recovery, with only a 
8% coefficient of variation for six samples at 10 yg/ml (Table 
3.6). This method was thought suitable for clinical use in 
terms of ease of handling and performance. However the ether 
extraction seemed to accumulate other constituents of the 
plasma as signified by the large, highly fluorescent peak 
at the beginning of the chromatogram (Figure 3.14). Thus the 
ether extraction was of questionable value in protecting the 
column. The extraction step was also thought to be susceptible
136,
Figure 3.14 . HPLC Chromatogram of Gentamicin in plasma using
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to environmental changes and interday precision may have 
suffered.
Trichloroacetic Acid Precipitation with No Extraction 
This was a modification of the scheme shown in Figure
3.13 with the extraction procedure omitted and the volume of 
reagents reduced to a minimum to achieve adequate sensitivity.
The method developed for plasma assays was as shown in Figure 
3.15. Levels as low as 0.5 yg/ml could be determined although 
the precision was poor at this concentration. The average 
percentage recovery of the components using this method was 
106% as determined by comparison with an aqueous calibration.
The slight excess was probably due to the exact volume of 
supernatant produced being unknown, but taken as 0.4 ml. A 
good recovery is thus observed, suggesting that if plasma 
binding of gentamicin does occur, it does not interfere with 
the assay. Undecylamine internal standard had to be added 
after protein precipitation because of extensive protein binding 
of the compound if added before. This method required about —
1^ hours for a single assay but involved few manipulations and 
thus several assays could be performed concurrently. In practice 
one worker could complete twenty-five single assays in a day.
A typical chromatogram of a 2.5yg/ml sample is illustrated in 
Figure 3.16.
138,
Figure 3.15. Trichloroacetic.Acid Precipitation, No Extraction.
PLASMA (0.5 ml)
0.25 ml TCA. (10% w/v)





+ 4 yl UNDECYLAMINE
+ 0.25 ml BORATE BUFFER (10.4)
+ 0.50 ml OPA REAGENT
+ 6.80 ml METHANOL
LEAVE FOR SIXTY MIN.
FILTER AND INJECT (100 yl)
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Figure 3.16. HPLC Chromatogram of Gentamicin in plasma 
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Calibration for Plasma Assay
A series of calibrations in the range of 1 - 10 yg/ml 
were run with the spiked samples. A plot of one such calibration 
is illustrated in Figure 3.17. The parameters utilised for 
measurement were the peak height ratio of component to internal 
standard, and just the peak height of component without reference 
to standard. The latter was used in case the undecylamine 
showed variation in response due to unusual plasma binding.
The mean of eight calibrations was taken to provide regression 
values as shown in Table 3.7 .







Ci^/UND Cg/UND c ^/und:
Slope 8.750 13.250 6.570 0.1038 0.1697 0.0768'
Intercept 6.062 21.882 3.856 0.0680 0.2413 0.0587
% C.V. 10.3 7.5 6.5 8.0 7.3 6.5
The sloping baseline of the chromatogram meant that peak 
height measurement offered greater accuracy than peak area 
measurement. The high intercept observed for the gentamicin 
C^ was consistent and must have been due to an underlying 
peak which was undetected. The calibrations run on separate 
days indicated a stable system and so during the analysis of 
clinical samples, calibrations were not made each day. Instead 
to test the relative daily column response, standard spiked
141,
Figure 3.17. Calibration of Gentamicin Components in plasma 














plasma samples of 2.5 and 7.5 yg/ml were injected after every 
two patient samples. The mean of all of the standards used in 
a day was 'i compared with the expected value for all components 
and both sets of calibrations. The discrepancy of the observed 
and expected values was converted to a factor to adjust all of 
the days samples to the calibration figures of Table 3.7. This 
procedure saved time in performing a single calibration and 
was more flexible in that the columns response over a whole day 
was averaged. The mean of all of the factors used on the nine 
days of plasma sample assays are given in Table 3.8.
Table 3.8. Mean of factors used to correct calibration
^la C1
C^^/UND Cg/UND C^/UND
X 1.051 0.811 1.066 1.580 1.154 1.495
% CV 13.2 21.3 7.7 12.8 16.9 9.3
The factors used are seen to have varied significantly during
the sample analysis, with the gentamicin component experiencing 
large changes. In relation to the other two components it had 
decreased in size, although the reason for this is unclear.
It is also evident that the undecylamine peak height was reduced 
in respect to the gentamicin components from the calibrations.
A cause may have been increased protein binding even though 
the methodology was constant throughout. The intra-assay and 
inter-assay variance of the injected standards were calculated 
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The intra-assay coefficient of variation for four samples of 2.5 
and 7.5 yg/ml was 5.1% and 8.3% respectively. The coefficient 
of variation of the interassay study of twenty determinations 
analysed on five consecutive days is given in Table 3.9, for 
both sets of calibrations. These figures were taken from the 
standards used and thus also include a measure of the precision 
throughout the day.
The interday assay figures reflect the variation in response 
of the system, with the lower concentration range especially 
susceptible. The undecylamine when used as an internal standard 
only added to the variation and this was probably related to 
the protein binding effect. Table 3.9 also shows the expected 
concentration of the individual components calculated from 
composition of standard gentamicin solution used. There is no 
apparent trend between the observed and expected concentrations 
except that the gentamicin component is the most accurately 
defined. This is not unexpected because unlike the other two 
components the gentamicin peak is not on the tail of the 
solvent front peak. The percentage accuracy with 95% confidence 
intervals is given in Table 3.10, calculated from the values 
obtained in the precision studies.
Table 3.10 Accuracy of assay method
Strength
(yg/ml) % Accuracy Confidence Ints.
Interassay 2.5 99 ± 7.5
(n=20) 7.5 97 ± 4.1
Intra-assay 2.5 97 ± 7.1
(n=4) 7.5 98 ±11.5
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The accuracy in both cases is good and further justifies 
the use of standards instead of daily calibrations. The factors 
which are calculated from these standards can adjust the cali­
bration to optimise the accuracy. This compensates for the in­
herently poor precision which may be due to column instability 
caused by the elution of methanol at the end of each day, to 
remove a build-up of bound material.
Assay of Patient Blood Plasma Samples 
To assess the performance of this HPLC assay a 
total of sixty-four samples of plasma, from five patients 
receiving gentamicin therapy, were assayed for gentamicin.
The determinations were in duplicate, assayed blind, and cal­
culated using peak height measurement with and without internal 
standard. The results obtained were compared with those found 
by microbiological assay, supplied by Dr. D. Scott, The 
General Hospital, Birmingham. Only fifty-seven of the readings 
determined could be compared with those found by microbiological 
assay. The regression of the values found by HPLC on those of the 
microbiological assay is shown in Figure 3.18. The value of 
total regression analysis and individual patient regression 
is given in Table 3.11. The slopes are all similar in magnitude 
though variation is seen between patients. The different 
slopes obtained for the various patients may be a measure of 
the variation in column response or due to the differing compo­
sition of the individual patients plasma.
Figure 3.18. Regression of HPLC Assay on Microbiological 













Table 3.11. Regression of HPLC on Microbiological method
Patient r Slope Intercept n
Total 0.958 0.669^ 0.177 57
Patient A 0.978 0.746^ -0.461 11
Patient B 0.978 0.761^ 0.048 13
Patient C 0.971 0.611^ 0.363 13
Patient D 0.964 0.691^ 0.129 13
Patient E 0.917 0.497^ 0.936 7
1. p < 0.01, Students t-test
The total correlation coefficient (r) is significant 
(p O.Ol) and suggests that the HPLC assay is comparable to 
the microbiological assay. However the slopes of the regression 
are significantly different from unity in all cases (p < 0.01) 
as indeed is the total slope.
Various explanations can be proposed for the slopes not 
equalling unity. Firstly the samples were old and had been 
stored at c -20°C for about four years. In this time the samples 
may have deteriorated with gentamicin binding irreversibly 
either to plasma constituents, or to the glass vials the 
plasma was stored in. Secondly, if high concentrations of peni­
cillin were present, the well documented inactivation of 
gentamicin may have occurred^^^ 138^ Lastly, it could be 
an indication of a methodology difference due either to the 
different properties assayed or caused by a difference in standards,
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It was observed that freezing the plasma, after spiking
with gentamicin standard solution, decreased the peak height
of the components, as measured by HPLC.This may have arisen
from adsorption of gentamicin, but standards used for the
calibration were stored frozen before use to overcome this loss.
No significant loss of gentamicin was observed for frozen
samples in the short term (seven days). However study of
the storage characteristics up to 3 months produced results
too variable to quantitate, but revealed no apparent trend in
242deterioration. One study in the literature , using a 
bioassay found no loss on storage for two days in plastic or 
glass containers at -20°C, 4°C and 25°C. However decrease in 
the gentamicin level was observed when carbenicillin was present 
(> 500 yg/ml) at all temperatures. A study^^^ comparing the 
EMIT method with the bioassay found a relationship with a 
correlation of 0.96 and slope of 0.91 when assayed on the 
day of collection. However when specimens were stored at -60°C 
for one to sixty three days before EMIT measurement the corre­
lation was 0.95 with a slope of 0.69. This compares with a 
slope of 0.67 for the similar regression of HPLC on the micro­
biological results observed here. The authors of the paper 
ascribed the loss of gentamicin to a general phenomenon on 
freezing and not to a difference in the two techniques. However
some other comparisons in the literature also show similar
177differences. In a paper by Mannisto the slope of EMIT 
results regressing on the bioassay is 0.67 (r = 0.92, n = 62). 
Here the bioassay was performed on the day of collection and 
the EMIT methods on samples stored for 1 - 2  months at -27°C.
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However the slope of the EMIT results regressing on a fluoro-
immunoassay was only 0.78 (r = 0.86, n = 62) where the samples
were stored identically. This variation in the calibration
212of different methods is also shown in another paper where
the regression of a fluoroimmunoassay on a bioassay for amikacin
has a slope of 0.69 (r = 0.81, n = 160). This difference was
attributed to a difference in standards, and although this is
plausible for radioimmunoassays it is less likely here.
Studies in the literature do not report many direct comparisons
of the EMIT method with a bioassay, and although many papers 
221 227 231 233of HPLC methods ' ' ' have reported good correlations
with slopes close to unity, in respect to the bioassay, the
discrepancies noted here do cause concern. This was highlighted
243in a paper by Faber et al. where the bioassay was found not 
to agree with results determined by HPLC. A comparison showed 
the HPLC method to agree with the EMIT method and to be highly 
specific, especially in the presence of other antibiotics.
It was suggested that, with gentamicin present, the penicillins 
were not totally inactivated by penicillinase and gave falsely 
high readings for the bioassay.
In this study the difference between the two methods may be 
explained in a number of ways, but the most feasible is that 
of a loss on freezing as noted in other pepers.
The time course of the gentamicin concentration in plàsma 
can be plotted though more results would be required for a 
complete analysis. The decay curve is typical for aminoglycoside
150.
administration and is described by a two compartment open model
118which accounts for tissue accumulation of gentamicin . However 
for simplicity, and insufficient time points it is here
119assumed to follow a one compartment model with the equation :
C = Be
where C is concentration in plasma
B is extrapolated concentration at t = O 
3 is apparent elimination rate constant 
t is time after administration
For patient B a time course curve is shown in Figure 3.19. 
This can be translated to a linear format by taking logarithms.
In C = In B - 3t
The plasma half life (t̂ ) and apparent volume of distribution 
(V̂ ) can be calculated from:
0.693t, = -3
and
From the plasma concentrations determined by the assay, 
estimates of these pharmacokinetic parameters were made as 
defined in Table 3.12. As slopes were estimated from three
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points, in some cases, the results were not regarded as accurate.
Table 3.12. Calculation of pharmacokinetic parameters
Patient n r t^(hr) %  (1) V^^%)
A 4 0,994 1.65 11,82 24
A 3 0,922 1.31 2,60 5
B 4 0,988 2.75 21.06 36
B 5 0,911 1.45 10.94 19
C 3 1,000 2.54 20,39 25
C 3 1,000 2,17 20,87 28
c 3 0,996 4.04 12,87 16
D 7 0,948 1,31 19,25 31
D 3 0,999 1,59 12,52 20
E 6 0,966 3,23 23.05 33
The values reflect the variation due to the small sample
size and the use of the one compartment model. The average
mean half life in the patients, using HPLC , was 2,20 ± 0.66 
compared to 2,44 ± 1,02 found by the microbiological assay. 
These figures compare well with the expected value of hbout 
two hours for individuals with normal renal function^^^.
The apparent volume of distribution also varied due to the 
small sample size but the average of 23,7% is close to the 
20% value reported for the aminoglycosides^^^, With more 
readings for a single injection a more accurate estimation
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of the pharmacokinetic parameters could be made. It does, 
however, illustrate the usefulness of determining the plasma 
concentrations for aminoglycosides. These values can be deter­
mined by any of the plasma assay techniques, yet only HPLC can 
offer the estimation of individual component parameters.
Using the peak height determinations of the individual 
components a plot of component concentration against time 
could be produced as in Figure 3.20 for patient D,
Assuming again, the one compartment model, the half-life 
and apparent volume of distribution can be calculated for the 
components and patients. These values are given in Tables
3.13 and 3.14. The volumes of distribution were calculated 
by assuming the gentamicin administered to be composed of
Table 3.13. Half life of components in patients
Patient t%(Cla)
A 1.99 1.51 1.99
1.56 0.73 1.36
B 3.82 1.73 2.11
B 1.81 1.61 1.09
C 4.42 2.65 1.80
C 3.31 1.54 1.64
C 4.25 3.42 3.35
D 1.88 1.37 1.18
D 2.54 1.16 1.71
E 5.58 3.66 2.22
X 3.12 1.94 1.85
Stand. Dev. 1.37 0.97 0.65
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Table 3.14. Volume of Distribution of Components
Patient
(litres)
^la s Cl ^2 Cl
A 13.54 18.45 14.89 27.1 36.9 29.8
A 3.52 0.38 2.82 7.0 0.8 5.6
B 23.88 19.66 15.90 41.1 33.9 27.4
B 12.11 12.86 7.88 20.9 22.2 13.6
C 26.57 23.42 14.53 33.2 29.3 18.2
C 25.96 19.51 20.60 32.5 24.4 25.8
C 12.66 11.13 10.02 15.8 13.9 12.5
D 16.54 20.92 19.16 26.7 33.7 30.9
D 15.40 10.12 13.68 24.8 16.3 22.1
, 25.10 28.05 _ 20.63 35.7 39.8 29.3
X 17.53 16.45 14.01 26.48 25.12 21.52
the mean of the composition of samples A1 - B3 in the component 
analysis section because the composition of the injection 
was unknown. That is 26.7% C^^y 39.9% C^ and 33.4% C^. It 
is apparent from Table 3.13 that gentamicin C^^ has a longer half 
life than the other two components, even though the figures 
are only estimates. Riff and Jackson^^^ noted that patients 
with normal renal function could be divided into those with 
an accelerated response, those with a typical response and 
those with a damped response in terms of the gentamicin plasma 
concentration profile. They postulated that the difference
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could be due to a reversible binding of gentamicin by constituents 
of blood, possibly the red blood cells. Such binding may also 
account for the relative differences in half life of the individual 
components.
Lachatre et in experiments on rabbits found that
the cumulative urinary elimination of gentamicin C^^was signi­
ficantly lower than for the other two components. This was partly 
explained by a greater renal accumulation of the conponent.
The volumes of distribution calculated for the components given 
in Table 3.14 are relatively similar with the gentamicin 
having the smallest volume. If gentamicin was bound to a 
larger extent in another compartment the volume of distribution 
should be larger. That this is not the case suggests the 
components behave in a comparable manner in terms of tissue 
di stribution.
The HPLC method developed for the assay of gentamicin in 
plasma proved to have good accuracy with a high correlation with 
the microbiological assay. The difference between the two 
methods is relevant and the possible loss of gentamicin on 
freezing warrants investigation. The HPLC method was found to 
be useful in pharmacokinetic studies and pointed to possible 
differences in the handling of components which may be of 
importance in terms of relative toxicity.
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CHAPTER 4
ORTHO PHTHALALDEHYDE REACTION IN RELATION TO GENTAMICIN
4.1 Introduction
237The ortho-phthalaldehyde reagent (OPA), described by Roth
has proved to be extremely useful in the high-performance liquid
279—285chromatography (HPLC) of amines and amino acids . The fast
reaction with such compounds has made it an ideal reagent for
both post- and pre-column derivatisation^^^. The fluorescent
product exhibits an excitation maximum wavelength of 340 nm and
283 286—8an emission maximum at about 430 nm ' An excitation
maximum at 229 nm which is reportedly more intense than at 340 nm 
282also exists . However problems of interference at the lower 
wavelength by constituents of plasma have been envisaged. The
reagent used for derivatisation requires a thiol to be present
289with the dicarbonyl aromatic, before an amine is added . If
the amine is added before the thiol, the fluorescent yield is
289reduced, probably because of a different reaction pathway
The nature of the thiol used can have a significant effect on
the maximum emission wavelength, whilst the amine is less
285critical in this regard . Alcohol has been reported to
enhance the fluorescence produced, whilst a solvent such as
chloroform can quench The pH of the reaction
has also been discovered to be an important determinant of
283 286fluorescence yield and stability of the product ' . The
fluorescence produced is diminished below pH 7.5 and boric 
acid as a buffer species is thought to promote greater stability 
than phosphate^^^'^^^. The amine involved in the reaction 
can affect the stability of the product since bulky groups
158,
adjacent to the amino function protect against decomposition289,290
The structure of the fluorescent product was discovered 
to be that of a l-alkylthio-2-alkyl substituted isoindole (4.1) 291
(4.1) (4.II)
This structure was postulated by Simons after examination
of the product by high resolution mass spectrometry, proton
291nuclear magnetic resonance and infra-red spectroscopy 
Mass spectrometry defined the molecular formula, whilst the 
infra-red failed to show adsorption bands due to carbonyl or 
sulphydryl groups, thus eliminating some structural possibili­
ties. The proton NMR spectrum revealed a 2:1:2 proton split
in the aromatic region which was in accord with the spectrum
^ ^ , 292-3of isoindole
Isoindole is an unstable compound with a tendency to
form the isoindolenine isomer (4.II) instead of the o-quinoid 
293,296form . Substitution at the nitrogen is known to stabil-
293ise the isoindole structure , and substitution of the thiol
289at the 1 position probably exerts a similar influence . The 
extended conjugation of the molecule (4.1) is responsible 
for the observed spectral characteristics.
159,
The fluorescent product of the OPA reaction undergoes
photodecomposition, which may arise from intramolecular attack
289by the hydroxy group of the mercaptoethanol , or to inter-
290molecular attack by excess OPA . The mechanism of both 
reactions could be by nucleophilic addition.
The gentamicin-o-phthalaldehyde derivatives when assayed
223by HPLC have shown different retention orders. Maitra 
231 233and others ' , have reported the gentamicin derivative
to elute first, followed by gentamicins C and C . However,
7 7 78in the assays reported in Chapter 3 and in a previous study ' ' ,
the order of elution was gentamicin C^^, C^ with C^ last to 
elute. Since nearly identical conditions to those of 
Maitra were used, it was important to determine the source of 
this variation, to ensure integrity of the assay procedure.
The difference in retention order may have arisen from either 
distinct reaction products, or frcxn a variation in column 
response to the derivatives. Before the latter could be fully 
investigated the former potential source of inequivalence 
had to be eliminated.
It is known that the OPA reagent will only react with
primary amines to form the fluorescent product; secondary
291amines being unsuitable as substrates . The gentamicin C 
and C^ components each have four primary amino functions on 
each molecule, whilst gentamicin C^ has only three. Thus if 
all groups were reacted to form the hydrophobic isoindole 
functions, the retention order on a reverse phase column
160.
would be expected to be C^, then . However, if not all
of the primary amino groups on the components reacted, perhaps 
for steric reasons, then the retention order would be C , C2
then C^, if an equal number on each component reacted.
The estimation of the extent of the reaction was believed 
to be best accomplished by use of proton NMR. Figure 4.1 illus­
trates the 60 MHz spectrum of o-phthalaldehyde (OPA) in chloro­
form. The aromatic protons are distinguished by a multiplet 
at 67.7 to 8.3, and the aldehyde protons as a singlet at 610.68.
It was thought that the reaction could be easily followed by 
the disappearance of the aldehyde protons, whilst the gentamicin 
concentration could be monitored by the C-methyl peak at 61.18 
common to all three of the gentamicins. However, Figure 4.2 
shows the proton NMR spectrum of the reaction mixture equivalent 
to that used in the HPLC derivatisation method. It is clear 
that the aldehyde protons are no longer present, though a 
peak at 66.63 may represent the same protons. The aromatic signals 
are also simplified to a single broadened peak at 67.53.
Triplets at 63.7 and 62.7 are due to the methylene groups of
mercaptoethanol. This spectrum was thought to belong to a
289reactive species not described by Simons , which raised the 
possibility that a different pathway to that proposed by him 
was occurring with the reaction mixture. The reaction mixture 
required another measure of the extent of depletion of OPA 
during reaction with amines, and thus an investigation of the 
nature of the reaction mixture was made, using NMR.































of estimating the extent of reaction of gentamicin with OPA 
were sought. The feasibility of using fluorescence yield 
produced by the individual components as such a measure was 
investigated. Another spectroscopic method of assessing the 
extent of reaction was to use ninhydrin as a marker of un­
reacted amino groups. This presumed that ninhydrin would 
react with all of the primary amino groups on the gentamicins 
and fail to react with secondary functions.
4.2 Materials and Methods
4.2.1 Materials:
Ortho-phtha1aIdehyde (Sepramar), boric acid, 
mercaptoethanol, potassium hydroxide and Zerolit 325 (Ĥ ) 
resin were all obtained from BDH Chemicals Ltd. Deuterium oxide, 
methanol-d^, acetonitrile-d^ were supplied by the Aldrich 
Chemical Company Ltd. Methoxyethanol was obtained from Koch 
Light Laboratories Ltd.
4.2.2 Methods :
4.2.2.a.Nuclear Magnetic Resonance Study of the Reaction 
Nuclear Magnetic Resonance
Proton 60 MHz spectra were determined on a JEOL 
PMX 60 SI spectrophotometer. Mr. H. Hartnell determined the 
carbon-13 NMR spectra on a JEOL FX 90Q Fourier Transform NMR 
spectrometer, in the School of Pharmacy and Pharmacology, 
University of Bath.
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General Reagents and Solutions for NMR 
Deuterium Oxide Buffer (pH 10.4)
Boric acid (1 g) was dissolved in distilled water 
(38 ml). The pH was adjusted to 10.4 with the use of a 45% w/v 
potassium hydroxide solution. Buffer solution (2 ml) was 
transferred to a flask and lyophilised. Deuterium oxide (2 ml) 
was used to redissolve the residue and the solution was again 
lyophilised. Deuterium oxide again was used to effect solution, 
which was stored in a desiccator.
Ortho-phthalaldehyde Reagent (OPA)
A general preparation used in the NMR studies 
was ortho-phthalaldehyde (35 mg) dissolved in methanol-d^
X150 Tjl) in a UMR tube. To this mercaptoethanol (20 mg) and 
deuterium oxide buffer (pH 10.4), 150'-(jl, was added. Stability 
was adequate for several hours if protected from iight.
Proton NMR Instrument Settings 
Sweep width: O - 600 Hz
Sweep rate: 2.4 Hz/sec
Filter: 20 Hz
H^ Level: 0.5
Phase: Pure Absorption Waveform
Amplitude : X 10
Internal Standards: sodium-3-trimethyl silyl propane
sulphonate (DSS) or tetramethyl- 
silane (TMS)
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Proton NMR Samples 
Individual Reactants
Ortho-phthalaldehyde, mercaptoethanol and the amines 
used in the reaction were measured in various solvents depending 
on solubility. Amines used in the reaction apart from the 
gentamicin components were methylamine hydrochloride, butyl- 
amine, isopropylamine, glucosamine hydrochloride and ethanolamine.
OPA Reagent
Variations in the concentration and stoicheometry 
of the reaction mixture were studied. These included different 
ratios of OPA to mercaptoethanol and variation in the composition 
of solvents used.
OPA Reaction with Standard Amines
Amines were added to an already prepared OPA reaction 
mixture, either by weighing or by volume. Various proportions 
of amine to ortho-phthalaldehyde were used and spectra were run 
within ten minutes of initiation of reaction.
OPA Reaction with Gentamicin
Gentamicin (40 mg) was dissolved in deuterium 
oxide buffer (pH 10.4), 20 yl and methanol-d^ (150 yl) in a NMR 
tube. OPA reaction mixture was prepared in a reaction vial 
by dissolving o-phthalaldehyde (45 mg) in methanol-d^ (lOO yl)
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and adding mercaptoethanol (46 yl). The OPA reagent was trans­
ferred by microsyringe to the gentamicin solution and the 
vial was washed with methanol-d^ (50 yl) and added to the NMR 
tube. Spectra were run within ten minutes. Gentamicin was
used in the same fashion except that 29 mg was used.
Carbon-13 NMR spectra
Samples of a similar description to those used in 
the PMR study were examined, except that acetonitrile was used 
instead of methanol as a co-solvent. Composition of each sample 
run is given:
(i) OPA (35 mg) in acetonitrile (200 yl)
(ii) OPA (39 mg) and mercaptoethanol (45 mg) in aceto­
nitrile (200y 1)
(iii) OPA (40 mg) and mercaptoethanol (23 mg) in deu-
teriated buffer (120 yl) and acetonitrile (120 yl) 
(ivj OPA (89 mg) and mercaptoethanol (52 mg) in
deuteriated buffer (150 yl) and acetonitrile (150 yl) 
(v) OPA (30 mg) and mercaptoethanol (18 mg) in
deuteriated buffer (150 yl) and acetonitrile (150 yl) 
Ethanolamine (14 mg) was added to the mixture after 
solution of initial components was complete.
Internal reference in the spectra was set to acetonitrile 
methyl peak taken as 1.07 ppm in respect to TMS by reference 
to methanol (49.5 ppm). Proton NMR spectra of these solutions 
were recorded first then carbon-13 NMR spectra were run within 
one hour of preparation.
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4.2.2.b Fluorescence Measurement of Gentamicin-OPA Reaction
A Perkin-Elmer 204A spectrofluorimeter was used to
measure the extent of reaction. Excitation wavelength was set
at 345 nm and emission at 440 nm with photomultiplier gain set
at 2, and sensitivity of 1 used. Solutions of gentamicin com-
-7ponents were prepared in concentrations of 5 x 10 M in 5 ml 
of ammonia-free methanol-water mixture (1:1). OPA reagent 
in the proportions of 4 molar and 3 molar equivalent with 
respect to each gentamicin component was added. The fluorescence 
obtained was measured 85, 110 and 120 minutes after the reaction 
started.
4.2.2.C Ninhydrin Reaction with Gentamicin 
Preparation of Ninhydrin Reagent:
The Ninhydrin Reagent of the British Pharmacopeia 
1980^^, was used in this determination. Preparation was as 
stated in Appendix lA^^ with the double distilled water used 
having first been freshly boiled and cooled.
Preparation of OPA Reagent:
0-phthalaldehyde (50 mg) was dissolved in methanol 
(1 ml). To this mercaptoethanol (0.1 ml) was added and the 
solution made to 10 ml volume with 0.4 M borate buffer (pH 10.4). 
The methanol had been shaken with a Zerolit 325 (H ) resin 
and filtered prior to use. The buffer was freshly prepared 
using boiled and cooled distilled water.
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Preparation of 95% Ammonia-free Ethanol-Water (1:1): 
Ethanol, 95% v/v, 50 ml was shaken with a Zerolit 
325 (Ĥ ) resin for five minutes, then allowed to stand for an 
hour with intermittent shaking. Water (50 ml) which had been 
double distilled was boiled and allowed to cool before adding to 
the filtered ethanol. All solutions were freshly prepared each 
day.
Gentamicin Standard Solutions:
Standard solutions for each of the three gentamicin 
components (C^^ÿ and C^) were prepared by dissolving base 
(20 mg) in water (10 ml) to give 2 mg/ml solutions.
Calibration of Ninhydrin Reaction with Gentamicin: 
Five aliquots of gentamicin component standard 
solution (15, 30, 45, 60 and 75 yl) were transferred to separate 
test tubes and the volumes made up to 1 ml with water. Ninhydrin 
reagent (1 ml) was added; the solutions mixed on a vortex 
mixer and placed in a boiling water bath for twenty minutes.
At the end of this time the solution was allowed to cool for 
five minutes then 5 ml of the 95% ammonia-free ethanol-water 
mixture was added. The absorbance was immediately measured on a 
Unicam SP 600 spectrophotometer at 565 nm using 1 cm matched 
cells against a blank prepared without the gentamicin present. 
This was repeated for all three components and a five point 
calibration curve was constructed for each.
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Ninhydrin reaction with Gentamicin in Presence of 
OPA Reagent:
To four test tubes containing 75 yl of the gentamicin 
component solutions were added varying amounts of OPA reagent.
For gentamicin volumes of 7, 15, 22 and 30 yl OPA added,
gentamicin volumes of 7, 14, 21 and 29 yl OPA added 
gentamicin volumes of 5,10, 16 and 21 yl OPA added.
After addition of the OPA reagent, water was added to give 1 ml 
of solution; this was vortex mixed and kept in the dark for 
fifteen minutes. At the end of this period, 1 ml of ninhydrin 
reagent was added, the solution mixed and put in the boiling 
water bath for twenty minutes. Throughout this period the 
solution was protected from cilight. After cooling for five 
minutes, the 95% ammonia-free ethanol-water mixture (5 ml) was 
added.- Absorbance was read at 565 nm against a blank.
A further five test tubes of the gentamicin components 
(75 y 1) had the following amounts of OPA reagent added, 
gentamicin 11, 22, 30, 34 and 37 yl 
gentamicin 11, 21, 29, 32 and 36 yl
gentamicin 8, 16, 21, 23 and 26 yl 
These were reacted as previously and the absorbances read at 
565 nm.
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4.3 Results and Discussion
4.3.1 Nuclear Magnetic Resonance Study of the Reaction
Mechanism between o-Phthalaldehyde and Primary Amines
4.3.1.a NMR of Individual Reactants:
The proton NMR of o-phthalaldehyde is shown in Figure
2974.1 and is in accord with published data . The proton spectrum 
of mercaptoethanol is illustrated in Figure 4.3. The singlet 
at 64.68 is the hydroxy proton whilst the neighbouring methylene 
group has a triplet at 63.7 with a coupling constant (J) of 
about 7 Hz. The other methylene group exhibits a signal at 
62.7 of two overlapping triplets. The thiol proton is seen as a 
multiplet at 61.8. In deuterium oxide solutions the thiol and 
hydroxyl protons are not observed, and the methylene groups 
appear as triplets at the chemical shifts indicated.
Ethanolamine, in acetonitrile/aqueous buffer, is similarly 
seen as two triplets at 63.6 and 62.7 (J - 7 Hz), with the 
hydroxy bearing methylene group giving the lowest field signal. 
The spectrum is shown in Figure 4.4.
Glucosamine gives a proton NMR spectrum as shown in Figure 
4.5, with a complicated splitting and overlapping of signals 
from 62.8 to 4.8. The anomeric proton is observed as a doublet 
(J = 4 Hz) at 65.5
Gentamicin C^, in deuterium oxide, exhibits a spectrum 
(Figure 4.6) similar to glucosamine. The large number of protons 
































































anomeric protons at 64.9 - 5.2 are readily seen, as are the 
singlets due to methyl groups at 62.58 and 61.14.
4.3.1.b NMR of o-Phthalaldehyde Reagent:
The composition of the OPA, in the reagent conditions 
used for pre-column derivatisation, was studied. The OPA reagent 
consists of OPA and mercaptoethanol dissolved in an alkaline 
buffer solution with a small amount of methanol also present.
Under reaction conditions the level of methanol is greater, 
and approaches 50% v/v. Methanol was not always used in the NMR 
experiment because of poor spectra and solubility difficulties. 
Acetonitrile was used instead as co-solvent, because of its 
polar characteristics and the better solubility of some of the 
compo:unds used in the study.
To assess the changes in the OPA in the reaction mixture
the proton and carbon-13 NMR spectra of the dicarbonyl compound
(4.Ill) was taken as standard. The proton spectrum of OPA in
chloroform is given in Figure 4.1, whilst the carbon-13 spectrum
is shown in Figure 4,7 of OPA in acetonitrile. The resonances
obtained from Figure 4.7 are assigned in Table 4.1. In this
274table, a comparison with literature values for OPA is 
made, with the different solvent perhaps contributing to the 
slight difference in chemical shifts. It is readily apparent 
from Figures 4.1 and 4.7 that the aldehyde groups are clearly 














Table 4.1. Carbon-13 NMR of OPA in acetonitrile
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7,8 d 193.61 196.10
1,6 s 137.32 137.20
3,4 / d 134.50 135.80
2,5 d 131.25 133.10
When methanol was added to the chloroform solution of OPA 
(Figure 4.8) a large singlet appeared at 67.48 in the proton 
spectrum. A series of small peaks in the 66 - ,6.8 region were 
also visible. The integral of the aldehyde protons was reduced 
with respect to that of the aromatic protons, presumably due 
to a nucleophilic attack on the carbonyl by the methanol, 
forming a hemiacetal function.
OPA in acetonitrile gives a similar spectrum to OPA in 
chloroform, but on the addition of deuterium oxide buffer in 
the proportion of 1:1 (Figure 4.9), two singlets appear at 
67.56 and 66.55 which appear to correspond to those found in 



































aromatic protons of a new species of compound present. The 
singlet at 6.55 could represent a nucleophilic addition of 
hydroxy ions from the base to one or both of the carbonyl 
functions.
On addition of mercaptoethanol to OPA dissolved in aceto­
nitrile a four proton singlet of aromatic protons is again 
formed (Figure 4.10). However, this time a complex splitting 
of signals occurs in the 66-7 region. The thiol promoted the 
production of the four proton aromatic singlet at 67.5 and a 
linear relationship between the integral ratio of "old" to 
"new" aromatic signal, and concentration of mercaptoethanol 
was seen (Figure 4.11). The correlation coefficient of the 
four point plot was 0.9996, with a slope of 1.90 and inter­
cept of -0.60. The "new species" is present in a proportion 
of over 50% at equal concentrations of mercaptoethanol and 
OPA, and 75% when mercaptoethanol is in a two fold excess 
of OPA.
Addition of deuterium oxide made no significant difference 
to the spectrum of such a mixture containing mercaptoethanol. 
However, the addition of deuterium oxide buffer (pH 10.4) 
to the solution removed all traces of the aldehyde singlet, 
the aromatic multiplet and the various split peaks in the 
66.4 - 6.6 region. The proton NMR spectrum of equal concen­
trations of OPA and mercaptoethanol in acetonitrile/deuterium 
oxide buffer (1:1) is given in Figure 4.12. This can be 




Figure 4.11. Relationship of appearance of 'new' Aromatic
Singlet (67.5) to Mercaptoethanol concentration,
Peak height 
ratio 

































composition, except that methanol replaced acetonitrile as 
the co-solvent. Both spectra reveal a four proton aromatic 
singlet at 67.5 and a two proton singlet at 65.7. The carbon- 
13 NMR spectrum of the reagent mixture in acetonitrile/buffer 
solution is shown in Figure 4.13. Chemical shifts with 
possible assignments are given in Table 4.2. The shifts 
for the 7 and 8 carbons are approximate and correspond to 
two broad disturbances of the baseline in Figure 4.13. It 
is assumed that there must be an equilibrium in the solution, 
possibly as indicated by the two species *(4.IV) and (4.V).
There are no aldehyde peaks visible in Figure 4.12 or 4.13 and this 
may suggest the total absence of (4.IV) due to the reactive 
environment. The hydroxy ions in the buffer are probably















































responsible for a higher activation of the thiol as a nucleo­
philic species by removal of the acidic proton, but they may 
also destabilise the formed product (4.V). The carbonyl species 
represented by (4.IV) may be present with a diol function on 
the C-7 instead of the aldehyde. The broad singlet at 66.7 
in the proton spectrum and the absence of sharp signals for 
the C-7 and C-8 atoms in the carbon-13 spectrum, both indicate 
that the reaction mixture does not contain a single species, 
but at least two very reactive intermediates.
To further characterise the mixture, a more concentrated 
solution of OPA and mercaptoethanol in the acetonitrile/buffer 
solvent was made. The proton NMR spectrum is given in 
Figure 4.14 and carbon-13 NMR in Figure 4.15 with resonances 
assigned in Table 4.3. The proton spectrum shows the singlet 
at 66.7 to be split into three broad overlapping peaks. There 
is also a broadening of the thiol methylene group, probably 
due to splitting, and a very small aldehyde peak is also 
present. In the carbon-13 spectrum in Figure 4.15 the 
signals of the C-7 and C-8 atoms are readily apparent at 
similar chemical^shifts to those given in Table 4.2, which 
confirms the assignment of Figure 4.13. A splitting of the 
signals of the aromatic carbons may be due to the individual 
carbons being in slightly different environments in respect 
to the hydroxy and thioether functions. Or it may be due to 
different isomeric compounds present in the mixture, occuring 
because of the asymmetric centres at C-7 and C%8. The 
C-9 atom of the thio substituent is deshielded by 4 ppm and 

































































Table 4.3. Chemical shifts of carbon-13 NMR spectrum of










1,6 s 138.62/138.24 139.40
4,3 d 129.30/128.71 127.20
2,5 d 122.48/122.10 121.00




ethanol. This is consistent with the mercaptoethanol being ad­
jacent to an aryl and ether function. Overall the resonances 
given in Table 4.3 are very similar to those in Table 4.2 
indicating the presence of a common intermediate in both. A
comparison of these shifts to those for 1,3 dihydro-isobenzo- 
274furan reveal a very similar pattern. It is likely that the 
intermediate present in the concentrated solution is a dihydro­
isobenzofuran derivative with a more stable structure as determined
190.
by NMR, due to an effectively lower concentration of hydroxide 
ions compared to the concentration of the reagent species. 
McDonald^found that 90% of OPA in aqueous solution existed
as the 1,3-phthalandiol (1,3-dihydroxy,1)3 dihydro-isobenzofuran)
351 289and this has been observed by other workers . Simons
discovered the 1,3-disubstituted, 1,3-dihydroisobenzofuran
(4.V) intermediate to be present in the OPA/mercaptoethanol
mixture in ethanol, and found it to be in equilibrium with the
starting materials. He described the proton spectrum as having
an aromatic signal at Ô7.33 and the C 7,8 protons as two pairs
of unequal singlets centred at 65.45. However, he considered
this compound to be unimportant in the reaction with amines.
Since the reaction mixture used in the HPLC analysis has 
a four-fold molar excess of mercaptoethanol compared to OPA, 
the effect of increasing the concentration of mercaptoethanol 
over the 1:1 ratio used previously was investigated. An 
excess of mercaptoethanol in an acetonitrile or methanol/ 
deuterium buffer mixture only sharpened the proton spectrum 
of Figures 4.2 or 4.12. A two-fold excess of mercaptoethanol 
to OPA in pure acetonitrile gave the proton spectrum illus­
trated in Figure 4.16, and the carbon-13 NMR spectrum in 
Figure 4.17, with shift values assigned in Table 4.4. The
proton spectrum showed aldehyde peaks soon after the 
reaction mixture was made up. The signal decreased with time, 
and when the carbon-13 spectrum was produced there was little 
sign of the aldehydes. The proton spectrum shows the two 

































































Table 4.4. Carbon-13 chemical shifts of OPA with two-fold 
































protons. The thiol proton is also present as signified by 
the triplet at 61.8. This is further confirmed by the diff­
erence in shifts of the two sets of triplets for the methylene 
group adjacent to the thiol function (A 60.1). Thus from 
Figure 4.16 it appears that only about 40% of the mercapto- 
ethanol has reacted as quantified by integrals. The carbon- 
13 NMR spectrum confirms only a partial reaction, with the 
excess mercaptoethanol chemical shifts denoted by 9' and 10'.
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This figure also shows more splitting of the aromatic carbons 
than in Figure 4.15, which could indicate the formation of 
more stable compounds than on the acetonitrile/buffer mixture. 
If there is an equilibrium present it is very slow and thus 
all possible conformations of (4.V) can be registered. The 
equivalence of the carbon-13 NMR spectra of these three 
mixtures (Figures 4.13, 15 and 17), indicate that the reactive 
intermediate is the same for each, with the only difference 
being the relative stability of the compound. The excess of 
thiol clearly did not produce significant amounts of a 
disubstituted intermediate. The reaction mechanism in this 
medium may be as shown by:
OH
In acetonitrile there is presumably little reverse reaction, 
the aldehyde peaks being produced by unreacted OPA. In methanol 
the structure would be more unstable due to nucleophilic 
attack by the solvent at the hemiacetal carbon. The presence 
of hydroxy ions would exert a similar influence although the 
formation of more than transient carbonyl bonds appears to 
be highly unlikely. The reaction mixture used in the HPLC 
assay is thus considered to be a rapid equilibrium, possibly 
of the type shown:
195
SChyZHjOH H
4.3.1.C o-Phthalaldehyde Reaction with Standard Amines
The OPA reaction, using equimolar concentrations 
of OPA and mercaptoethanol in methanol/buffer, with methylamine 
as amine substituent gave a black precipitate in a dark brown 
solution. This may have been a decomposition product since the 
proton NMR spectrum showed no evidence of an isoindole (Figure 
4.18). This may occur because the methyl group is too small 
to sterically hinder attack on the formed isoindole ring.
For butylamine in a chloroform OPA reaction mixture 
(Figure 4.19) a different pattern arose which might represent 
a partial reaction. This was thought possible because of the 
small multiplet at 67.1. This can also be seen in Figure 4.18 
though it is less prominent there. Chloroform had to be used 
as a solvent because of the limited solubility of the product 
in the standard methanol/buffer mixture. Isopropylamine 
also showed similar solubility difficulties. Little success 
generally was achieved using these amines in the desired












































A potential model compound, glucosamine hydrochloride, 
was used in the OPA reaction owing to its structural similarity 
to gentamicin. Insolubility in the organic co-solvent was a 
major disadvantage especially at the high concentration used. 
Spectra produced using this amine were mostly of two types, 
although the circumstances for their appearance were not 
deduced. One type of proton spectrum was very similar to that 
illustrated in Figure 4.18 for methylamine and presumably 
represents breakdown of any isoindole formed. The other type 
shown in Figure 4.20 is similar to that of Figure 4.19 fcr 
butylamine. There is a multiplet at about 67.7, downfield from 
the singlet for aromatic protons found in the reaction mixture. 
There is another multiplet at 67.1 which may also be due to 
aromatic protons. The methylene group adjacent to the thiol 
is split which indicates that a partial reaction has occurred.
It is possible that the signals at 6 6.7 represent unreacted 
OPA, perhaps in the dihydro-isobenzofuran form. Thus it is 
possible that glucosamine did react to an extent with the OPA 
reagent, but a total reaction was never recorded, and often 
no reaction was adjudged to have occurred.
Ethanolamine was selected as a model for the reaction
because of its suitable solubility properties. Results with
this amine were more successful and reproducible. A proton
NMR spectrum of a mixture of equal concentrations of OPA reagent
and this amine in methanol/buffer is shown in Figure 4.21.
The pattern of splitting of resonances in the aromatic region










of a 2:1:2 split there is a 3:2 split observed. The C-8 proton
appears to have joined the lower field multiplet. The peaks in
this region are also similar to that found for glucosamine
in Figure 4.20, and confirms the assumption that a partial
reaction had occurred. The carbon-13 NMR spectrum of the
ethanolamine-OPA derivative is shown in Figure 4.22 with
the shifts assigned in Table 4.5. The structure of the product
is thought to be as shown in (4.VII),.The high field multiplet
289at 66.9 - 7.2 in the proton spectrum was assigned by Simons
to the 3,4 protons (Simons; 66.8 - 7.1), whilst the low field
multiplet at 67.4 - 7.9 (Simons; 67.4 - 7.7) was assigned to
289the 2,5 protons. The proton on C-8 was found by Simons 
to have a shift of 67.31, but this was thought to be at 67.4 
and part of an aromatic multiplet in Figure 4.21.
The assignment of the aromatic carbon atoms in the
carbon-13 spectrum in Figure 4.22 is not absolute because of
the small shift difference between them. The aromatic chemical
shifts are of a similar magnitude to those reported for 
298N-methylisoindole , but the 7,8 carbons appear to be in­
consistent with those of (4.VII). The thioether substituent 
which is electron withdrawing would be expected to deshield 
the C-7 carbon and this may be responsible for the peak at 
121.55 ppm. However, it is unlikely to shield either the C-1 
or C-6 carbon by 14.5 ppm and deshield the other (C-1 or C-6) 
by 7.2 ppm. More anomalous is the deshielding of the C-8 
carbon by at least 6 ppm when shielding is a more usual long 



































Table 4.5. Carbon-13 NMR chemical shifts of ethanolamine- 
OPA reaction in comparison to N-methylisoindole
203



















6 s 131.47 1,6 s 124.3
4 d 125.45 3,4 d 120.2
3 d 123.50 2,5 d 119.1
5 d 122.47 7,8 d 111.3













effect of (-S-CH^) is only weak, apart from on the carbon of 
273attachment . The difference in shifts between (4.VII)and 
(4.VIIX)appears to be too great to be accounted for by the 
structure (4.VII) ,although the lack of detailed knowledge 
on the effect of substitution in this ring system suggests 
that no definite conclusion can be reached.
289Simons did not examine the product by carbon-13 NMR, 
but found in the proton NMR spectra of the isoindoles that 
the methylene protons of C-11 were considerably shielded.
A similar shielding of 7 ppm was found here for the C-11 
carbon in Figure 4.22. However the C-9 carbon is substantially 
deshielded by about 14 ppm in respect to the free mercapto­
ethanol, whilst Simons found the corresponding protons to 
be unaffected.
The reaction of the OPA reagent with amines was considered 
289by Simons , to proceed by the thiohemiacetal (4.IV). He 
thought the formation of the disubstituted, dihydro-isobenzofuran 
(4.V) to be a side reaction, as the concentration of it in 
the reagent was dependent on the thiol present. He also con­
sidered it to be unreactive towards amines especially in com­
parison with (4.IV). However under the conditions studied here 
the intermediate was found to be highly unstable and apparently 
susceptible to nucleophilic attack. The structure (4.IV) was 
not recorded by either of the NMR methods and the possibility 
of it reacting with the added amine seems remote.
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Simons postulated the following reaction to occur289
H
SR











This reaction is fairly plausible except for the condition that 
it usually occurs at a high, alkaline pH.The .primary amine nucleo­
philic addition reaction with carbonyl compounds, such as alde­
hydes and ketones, is known to produce a Schiff base if one of
the substituents is aryl. However the reaction can be sub- 
299divided into two ; the initial addition reaction of the 
amine and followed by dehydration of the carbinolamine thus 
formed. The latter pathway requires a pH of 2 - 5, and at a 
pH of 10, will be very slow. Also if an imine was formed, 
it would probably be more liable to nucleophilic attack than 




/ \ HO H
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The isobenzofuran derivative is thought to be susceptible 
to nucleophilic attack in the conditions prevailing, and in 
this regard the primary amine is a more reactive agent than 
the thiol or other species present. The carbinolamine formed 
is likely to react with the electrophilic centre close to it, 
rather than undergo an unfavourable dehydration reaction. Once 
the nitrogen-containing ring is formed, dehydration of the 
dihydroisoindole to the more aromatic isoindole is favoured.
Without the thiol present a series of decomposition 
products form from the dihydroisoindole produced^^^. The 
thiol is therefore necessary to ensure stability of the 
formed isoindole, presumably because it is a poor "leaving" 
group.
4.3.1.d Quantification of Extent of OPA Reaction BY NMR
The formation of the isoindole type product (Figure 
4.21) from a reaction mixture (Figure 4.2) shows a dramatic 
change in the signal corresponding to the aromatic protons.
A possible marker of the change in species in the reaction 
mixture was the two proton singlet at about 66.7 in Figure 4.2. 
This signal was undisturbed by the new peaks created by the 
formation of the isoindole derivative, unlike the four proton 
singlet at 67.5 which was overlain by the new aromatic multi­
plets. Quantitation of the reaction could therefore be 
achieved by measuring the ratio of the integral of the peak 
at 66.7 to that of the newly formed higher field multiplet 










spectrum of ethanolamine in a 0 .6:1 molar equivalent relationship 
with OPA. This shows the singlet of the OPA reaction mixture 
and the newly formed multiplet of the isoindole analogue. The 
reaction of ethanolamine and the OPA reaction mixture over a 
series of concentrations from 0 .2:1 to 0.8:1 molar relationships 
was performed to give the ratio of new aromatic multiplet to 
reaction mixture singlet. The four point calibration graph 
is illustrated in Figure 4.24. The correlation of the line 
is 0.9952 which indicates a significant relationship at the 
0.1% level as determined by Student t-test. The slope of 
the line is 1.09 which is not significantly different from 
1 at the 5% level.
Thus using this model, a method of estimating the extent 
of reaction of an amine with OPA was discovered, because there 
was a direct relationship between appearance of the isoindole 
multiplet and disappearance of the reaction mixture singlet.
The reaction of the gentamicin components did not provide 
spectra as sharp as those for ethanolamine. The product and 
reaction still exhibited the same general characteristics, 
but the peaks were considerably broadened. An example of 
a 0.75 molar equivalent reaction of gentamicin amino groups 
with OPA is illustrated in Figure 4.25. In this mixture the 
concentration of OPA was 4 times greater than the concentration 
of gentamicin (3 amino groups/molecule). The broadness
of the aromatic peaks may be a reflection of the different 
amino functions reacted in the gentamicin compound. For quanti­
tative analysis ratios of 5.33:1 and 4:1 OPA to gentamicin
209,
Figure 4.24. Plot of Calibration of Ethanolamine Concentration 
to newly formed Multiplet (PMR)






















component, were used for gentamicin and respectively. 
This was set to achieve a concentration of 0.75 equivalents 
of primary amino functions in respect to 1 equivalent of 
OPA for both components. The quantity of reactants used was 
assessed by weight since it was difficult to accurately deter­
mine the concentration of gentamicin component by integrals. 
The fraction of reatted OPA calculated by the integral ratio, 
by reference to the calibration graph (Figure 4.24) is given 
in Table 4.6. Also included in this table is the expected 
amount of OPA consumed for the two components if various 
numbers of amino functions reacted.











Actual % OPA 
consumed 89 85
The actual amount of OPA found to have reacted are not 
significantly different from 75 at the 5% level (Student t-test), 
though a much closer agreement would be preferable. The table 
also shows that if fewer than all available amino groups had 
reacted then the expected amount of OPA consumed would have
212
been much smaller. It is fairly conclusive proof that the 
OPA reagent does react with all the primary amino groups in 
gentamicin. The apparent excess of OPA which reacted can 
be explained as loss in transfer of the OPA reagent to the 
gentamicin component. The problem of the different solubilities 
of the product and reactants was difficult to overcome at the 
high concentrations required for NMR analysis, and losses due 
to the enforced experimental procedure reduced the accuracy 
of the technique.
4.3.2 Fluorescence Measurement of o-Phthalaldehyde Reaction 
To provide alternative evidence for the results ob­
tained by proton NMR for the stoicheometry of the OPA-gentamicin 
reaction, the fluorescence yield obtained for each of the 
components was studied. It was discovered that no simple 
relationship between the maximum fluorescence yield and numbers 
of primary amino groups on the parent gentamicin component 
existed. An alternative measure of the reaction was thus
sought. Gentamicins and each possess four primary
amino groups and can theoretically react with four molar 
equivalents of OPA, whereas^gentamicin has only three 
primary amino groups and can react with three molar equivalents 
of OPA. Accordingly an experiment was carried out in which 
the fluorescence obtained when OPA was used at a three fold 
molar excess was compared with that obtained when OPA was 
used at a four fold molar excess. With gentamicins and 
the fluoresdence might be expected to fall by 25% whereas
213
the fluorescence of the derivative should remain more or 
less constant.
The percentage reduction in fluorescence observed for 
three different reaction times is given in Table 4.7.









85 32.6 42.9 35.7
110 30.4 45.2 34.0
120 32.0 48.6 34.8
Mean 31.7% 45.6% 34.8%
It is obvious that the relationship was not observed and 
no trend between the components could be detected. A possible 
explanation of this is that in the absence of an excess of 
OPA reagent the rate of reaction may have been reduced and 
may not have gone to completion. In the preparation of OPA 
derivatives for HPLC a substantial excess ofOPA reagent is 
routinely used.
Due to the susceptibility of the fluorescence determination 
to impurities and the interpretational difficulties of results 
discussed above, a means of estimating the extent of reaction 
of the OPA reagent which was independent of fluorescence measurement 
was sought.
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4.3.3 Combined Ninhydrin/o-Phthalaldehyde Reaction with 
Gentamicin
The method developed involved the construction of a 
calibration graph of the absorbance obtained on reacting nin­
hydrin with varying concentrations of the gentamicin components. 
Then OPA was reacted with the components in a range of concen­
trations and the primary amino functions left underivatised 
were reacted with ninhydrin. From the calibration graph already 
made the amount of amino groups reacting with ninhydrin could 
be calculated, thus giving the extent of reaction of OPA.
This assumed that all the available primary amino groups would 
react with the ninhydrin reagent, which appears reasonable 
considering the reaction conditions.
A calibration graph for each component of concentration 
against absorbance (565 nm) was made for the reaction with nin­
hydrin. This plot is shown in Figure 4.26 with each component 
exhibiting a linear relationship of significantly high corre­
lation. Regression analysis figures of the plots in Figure 
4.26 are given in Table 4.8.
Table 4.8. Regression Analysis of Calibration Lines
S a Cl
r 0.9996 0.9983 0.9995
slope 0.01703 0.01310 0.00986
intercept -0.0177 -0.0206 0.0098
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A further calibration was made to ensure reproducible 
behaviour of the reaction, using identical conditions, but 
with a freshly prepared reagent on a different day. Again a 
linear relationship for all three components was observed 
and a statistically close match of the plots resulted. There 
was some variation but nonetheless the hinhydrin reaction was 
more stable than the fluorescence reaction. However this 
variation required the experimental determination of the com­
ponent reaction with OPA to be carried out on the same day 
as the calibration.
The initial concentrations of OPA chosen to react with 
the gentamicin was in the range of 20 - 80% of total amines 
present. The OPA when added, produced a fall in the observed 
absorbance vÆien reaction followed with ninhydrin. The per­
centage of gentamicin left to react with the ninhydrin was 
determined by reference to the constructed calibration graph 
(Figure 4.26). A plot of gentamicin component remaining 
against the fraction of total OPA used yielded a linear plot 
as shown in Figure 4.27. The three components had a signi­
ficant high correlation with a slope of about -1.0 for each, 
where OPA is expressed in terms of primary amino group equi­
valents. This suggests that OPA is reacting with one mole 
of primary amino functions per mole of OPA. The reaction 
was extended to 100% completion to ensure that all of the 
amino groups will react. A further study of the 30 - 100% 
concentration was thus made with the results plotted in 
Figure 4.28. The slopes shown are linear except when total
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Figure 4.28. Plot of Effect of OPA on Reducing Available Amino 
Functions - extended to Total Reaction.
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reaction is approached. This was due to the OPA reagent 
absorbing slightly at this wavelength. This absorbance was 
not important at low concentrations of OPA, but as 100% 
reaction was approached it became more dominant because of 
the general fall in absorbance. The plots in Figure 4.28 
are not significantly different from those in Figure 4.27 at 
the 5%. level (Student t-test). The mean of the slope of the 
three lines in Figure 4.28 was -0.995 indicating that the 
-1.0 relationship still held. Figure 4.27 illustrates that 
OPA is able to react with all the primary amino groups 
available for reaction with ninhydrin.
Assuming that ninhydrin does react with all primary amino 
functions on the component, then OPA can be said to react with 
all the primary amino groups for all of the components. This 




HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC RETENTION CHARACTERISTICS 
OF GENTAMICIN-ORTHO-PHTHALALDEHYDE DERIVATIVES
5.1 Introduction
The three components of gentamicin have shown different
retention orders using very similar high performance liquid
78 223 233 234chromatographic methods ' ' ' . This is not desirable
since a standard-assay technique requires reproducible responses. 
The lack of available standards for these components only heightens 
this disadvantage. The o-phthalaldehyde derivative of the
gentamicin C^ component has been shown to elute either as the
223 233 78 234first ' or the last ' of the components, in HPLC
systems, depending upon the paper consulted. The reaction of 
the fluorescent reagent with the primary amino groups, 
reported in Chapter 4, was studied to ensure complete and re­
peatable derivatisation. The lack of any potential reaction 
problem suggested that the anomalous retention behaviour must 
have arisen from the conditions used in the chromatographic 
stage of the respective assays. To understand the retention 
mechanism involved a brief summary of the possible variables 
will be made.
The development of HPLC has produced a technique which 
is sensitive, versatile, and well adapted to the analysis of 
typical biological and pharmaceutical compounds^^^'^^. The 
chromatographic processes involved in the separations are heavily 
dependent on the type of stationary phase used. These have been
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classified as being liquid-solid (LSC), liquid-liquid (LLC),
bonded phase (BPC), ion-exchange (lEC) and gel permeation
241chromatography (GPC) . The theory of the retention mechanisms
in LSC, LLC and GPC are fairly well understood but doubt exists
as to the exact mechanism in ion-exchange or bonded phase 
241chromatography . In the case of lEC the uncertainty arises 
mainly because other factors apart from ion-exchange are thought 
to be involved. In BPC the nature of the retaining phase is 
the principal source of the ambiguity^^^ 305^
Bonded phases were used in the gentamicin assays, and
indeed BPC is the most widely used method in HPLC and has the
widest range of commercial packings^^^. It cam be termed
either normal or reversed phase chromatography, depending
upon the functional groups which are attached to the silica 
241microparticles , Normal phase packings have groups such 
as diol, dimethylamino, nitro, cyano and amino bonded to the 
silica surface^^^. These groups confer differing properties 
to the stationary phase which is used with mobile phases similar 
to those used for silica. The groups used for reverse 
phase packings are more hydrophobic, being straight chain
301paraffins, and include methyl, octyl and octadecyl functions 
These groups produce a hydrophobic surface, unlike the highly 
polar silica surface, and the solvent strength of eluting 
solvents is reversed^^^.
The bonded groups are formed after reaction at surface 




1) = Si - OR ester type
2) 5 Si - NR^ amino
3) 5 Si - CR3 carbon
4) = Si-O--Si-CRg siloxane
The siloxane type is the most frequently used in reversed 
phase BPC and are synthesised using an organohalogenosilane^*^^. 
This can be either mono, di, or tri-alkyl substituted and 
usually a chlorosilane is used. The monochlorosilanes such 
as dimethyloctadecylchlorosilane produce a monomeric bonded 
phase on the silica and are the most frequently used^^^. With 
di and trichlorosilanes some of the chloro groups will be 
unable to react with the surface silanols and are free to react 
"with other reagent mblecuTes^^^,306^ A polymerised layer is 
thus produced which can shield the silica surface from dissolution 
in severe conditions of use, such as high pH. However these 
phases exhibit slow mass transfer of solutes which decreases 
efficiency^^^. Batch variability is another drawback to 
this type of phase^^^.
The actual conformation of the bonded groups will ultimately 
depend on the position and number of silanol groups on the silica 
surface^^^. These factors are dependent on the manufacturing 
process and conditions used to produce the silica microparticles^^^. 
The silanols are randomly distributed on the surface and can 
be described as being paired or isolated^^^'^^^. The paired 
hydroxy groups are hydrogen bonded to each other and are less
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than 0.31 nm apart. The isolated hydroxyls are separated
by a mean distance of 0.65 nm and are more exposed for
reaction^^^. The ratio of the two types of silanols will
dictate the extent of the reaction with chlorosilane. An
estimate of the surface coverage of free silanols is of about
8 ymol m % 303,309^ Maximum reaction with these groups with
-2a mono-chlorosilane has been 4.5 ymol m for trimethyl-
chlorosilane and 2.36 ymol m  ̂for n-hexyldecadimethylchloro-
silane^^^. Thus although a 100% coverage of the surface with
the trimethylsilane will have occurred, only 60% of the surface
silanols have reacted. The residual silanols are believed to
be inaccessible to solutes, either from steric hindrance by
the organic layer or due to the location of the silanols in
micropores^^^. The size of the organic bristle is an important
consideration ,especially in relation to pore size, when
contemplating the effect of the bonded p h a s e ^ ^ ^ I t  is
the pores of the silica particles which are responsible for
the high specific surface area associated with the packing.
Silica, with a particle size of 10 ym and a specific surface
area of 300 m^g has an external surface of only 0.3 m^g ^
with the remainder residing in the pores^^^. The diameters
of these pores are mainly in the 5 - 12 nm range. The length
of an octyldecyl (ODS) group is about 1 nm^^^, and thus
complete reaction should decrease the diameter by about 2 nm.
This will thus decrease the surface area and pore volume,
depending on the diameter of the pore^^^, and such a reduction 
302can be up to 50% . However, this has not always been
confirmed by gas adsorption experiments^^^.
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Since the large organic reagents do not always react 
to completion, a small chlorosilane is often used to cover any 
remaining silanols. This procedure is called "endcapping" 
and helps produce a more homogenous phase^^^. Tests for 
residual silanols are usually carried out either by determining 
methyl red adsorption by the support or by measuring the 
retention of a polar solute on a column of the support using 
a non-polar solvent as eluent^^^'^^^. By the first method 
a silanised material shows no red colour and by the second 
a capacity factor of less than 0.5 should be observed. Any 
residual silanols are believed to decrease the efficiency 
and stability of the column^^^'^^^.
General statements on the retention behaviour of compounds
in reversed phase BPC can be made even though the exact mechanism
is not understood. If the length of the hydrocarbon chain
of the bonded phase is increased the retention will also in-
crease^^^'^^^'^^. The solvent strength of the eluent is
the inverse of that found in LSC on silica^^^'^^^. The mobile
phase consists usually of a binary mixture of water and an
organic modifier. A plot of the percentage modifier present
against the logarithm of the capacity factor (%') (3.2.2.a)
313,314,307IS usually linear
As with other forms of HPLC an increase in temperature
of the column will reduce the k' value^^^'^^^ . This is
because the thermodynamic distribution constant (k°) is
318related to temperature by:
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At low concentrations of solute the thermodynamic distribution
constant (K°) is equal to the concentration distribution 
319coefficient (K)
V
and K ' = K ( ^  )
y
In K' = - + In (J)
V
where (j) is the phase ratio (;^ ) of mobile and stationary phases
A linear relationship is therefore expected between Inx' 
and the inverse of temperature with the slope equal to the 
change in enthalpy on binding^^^'^^^.
Compounds which belong to a homologous series can also show 
a linear relationship between Inx' and the number of functional 
groups present. From this independent estimates of group 
contribution to retention can be made (3.3.1)^^^'^^^'^^^.
The mode of retention in BPC has been described as being
302either by adsorption or by partition ; the two major 
mechanisms in chromatography.The fixed ODS chains in BPC 
restrict conformational freedom, unlike the corresponding 
apolar liquid in conventional partition systems^^^, whilst 
the adsorptive properties of the ODS groups are only weak 
when compared to such adsorbents as alumina or silica^
The driving force for retention is therefore unlikely to
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be entirely due to one of these processes solely and some 
other factor must be involved. Locke^^^ determined that elution 
order in BPC with alkyl side chains was in inverse relation 
to the solute solubility in the mobile phase and that selec­
tivity was due entirely to the eluent.
A more comprehensive expression of retention has been the 
development of the Solvophobic theory by Horvath and co-workers^^gg^^^' 
The solute is assumed to bind to the non-polar phase with 
a free-energy change associated with the binding. The magnitude 
of this change is the difference in energy between bringing 
the bound complex into solution and placing the individual com­
ponents into the solvent. The main determinants of the free 
energy cf binding are the surface tension of the solvent, 
the molecular contact area taken up on binding of the solute, 
and electrostatic and van der Waals interactions between sol­
vent and components of binding. For unionised solutes the
largest effect is due to surface tension; an increase of.
321which leads to an increase in retention time . For ionised 
solutes there is a more complex relationship since the electro­
static terms are more important.
However, anomalous retention of ionic compounds has been
observed which cannot be explained hy the solvophobic ;
311 313 322""30theory ' ' . This is readily apparent in a plot of
Inc' against percentage organic modifier in which ionic
compounds often show a curve whereas the theory would predict
313 39? 39ft 39Q a linear relationship ' This effect can be
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reduced by suppression of ionisation by adjustment of the pH 
308of the eluent . However for a base with a pKa of 9 the
pH of the mobile phase would have to be at least 9,5, and
under such conditions the lifetime of the column would be
short. Another method is to use alkylamines which can restore
313 326“32regular retention behaviour ' . The apparent discrepancy
with ionic compounds in reversed phase BPC has been attributed 
to a dual site mechanism of retention^^^'^^^'^^^. Various models 
have been proposed to account for the two sites^^^'^^^'^^^, 
which are generally believed to be the ODS chains and the 
residual silanols present.
Another method for minimising the possible influence of
the silanols on ionic compounds is to interact the solute
ions with ions of opposite-charge dissolved in the solvent^^^'^^^
These counter ions usually possess hydrocarbon chains and often 
339are surfactants . Several mechanisms have been proposed
334to account for this effect
i) Ion-pairing of the ions in solution followed by
1 . 317,331,333,336adsorption on the ODS packing
ii) Dynamic ion-exchange of the solute with the
adsorbed counter ion on the ODS phase^^^'^^^'^^^'^^^ 
iii) Ion-interaction mechanism, with an electrostatic
double layer formed on the surface of the particles 
attracting the solute by electrostatic force^^^'^^^'^^^.
It is possible that any or all of these may occur depending
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333upon the hydrophobicity of the counter ion . Ion-pairing 
may well overlap other forms of BPC since ion-interaction 
will occur to some extent with any ions which may be present 
in the mobile phase such as buffer ions.
The relationship between retention of a solute in BPC 
and its retention on silica is also important in understanding 
the chromatographic behaviour of the differing samples. Under 
certain conditions the behaviour of amines on unmodified silica 
is similar to that observed on ODS bonded silica^^^'^^^'^^^. 
Some authors regard this as evidence that silica itself can 
behave as a reverse phase material with the hydrophobic 
siloxane groups exerting an influence^^^'^^^. On the other 
hand others suggest that the mechanism on ODS bonded packings 
involves ion-interaction with the silanol groups^^^.
In applying these factors to the separation of gentamicin 
components, the nature of the stationary phase is of prime 
importance especially with respect to the presence of silanol 
groups.
5.2 Materials and Methods
5.2.1 Materials;
Spherisorb ODS, 5 ym packing material was obtained 
from Phase Separations Ltd., Zorbax ODS, 7 ym, silica was 
from DuPont (UK) Ltd. and Hypersil ODS, 5 ym was obtained 
from Shandon Southern Ltd. Gentamicin components had been
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separated by column chromatography, and netilmicin sulphate was 
a gift from Kirby-Warrick Pharmaceuticals Ltd. Potassium 
iodide, potassium nitrate, potassium thiocyanate, sodium nitrate, 
sodium iodide, barium chloride and lithium chloride were all 
supplied by BDH Chemicals Ltd. Acetic acid (glacial) and 
ammonia (0.88 gr) were supplied by Fisons Scientific Ltd.
HPLC instrumentation was the same as that used in(3.2.1). 
Columns used were all of 150 x 5 mm dimensions.
5.2.2 Methods:
5.2.2.a.Effect of Temperature on Retention;
Reaction mixtures injected contained gentamicin
(0.4 mg/ml) standard solution (50 yl), netilmicin (0.5 mg/ml)
I
(20 yl) with OPA reagent (0.5 ml) and methanol (1 ml). Mobile 
phase was 80:20, methanol:water with 2 g/L EDTA, tri-potassium 
salt. The temperature of the water bath, in which the column 
was immersed, was varied in steps of 5° from 20° to 45°C.
At each tenderature at least three determinations of retention 
time of the gentamicin components and netilmicin were made. 
Individual components were also injected separately to 
identify peaks. The position of the non-retained solùte 
was taken as the initial leading edge of the solvent front 
for all injections.
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5.2.2.b Effect of pH on Retention;
Ammonia-Acetic Acid Buffer
Ammonia and acetic acid solutions of concentration 
of about 0.017 M were prepared by diluting 1 ml ammonia (0.885g) 
and acetic acid (glacial) ( 1 ml) to 1000 ml with distilled 
water. The strength of the ammonia solution was determined by 
neutralising an aliquot with excess 0.01 M hydrochloric acid 
and back titrating with a 0.01 M sodium hydroxide solution 
using methyl red as indicator. The strength of the acetic acid 
solution was determined by titration of a solution with 0.01 M 
sodium hydroxide using phenophthalein as indicator. The strengths 
thus found were 0.018 and 0.014 M for acetic acid and ammonia 
respectively. Using these solutions a series of buffers were 
prepared ranging from pH 3.5 to 10.5 with potassium iodide added 
to give a constant ionic strength of 0.075 M for all solutions. 
Methanol (80 ml) was added to 20 ml of each of these buffer 
solutions and each was used as the mobile phase. The column 
was allowed to equilibrate with each mobile phase for fifteen 
minutes before injection. At least three injections of all 
components were made at each pH.
5.2.2.C. Addition of Salts to the Mobile Phase
Mobile phase (300 ml) of 80:20 methanol:water 
composition was prepared with an initial concentration of salt 
present. The column was allowed to equilibrate for at least 
fifteen minutes before injection of the gentamicin components. 
After at least four injections the mobile phase was changed
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by dissolving in the same solution a measured quantity of salt. 
Volume of mobile phase was determined by measuring cylinder. 
Therefore the same mobile phase was used throughout for one 
individual salt with up to eight different concentrations of 
the salt used. At the end of each day, columns were washed 
with methanol to prevent halide attack of stainless steel 
fittings. No buffer was used but the pH remained about
6.5. Salts used in these determinations were EDTA, tri­
potassium salt; potassium iodide; potassium nitrate; potassium 
thiocyanate; sodium iodide ; sodium nitrate; lithium chloride 
and barium chloride. The range of concentrations used 
depended on the effect on component retention. Three different 
reverse phase packing materials were compared in this study; 
Zorbax ODS, Hypersil ODS and Spherisorb ODS. The Spherisorb 
an̂ d Hypersil columns were thermostatted at 30°C whilst the 
Zorbax column was kept at 44°C.
5.3 Results and Discussion'
5.3.1 Effect of Temperature on Retention
The capacity factor (k ') was measured for each of 
the gentamicin components (C^, and C^) and netilmicin 
at various column temperatures on the Spherisorb column. A 
plot of k ' against column temperature is shown in Figure 5.1. 
The relative retention of the components does not seem to 
be affected by temperature variation and the shape of the 
curves is as expected with the distribution coefficient de­
creasing with increasing temperature. As the logarithm of
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Figure 5.1. Effect of Temperature on Retention of the
Gentamicin Components
Conditions : Spherisorb Column; mobile phase, Methanol/ 











Figure 5.2. Plot of the logarithm of k' against the reciprocal 
of Temperature
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k ' is linearly related to the reciprocal of temperature (°K) 
a graph can be made of this relationship. The plot of Figure 
5.1 adjusted to these terms is shown in Figure 5.2 with 
regression analysis given in Table 5.1.
In K' = - ^  + —  + In (j)RT R
Table 5.1. Regression analysis of In K against 1/Temp
Gent Gent Cg Gent Netilmicin
(r) 0.955 0.962 0.935 0.928
slope 2584 2994 4121 5280
intercept -7.66 -8.82 -12.21 -15.63
From the correlation coefficient (r) and Figure 5.2 it
is apparent that the fit is not completely linear with a
tendency to a curve, especially seen with netilmicin. The
enthalpy of binding must be varying with temperature, which
may be because of a two site adsorption with different ad-
313sorptive properties as suggested by Nathum . A rough'
estimate of the AH° from the graph is given for each component.
-1Gentamicin 22 Kj mol
-1Gentamicin 25 KJ mol
-1Gentamicin 34 KJ mol
-1Netilmicin 44 KJ mol
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These figures suggest that gentamicin C and C are bound 
in a similar fashion whilst the binding of gentamicin and 
netilmicin may involve an extra factor since the energies are 
higher.
5.3.2 Effect of pH on Retention:
If the gentamicin components exhibited unusual
chromatographic behaviour due to differing ionisation profiles
it would be expected that pH would be an important indicator
of such variation. From studies on the ortho-phthalaldehyde
reaction the primary amino groups were believed to be totally
reacted to form isoindole derivatives and thus not be liable
to protonation (Figure 5.3.) However, the secondary amino
groups should be unaffected hy the reaction and therefore
potential sources of ionisation. The pKas of the primary
354amino groups of gentamicin are about 8.2 but those of
the secondary amino groups have not been well established. One 
346report gives the value as 6.2 which is markedly different 
from the primary amino figure. This may correspond to the 
secondary amino function in the garosamine ring Which is 
sitii^ted between two carbon atoms bearing hydroxy groups. As 
well as inductive effects, hydrogen bonding could occur, 
reducing the base strength of this group. In contrast the 
additional secondary amino functions in netilmicin and 
gentamicin do not possess such neighbouring groups. Thus 
a pKa of about 9.0 is envisaged since the basicity of a 
secondary amino group is usually slightly greater than that 
of a corresponding primary function.
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In this experiment the buffer solution was devised to 
have a wide buffering range with low ionic strength and simple 
ions in solution. The buffering capacity was low in the middle 
of the range (pH 5.5 -8.5) but adequate for the purpose of 
investigation. The ionic strength of the buffer was calculated 
from the equation:
1 = h E(C^Z^^)
c^is the concentration of each ion 
Z^is the valency of each ion
The maximum ionic strength of the buffer, at a pH of 8.5, 
was 0.001 and potassium iodide was added to keep the ionic 
strength constant at 0.015.' A pH against k * grajh for all 
compounds was constructed using a series of 80/20 methanol/ 
water mobile phases on a Spherisorb column. The graph is 
shown in Figure 5.4 and the pH plotted is that measured in 
aqueous solution before addition of methanol. This was to 
relate all factors to a standard state (aqueous) since the 
ionisation behaviour of the amino functions of interest, was un­
known, vAien in an environment such as the mobile phase.
From Figure 5.4 it is apparent that the components behave 
differently with respect to change in pH. Gentamicins and 
show a slight sigmoid curve with increase in pH. The curve 
for gentamicin is more pronounced, whilst that for netilmicin 
shows a dramatic increase in retention with increase in pH.
The retention characteristics expected for an ionised/unionised
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Figure 5.4. The variation of Retention with change of pH of the 
Mobile Phase.
Conditions; Spherisorb Column; Mobile Phase - Methanol/ 
Water; (80:20); I =0.075 w.r.t. aqueous, 













334equilibrium in reverse phase BPC is a sigmoid curve of 
the type seen for gentamicin C^. The ionised form is retained 
the least because of the greater solvation experienced. If 
ionic or hydrogen-bonding interactions were occurring with 
the residual silanol groups, then the pH curve would be 
reversed, with the ionic form being retained the most. To 
explain the curves found in Figure 5.4 account has to be made 
of the conformational characteristics of the aminoglycosides 
The presence of the two glycosidic bonds in the molecule, 
around which the subunits can rotate, create a very flexible 
compound. The conformation of the gentamicin-OPA derivative 
can be changed to match that of the immediate environment.
In Figure 5.3 is illustrated the position of the planar iso­
indole functions. The C-ring is free of such groups and 
it is relatively more polar than the other rings. By rotation 
the compound could possibly either present all isoindole 
groups to the outside, with polar functions hydrogen-bonded 
to the interior, or else the polar groups can be facing the 
exterior with the non-polar functions partly hidden. However 
the secondary amino group in the A ring in gentamicin may 
disrupt this micelle type separation of groups if it cannot 
be grouped with the other polar functions. The two types 
of conformer would be expected to be in equilibrium in 
both the mobile and stationary phases as shown in Figure
5.5, where GM-OH (P) is the polar conformer and GM-^3^ (A)
is the apolar form. There are two other types of equilibria 
occurring apart from that between conformers. There is the 
equilibrium of distribution between the mobile and stationary
240.
Figure 5.5. Equilibrium of Gentamicin-OPA Conformers 
in Reversed-Phase Systems














phase, and also the equilibriuiO: between binding sites on the
stationary phase. The position of the equilibrium of the
latter may be influenced by pH due to the ionisation of the
347silanols. These are known to be capable of ion-exchange 
and are thought to have a pKa of about 7.1^^^. Weak ion- 
exchange can occur in neutral solutions and in the range of 
pH 2 - 6 .  However maximum capacity is only attainable at 
high pH values (9 - 11) where the sorption capacity of 
multivalent cations is considerably e n h a n c e d ^ . Thus as the 
ion-exchange capability of the silanols increases with in­
creasing pH the ionisation of the secondary amine groups 
decreases. The two effects might counteract and therefore 
not upset the equilibrium of binding to a great extent.
In such circumstances the dominant effect on change of pH 
will be determined by the distribution equilibria. The genta­
micins C- and C if they are able to successfully mask the 
ionic charge in conformer A will not alter the equilibrium 
between the mobile and stationary phases, from that observed 
with the unionised form. On the other hand, in the case of 
gentamicin and netilmicin, the exposed ionisàble group 
in conformer A would significantly alter the equilibrium.
The gentamicin and netilmicin derivatives would be ex­
pected to show a large decrease in retention on ionisation 
compared with little effect for the gentamicin and 
derivatives. This is borne out by Figure 5.4.
It is noticeable that on this column, with a constant
242
salt concentration, the relative order of retention of the 
components did not alter when the pH was varied. It suggests 
that the gen tamicin and netilmicin derivatives were more 
strongly bound to the stationary phase than either gentamicin 
C or C- in both the ionised and unionised form. The most 
likely explanation is the greater basicity of the additional 
amino groups the components possess.
5.3.3 Effect of Salt on Retention
The effect of salts on the retention of the genta­
micin derivatives was investigated because an impure water 
source was observed to affect the order of retention vÆien used 
in the mobile phase.
312The solvophobic theory predicts a linear increase in
the retention of a neutral solute as the ionic strength increases,
because of the corresponding progression in surface tension.
The surface tension of the eluting solvent is proportional
to the concentration of the electrolyte, and a plot of In k '
against I is linear. With ionised solutes, the electrostatic
effects associated with the salt influences retention as well
as the surface-tension. The reduced electrostatic repulsion
between solutes at low ionic strength dominates over surface
tension and an initial fall in k ' occurs. This is at a mini-
321mum at I = 0.3, with about a 25% decrease in retention , 
and after this the retention increases due to the surface 
tension effects. The general increase in retention with
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surface tension can be explained by an increase in the free 
energy of cavity formation in the mobile phase.
The concentration of potassium iodide in the mobile phase 
was varied from 0.05 to 0.80 M (in respect to the aqueous 
fraction) using the 80:20, methanol-water, mobile phase and 
a Spherisorb column. A plot of the k ' value for each of the 
components against concentration of salt is given in Figure
5.6. In the absence of salt no peaks were observed for 
any of the compounds indicating that they were irreversibly 
bound in those conditions. The figure shows the retention 
behaviour of the gentamicin and components to be similar
yet the netilmicin and gentamicin components show different
curves. The gentamicin derivative elutes after the two 
other components at low ionic strength, crosses the deri­
vative at about 0.2 M and the derivative at about 0.4 M.
The netilmicin derivative shows a nearly parallel profile to 
that of gentamicin C^. The reduction in k' value of the 
gentamicin was by about a factor of 16 over this concen­
tration range, which cannot be accounted for by the solvophobic
theory. However, the resemblance of Figure 5.6 to retention
348behaviour on ion-exchange columns raises the possibility
that ion-exchange is occurring at the silanol groups. 
Accordingly, a more thorough investigation of the nature of 
the electrolyte species on retention was carried out. For a 
cation exchanger the nature of the cation used in the mobile 
phase is important, with selectivity dependent on several 
factors. The ion-exchanger has a high affinity for ions of 
higher valence, with greater polarizability and with a smaller
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Figure 5.6. Effect of Potassium Iodide on Retention.
Conditions : Spherisorb Column; Mobile Phase as
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319,349solvated equivalent volume . For cation exchange resins
319of relatively large fixed site ions the selectivity order is:
2+ + + + + + Ba > Cs > Rb > K > Na > Li
However this is not a general trend and a cation exchanger
with a small fixed ion can show a reversal of this selectivity
^ 319order
The. nature of the anion will be unimportant unless ion- 
pairing of the solute and salt occurs. The salts used in the 
study were limited to those of high methanol solubility and 
were univalent unless indicated.
An estimate of the relative strengths of the ions used 
could not be based on retention times alone. The variation in 
methanol content of the mobile phase due to degassing had a 
significant effect on retention times. An internal standard 
of the effect of the salt was to take the point when the 
retention of the C component equalled that of the C component. 
This was termed the crossover point and is used in
comparisons between solvents.
Plots of the retention characteristics of the components 
in mobile phases containing sodium iodide, lithium chloride 
and barium chloride are shown in Figures 5.7, 5.8, and 5.9 
respectively. The crossover points estimated from graphs is 
given in Table 5.2 along with values found for other salts.
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Figure 5.7. Effect of Sodium Iodide on Retention.
Conditions: As in Figure 5.6.
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Figure 5.8. Effect of Lithium Chloride on Retention












Figure 5.9. Effect of Barium Chloride on Retention
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Table 5.2. Cross-over points of gentamicin C^ and C^^ with 
different salts; observed and calculated
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Column Salt Observed (M) Calculated(M) 
log k ' v s . 
log [x]
Spherisorb BaClg 0.08 0.09
II KI 0.45 0.37
II KSCN 0.45 0.39
II KNO3 - 0.52
II Nal 0.80 0.68
It NaNOg 0.80 0.78
II LiCl 1.40 2.10
II EDTA,K3'*’ - 0.56
Zorbax KI 0.20 0.21
EDTAfKg 0.50 0.45
Hypers i l KI 0.004 0.004
The figures show that the components do behave in a similar 
fashion for all four cations,though as can be seen in Table
5.2 there is a significant difference in the respective 
eluting strengths. This is indicative that the column does 
differentiate between cations, which can only be explained 
by an ion-exchange mechanism. The concentrations given in 
Table 5.2 are the molar concentrations in the aqueous phase. 
However if the ionic strength contribution of barium is compared
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to that of potassium the comparison of the cross-over point 
is of I = 0.16 to I = 0.20. This is perhaps a better comparison 
of the two ions of differing valency, although the barium ion 
is still stronger than the sodium and lithium ions. An inter­
esting feature of Figure 5.8 is the rise in k ' value for the 
gentamicin and components with increasing salt concen­
tration. This is as predicted by the solvophobic theory and 
reflects the concentration of salt exceeding 1.5 M (0.3 M 
mobile phase). The gentamicin and netilmicin curves do not 
show a similar increase perhaps reflecting a different mechanism.
The variation in column response to salt concentration was 
investigated, using column packings of Zorbax ODS and Hypersil 
ODS. The effect of potassium iodide concentration on the
retention of the four compounds on Zorbax is shewn in Figure 5.10.
The column temperature had to be maintained at 44°C to produce 
satisfactory retention times and good peak shape. The graph 
is very similar to that found for the Spherisorb column (Figure 
5.6) except that the intercept of the and lines is
at a lower concentration of 0.2 M. The Zorbax ODS material is 
a monolayer coverage of ODS but with a high carbon loading of
about 16% with no endcapping. It was thus expected to behave
similarly to the Spherisorb column. The Hypersil column on 
the other hand has a monolayer coverage with a 9% carbon bonding 
but it is extensively endcapped with presumably few residual 
silanols present. This difference is reflected in Figure 5.11 
which illustrates the effect of retention of potassium iodide 
on this column. All three components of gentamicin are eluted
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Figure 5.10. Effect of Potassium Iodide on Retention on 
a Zorbax Column
Conditions ; Zorbax column; Mobile phase, 
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Figure 5.11. Effect of Potassium Iodide on Retention on a
Hypersil Column
Conditions : Hypersil column. Mobile Phase,
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in the absence of salt, which is different frcxn the other two 
columns. Also a lower potassium iodide concentration is 
required to produce crossover and the gentamicin
derivative is never retained for as long as on the two other 
columns. A comparison of retention on the three different 
columns with the same salt used indicates a common mechanism 
of retention operating, with the salt having an important 
role in determining the relative retention.
In published HPK: assays of gentamicin, ethylene- 
diaminetetra-acetic acid (EDTA), tripotassium salt is generally 
used in the elution solvent^^'^^^. Since the anion is more 
complex than the simple electrolytes used in Table 5.2 the 
effect of varying its concentration was examined. This is 
plotted in Figure 5.12 for the Spherisorb column and the 
concentration related to that of the potassium ion. The 
retention of the gentamicin and is longer than that 
observed in Figure 5.6 using potassium iodide. This may not 
be significant as it could be due to variation in the methanol 
content. However the difference in the retention of gentamicin 
between the two figures is large. There is a maximum 
value for k ' at aboiit :a concentration of 0.04 M which is not 
seen for any of the other salts. After this peak the k ' 
decreases at about the same rate as in Figure 5.6. The 
reason for this peak is unknown but may be due to the 
multivalent, large, organic anion which could be ion-pairing^ 
or acting in an anomalous fashion at low concentration. The 
plot of the effect of EDTA, tri-potassium salt on retention
254
Figure 5.12. Effect of E D T A ^ o n  Retention on Spherisorb 
Column.
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Figure 5.13. Effect of E D T A ^ o n  Retention on Zorbax 
Column














using a Zorbax column is shown in Figure 5.13. This time it is 
all the other components except gentamicin which experience 
a maximum k ' value at low salt concentrations (0.05 M). No 
plausible reason can be suggested for the effect or why only 
some components experience this effect but not consistently.
The cross-over point of the is at 0.5 M indicating
that the EDTA salt is less effective than the simple electrolyte. 
This may arise from a low dissociation constant for the salt.
The EDTA salt on both columns has been shown to exhibit the 
same pattern of behaviour and a larger effective concentration 
of potassium was required to produce similar retention to the 
simple electrolytes.
If an ion-exchange process is a major determinant of
retention ±t would be useful to quantifete the amount of silanol
groups present in each stationary phase. Qualitative tests
for silanols were mentioned in the introduction, but a semi-
empirical estimate of silanol groups present can be made from
the surface coverage of the ODS material. This obviously is
limited and cannot take into account coverage by endcapping
reagents. It is assumed that the total amount of residual
-2silanols available for reaction is 4.5 ymoles m , and
that the figures taken for surface coverage from manufacturers
data are correct. The coverage of residual silanols is therefore;
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The figures are only intended as a rough guide to polarity 
of the phases and not as accurate determinations. Spherisorb 
probably has a greater coverage of silanols than shown because 
a partial end-capping reaction is performed. However, the 
effect of the silanols is likely to be greater than the Zorbax
material because of the lower carbon.loading .shielding the___
groups. Hypersil would have a much smaller influence of 
silanols and this is supported by Figure 5.11. The above 
order of values is consistent with the need for lower concen­
tration of potassium iodide with Zorbax and especially Hypersil 
when compared to Spherisorb.
For ion-exchange the capacity factor (k ') is usually
directly proportional to the reciprocal of the concentration
of the metal ion for a univalent solute ion and proportional
to the reciprocal of the square of the concentration of the
241metal ion for a divalent solute . The calculated slopes
of K ' against — —̂  and — —  for gentamicin C_ in a ̂ 2 cone ,----  1cone vconc
potassium iodide mobile phase are shown in Table 5.4.
Table 5.4. Slopes of possible ion-exchange relationships for 
potassium iodide
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A plot of K ' Xr's for all compounds in the
/cone
potassium iodide mobile phase on Spherisorb is shown in Figure 
5.14. For other salts the same relative correlations are found
for gentamicin with the / relationship giving the mostcone
linear fit. This was used because the k ' against cone graph
gave a curve and it was apparent that would decrease
/cone
this tendency, though not entirely eliminate it. The other 
components also show the highest correlation with k ' against 
^ — , but they are much less significant. The reason why
cone/
K ' against is not linear may arise from the retentioncone
not being solely governed by ion-exchange.
In ion-exchange the logarithm of the distribution co­
efficient (K̂ ) is related to the logarithm of the salt con­
centration 
to K' by




Vs is volume of stationary phase 





























































The two volumes are assumed to be constant for a given 
column and thus In k ' against In [saltj should be linear. 
However a general adsorption isotherm, the Freundlich is 
denoted by;
- b= a [salt]
In k ' = In a - b In [salt]
336Graving et al, used this adsorption isotherm to explain 
the effect of differing pairing ions on ion-pair adsorption of 
quaternary ammonium compounds, using silica as the stationary 
phase. Bromide and chlorate ions produced different retention 
values and ion-exchange was excluded because the nature of the 
cations did not influence retention behaviour. However it 
serves to illustrate that adherence to this relationship is 
not solely a property of ion-exchange and the equation could 
describe many types of adsorption. Using this equation for 
the gentamicin C components and netilmicin, the parameters 
a and b were calculated for the various salts and columns.
The results are given in Tables 5.5 and 5.6 and plots of 
some gentamicin C curves in different mobile phases, and all 
the components in the same sodium iodide mobile phase are 
given in Figures 5.15 and 5.16. The gentamicin plots 
showed the most significant relationship with the highest 
correlation (r). The 'a* quantity is the exponential 
intercept and b is the slope of the graph. The slope of the 
line is an indication of the strength of interaction of the 
salt and compound, whilst the intercept is a measure of the
Table 5.5. Gentamicin and calculated for various 
mobile phases (In k ' v 's  In jsaltj )
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Column Sait a b r
Gentamicin C, la
Spherisorb Kl 1.34 -0.24 0.985
KSCN 1.35 -0.29 0.959
KNO3 1.29 -0.32 0.996
Nal 1.49 -0.20 0.986
NaNOg 1.64 -0.21 0.981
LiCl 1.76 -0.25 0.982
BaClg 1.04 -0.13 0.939
EDTAfKg 2.08 -0.17 0.940
Zorbax Kl 2.34 -0.16 0.968
EDTAfKg 2.92 -0.15 0.936
Hypersil Kl 2.69 -0.09 0.965
Gentamicin
Spherisorb Kl 1.73 -0.22 0.987
KSCN 1.70 -0.28 0.969
KNO3 1.61 -0.31 0.994
Nal 2.00 -0.17 0.967
NaN03 2.28 -0.11 0.962
LiCl 2.16 -0.24 0.985
BaClg 1.37 -0.12 0.928
EDTA,K3 2.34 -0.19 0.965
Zorbax Kl 3.16 -0.15 0.964
EDTA,K3 3.86 -0.15 0.960
Hypersil Kl 3.78 -0.09 0.967
Table 5.6. Gentamicin and netilmicin, calculated for 
various mobile phases (In k ' v's In [salt] )
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Column Salt a b r
Gentamicin C^ 
Spherisorb KI 0.94 -0.60 0.992
KSCN 0.90 -0.72 0.986
KNO3 0.99 -0.73 0.996
Nal 1.29 -0.57 0.998
NaN03 1.48 -0.62 0.995
LiCl 2.37 -0.65 0.991
BaClg 0.38 -0.55 0.981
EDTA,K3 1.57 -0.65 0.998
Zorbax KI 1.35 -0.51 0.976
EDTA,K3 2.18 -0.52 0.984
Hypersil KI 1.48 -0.20 0.960,
Netilmicin
Spherisorb KI 2.24 —0 .39 0.978
KSCN 2.10 -0.56 0.952
KNO3 2.22 -0.47 0.991
Nal 3.13 -0.33 0.992
NaN03 3.13 -0.42 0.984
LiCl 4.87 -0.48 0.991
BaClg 1.61 -0.33 0.997
Zorbax KI 3.42 -0.31 0.919
EDTA,K3 5.37 -0.25 0.983
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Figure 5.15. Plot of In k ' against In concentration of salt for 
gentamicin in various mobile phases on a
Spherisorb column
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Figure 5.16. Plot of In k ' against In concentration of 
salt for all components in sodium iodide 
mobile phase
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K' value at unit concentration. The scatter of b values for 
one compound in the different mobile phases indicates that b 
is a measure of the general adsorption of the solute and is 
not a measure of specific interactions arising from the 
nature of the cation. The b value on the Hypersil column 
is smaller, but the Zorbax column yields similar b values to 
the Spherisorb column. The b value for gentamicin is greater 
than for any other component, whilst the and components 
are nearly identical, showing the same adsorption pattern.
The a values show the relative retention at [salt) = 1.00
and reveal the expected selectivity trend of the cation exchange:
2+ + + + Ba > K > Na > Li
The EDTA, tri potassium salt shows longer retention than 
the other potassium salts which, as previously mentioned, is 
probably an anion effect.
These results suggest that at least the gentamicin com­
ponent may be retained by an ion-exchange mechanism with the 
other components having other factors, and possibly another 
mechanism, involved. It thus also confirms the non-linear 
plot of the temperature dependence of retention (Figure 5,2).
Various authors have reported a two site adsorption 
retention model on reverse phase p a c k i n g s ^ ^ ^ a n d  equations 
have been formulated to express the unusual retention. Two
266
of these models were tested on the data obtained in this study 
in an attempt to gain further insight into the effect of salt 
on retention of the gentamicin components.
Stranahan^^^ developed a four parameter thermodynamic 
model to account for the effect of salts in reversed phase 
chromatography with special reference to ion-pair formation.
The distribution coefficient (K) of a solute was related to 
the concentration of an "ion-interaction reagent" (HR) with 
regard to various physical properties of the solute and system. 
The action of the H R  was described as comprising of ion- 
interaction and interfacial tension effects. In applying 
this equation to the present set of data it was decided to 
disregard the interfacial tension effect, as the simple 
electrolytes used here would influence the tension less than 
the surfactants used in the paper. It also simplified calcu­
lation as the equation was reduced to three unknown parameters. 
The equation devised by Stranahan was:
K = exp (In — g- + In yil +V o  ̂ RT RTa
where is average molar volume of solute in liquid phase
is average molar volume of solute in adsorbed phase 
is activity coefficient of solute in liquid phase 
6 is interfacial tension of system
0^° is interfacial tension of pure solute in equilibrium 
with solid adsorbent
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Si is area on surface of adsorbent of 1 mole of solute 
is energy of interaction in adsorbed phase of solute 
and IIR
is mole fraction of IIR in adsorbed phase
which can be expressed as:
K ' = exp [c/ (c + 62)]]
C is concentration of salt (IIR) in mobile phase
3 is constant of first three terms o
3^ is constant related to interaction energy of solute and 
salt (IIR)
^2 is constant related to energy of adsorption of IIR.
The determination of the three parameters in the equation 
was achieved by rearranging the equation to give:
(lnc'-3 ) ^1 1o
To calculate the best fitting straight line the parameter, 
3^, was estimated for the potassium iodide mobile phase on 
the Spherisorb column using the y-intercept of a plot of
against concentration for the first three points. The value 
of 3^ which gave the highest correlation coefficient for the 
equation, using the potassium iodide salt, was used to calculate
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the other parameters. The logarithm of the capacity factor 
at zero salt concentration is equivalent to 3^, so this could 
be used for the Hypersil column. For the individual components 
on the Spherisorb column the same 3^ value was used wherarer 
possible and separate optimum values were found for the Zorbax 
column. The values of the three parameters for all salts and 
columns are given in Tables 5.7 and 5.8, as are the Gibbs 
free energy of adsorption (AG°) calculated from:^^^
AG° = RT In ^277.5
The plot of the three parameter equation applied to the 
retention in the potassium iodide mobile phase is shown in 
Figure 5.17, and applied to the ordinary k' against concen­
tration plot in Figure 5.18. The latter shows that fitting 
the parameters can reproduce the k ' values fairly well though 
the flattening out of the netilmicin curve is not accounted for.
The term 3^ is a measure of the interaction of the salt 
(IIR) with the stationary phase, which is most likely to occur 
at the silanol groups. The AG° value calculated should ideally 
be the same for all solutes in the mobile phase since it is 
independent of solute. The larger the AG° for the salt the 
less concentration should be required to elyte the solutes.
The average AG° taken from all four compounds for all the salts 
is given in Table 5.9. The pattern of the figures in Table 5.9 
is not entirely consistent with experimental observations, 
since the sodium salts possess a larger AG° value than the
269,
Table 5.7. stranahan's equation applied to gentamicin and 
curves




KI 1.53 -1.29 0.09 0.999 -20.24
KSCN -2.17 0.35 0.971 -16.82
KNO3 -1.50 0.19 0.999 -18.36
Nal -1.08 0.05 0.985 -21.72
NaNOg -1.10 0.10 0.999 -19.97
LiCl -1.12 0.22 0.994 -17.99
BaClg -1.25 0.006 0.993 -27.06
EDTA K3 -0.56 0.20 0.888 -18.23
Zorbax KI 1.50 -1.18 0.36 0.955 -17.52
EDTAfKg —0.91 5.34 0.940 (-10.41)
Hypersil KI 1.51 -0.23 0.01 0.890 -25.77
Gentamicin
Spherisorb KI 1.67 -1.29 0.11 0.999 -19.73
KSCN -2.28 0.44 0.970 -16.24
II KNO3 -1.74 0.28 0.992 -17.38
II Nal -1.00 0.06 0.993 -21.26
II NaN03 -1.02 0.12 0.998 -19.51
II LiCl -3.18 1.04 0.939 -14.07
BaCl2 -1.14 0.005 0.986 -27.52
EDTA,K3 -0.90 0.08 0.974 -20.53
Zorbax KI 1.97 —0.86 0.08 0.993 -21.48
EDTA K3 1.79 -0.72 3.04 0.968 (-11.90)
Hypersil KI 1.88 -0.27 0.009 0.886 -26.04









Spherisorb KI 3.22 -3.21 0.06 0.999 -21.26
KSCN -3.76 0.13 0.995 -19.31
KNO3 -3.23 0.11 0.999 -19.73
Nal -2.83 0.06 0.990 -21.26
NaN03 -2.85 0.10 0.995 -19.97
LiCl -4.20 0.54 0.994 -15.72
B a d  2 -3.28 0.01 0.999 -25.77
EDTA,K3 -3.32 0.62 0.998 -15.38
Zorbax KI 3.22 -3.03 0.07 0.987 -21184
EDTA,K3 —2.03 0.16 0.948 -19.66
Hypersil KI 1.59 -0.53 0.01 0.858 -25.77
Netilmicin
Spherisorb KI 2.77 -2.50 0.15 0.998 -18.95
KSCN 3.55 -3.01 0.10 0.991 -19.97
KNO3 2.77 -1.92 0.12 0.991 -19.51
Nal -1.73 0.09 0.998 -20.24
NaN03 -2.01 0.22 0.996 -17.99
LiCl -1.62 0.45 0.989 -16.18
BaClg -1.70 0.01 0.993 -25.77
Zorbax KI 2.77 -3.37 0.34 0.972 -17.67
EDTA,K3 -1.04 0.34 0.978 -17.67
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Figure 5.17. Plot of form of Stranahan’s Equation to 
determine parameters.
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Figure 5.18., Plot of Theoretical Curves from Stranahan's 
Equation to points found in Experiment for 
Potassium Iodide.
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potassium salts although the difference is small. The barium 
and lithium salts behave as expected whilst the EDTA salt is 
close to the value for other potassium salts although it is 
subject to large variations. The value of the potassium ion
Table 5.9. Free energy of adsorption of the salts
Column Salt 0 —1 AG (KJ mol ) Standard Deviation
Spherisorb KI -20.04 0.97
KSCN -18.09 1.83
It KNO3 -18.75 1.09
II Nal -21.12 0.63
11 NaNOg -19.36 0.94
II LiCl -15.99 1.61
II BaClg -26.53 0.90
II EDTA,K3 -18.05 2.58
Zorbax KI -19.63 2.35
EDTAfKg -18.67 -
Hypersil KI -25.86 0.16
oh the Hypersil column is significantly larger than for the 
other two columns and may indicate that this is not a true 
measure of the AG° term. This is probably because the ions 
are not following surfactant behaviour, which is a premiss
of the equation for AG°. Stranahan^^^ determined a value of
-1 -1 “8.62 KJ mol for octylamine and -4.98 to -16,95 KJ mol
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for a series of anionic surfactants. These were most probably 
being adsorbed by hydrophobic bonding since there was little 
change in AG° between cationic and anionic species. The higher 
values of AG° reported here, may reflect the greater energies 
of ionic bonding, though comparison with Stranahan's results 
cannot be made with confidence.
The 3^ term is related to the interaction energy of the 
salt and solute, with the negative sign indicating a repulsive 
effect. The size of the repulsion is greatest for the gentamicin 
solute, with the netilmicin also larger than the gentamicin 
or C3 derivative values. This is possibly due to the 
presence of two secondary amino groups on the gentamicin 
and netilmicin, or to the greater basicity of the additional 
secondary amino groxç». The size of this interaction is variable 
and is also different on the individual columns.
A fairly good fit of the data is obtained by this method 
despite the IIR used being salts and not surfactants. The 
constraint of using the same 3̂  value reduced the correlation 
since there was some variation in the mobile phase composition 
in the absence of salt. The thermodynamic quantities obtained 
with the equation may not be completely trustworthy for the 
reasons mentioned and also because of the omission of the 
surface tension term. It does demonstrate that simple electro­
lytes can be compared with surfactants, at least in some 
applications of BPC.
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Organic amines have been used in reversed phase BPC 
because they are thought to mask silanol groups which:could 
influence retention. The theory of dual site adsorption 
has produced equations which directly relate the capacity 
factors of solute to the concentration of amine used^^^'^^^.
The masking of the silanols, by such amines as dimethyloctylamine 
and hexadecyltrimethylammonium bromide, is thought to increase 
the regularity of reverse phase characteristics. Bij et 
derived an equation, assuming that there are two binding sites 
of different affinity available, which are probably the hydro­
carbon ligand and the silanol groups. However since similar 
behaviour can be observed on silica^^^'^^^'^^^, the equation 
has to be considered as a general expression of reverse phase 
chromatography. The simple equation derived is:
•̂ 'o <2
where [a] is concentration of masking agent
K^' is capacity factor in absence of agent
is binding constant of agent to silanol groups 
<2 is capacity factor due to silanophilic binding in 
absence of agent.
Although this equation was devised to account for different 
sites of adsorption, where the silanols are thought to adsorb by 
hydrogen bonding or electrostatic interactions, it can also 
be applied to the ion-exchange/hydrophobic adsorption thought
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to be occurring here. The salt concentrations required would
be assumed to be greater than those required by the amine because
of the hydrophobic environment of the silanol site. Since only
the Hypersil column could elute peaks at zero concentration of
salt the K ' values for the other two columns were taken as the o
exponential (3̂ ) values from the Stranaham equation. Using
these figures the plot of — ,against [a ] was made for all
o
compounds and salts, with an example shown in Figure 5.19 of
the solutes in potassium iodide mobile phase on the Spherisorb
column. The k^, and values were calculated for each
*
salt and column as shown in Tables 5.10 and 5.11. Here C,A
represents the concentration of salt required to mask 90% of
the silanols present and is useful as a guide to the effective-
-1ness of the salt. This was calculated from lO K . TheA
figure is a measure of the affinity of the cations for the
silanol groups. This should be independent of solute but it
is obvious from Tables 5.10 and 5.11 that this is not the case.
There is also no real trend apparent in the difference between
salts. Papp et reported the use of this equation for
the effect of sodium and potassium ions on the retention of
-1aromatic amines. They reported (mmol ) values of 4.5 and
13.5 for sodium and potassium ions respectively although there 
was considerable scatter.’in the data presented. These are about 
a hundred times greater than the values found here, and no similar 
difference between the sodium and potassium ions is shown by 
these figures. The smaller concentrations of ions required to 
mask the effect of silanols in that paper may be reflective of 
the packing material; Lichrosorb RP-18 which has a high carbon
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Figure 5.19. Fitting Bij's equation to points found using
potassium iodide
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Table 5.10. Fitting Bij's equation to experimental data
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(Gentamicin Cia and
Column Salt %2 K^(mM” )̂ r C^* (mM)
Gentamicin -^la
Spherisorb KI 3.25 0.123 1.000 81.6
KSCN 3.37 0.068 0.997 147.9
KNO3 3.46 0.060 0.999 165.3
Nal 3.17 0.133 1.000 75.0
NaNOg 2.98 0.095 1.000 105.3
LiCl 2.72 0.096 0.998 104.5
BaClg 3.26 1.852 1.000 5.4
EDTA, K3 2.59 0.075 0.926 133.0
Zorbax ___KI 2.43 0.047 0.995 213.2
EDTAfK^ 2.53 0.011 0.842 892.9
Hypersil KI 1.65 0.169 0.945 59.2
Gentamicin -^2
Spherisorb KI 3.58 0.105 1.000 95.6
II KSCN 3.79 0.056 0.996 178.4
It KNO3 3.93 0.051 0.996 196.5
II Nal 3.47 0.119 1.000 84.0
II NaN03 3.34 0.074 1.000 134.7
II LiCl 2.94 0.089 0.996 112.9
II BaClg 3.56 1.890 1.000 5.3
II edta,K3 3.09 1.057 0.836 175.7
Zorbax KI 3.37 0.077 0.997 130.5
edta,K3 3.13 0.028 0.967 358.4
Hypersil KI 2.24 0.298 0.981 33.6
Table 5.11. Fitting Bij's equation to experimental data 
(Gentamicin and netilmicin)
279,




Spherisorb KI 24.20 0.355 1.000 28.2
KSCN 24.49 0.236 1.000 42.4
KNO3 24.47 0.200 1.000 50.1
Nal 24.16 0.250 1.000 40.0
NaNOg 24.03 0.177 1.000 56.4
LiCl 24.32 0.064 1.000 155.3
BaCl^ 24.16 2.381 1.000 4.2
EDTA^K^ 21.70 0.215 0.977 46.5
Zorbax KI 23.87 0.331 1.000 30.5
EDTA^K^ 23.52 0.160 0.999 62.4
Hypersil KI 3.07 0.272 0.973 36.7
Netilmicin
Spherisorb KI 14.01 0.135 0.999 73.9
KSCN 15.43 0.045 0.980 224.5
KNO3 12.95 0.388 0.983 25.8
Nal 12.22 0.248 1.000 40.4
NaNOg 13.62 0.064 1.000 156.6
LiCl 12.14 0.036 0.999 280.9
BaCl2 13.55 0.709 1.000 14.1
Zorbax KI 12.28 0.166 0.999 61.6
EDTAfKg 11.41 0.071 1.000 141.6
280.
loading (22%)^^^
The variation in column response dependent on the nature
*
of the solute is illustrated by the figures where about a
third of the amount of salt is required to make the equivalent
amount of silanols for gentamicin as for the other two
C-components. In comparison to the long chain amines used by 
*
Bij the values are about a hundred times greater in this 
case. This is as expected since the amines have a hydrophobic 
chain which can assist penetration of the stationary phase.
Bij also noted that amines with hydroxy groups adjacent to 
the amino function are less effective at masking than the 
analogue without a polar function. This may arise fran a 
decrease in basicity because of intra-molecular hydrogen 
bonding. This can be extended to the gentamicins since the 
secondary amino groiç> at C-3" in the garosamine ring is 
adjacent to two hydroxy functions. However the secondary amino 
in the purpurosamine ring is removed from any polar function. 
On this basis the gentamicin would be more likely to 
compete with the salt for the silanol than the other two 
components.
The <2 term can be used to calculate the amount of silano­
philic binding present in the retention mechanism. This is 
achieved by comparing to the value used in the calculations 
to give the percentage contribution as shown for differeing 
components and columns in Table 5.12.
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Spherisorb 70.6 67.5 96.8 87.6 70.4
Zorbax 52.8 51.8 95.5 76.7 45.7
Hypersil 36.5 34.1 62.8 - 23.5
The direct comparison of columns and column response to 
the different nature of solutes is interesting. The gentamicin 
and components behave in a similar manner and the extent 
of silanophilic interaction can be compared with the rough 
estimations of residual silanols from Table 5.2. It shows a 
direct relationship and justifies the use of the equation 
and also the assumption that the silanols are important in 
the retention mechanism. For the gentamicin component 
there is preferential adsorption of the solute by the silanol 
groups of the Zorbax and Spherisorb columns. Netilmicin is 
similarly more adsorbed at the silanols but not to such an 
extent as gentamicin C^. An explanation for this effect may 
be gained by referring to Figure 5.5 and considering the 
possible conformers. Conformer A is most likely to be pre­
dominant in the stationary phase for all components. However, 
as described before, the gentamicin component has an 
additional secondary amino function which may not be masked 
in this conformation. Thus if ionised it would readily inter­
act with the silanols on the surface. The extra secondary 
amino group in netilmicin may be partially masked and thus
282,
less able to interact. The presence of a positive charge in 
this environment will force the equilibrium to an ion-interaction 
with the silanol. The conformer A for gentamicin and C^, 
which can reduce the influence of the positive charge shows 
less binding to the silanol groups. The driving force is reduced 
and hydrogen bonding may be more frequent than ion-exchange.
The silanophilic interaction is only proportional to the amount 
of silanol groups which suggests little kinetic advantage 
over solvophobic binding. The Hypersil column packing material 
has fewer available silanols which may restrict the gentamicin 
interaction and reduce retention.
The effect of addition of salt to the system is probably
one of competition at the silanol groups. The greater the
frequency of these groups the higher the salt concentration
required to reduce the effect. The greater a solute interacts
with the groups, the smaller the concentration of salt needed
to reduce retention dramatically. The ion-exchange mechanism
is shown to be a stronger retaining force because of the
longer retention time of gentamicin and netilmicin. When
the ion-exchange interaction is overcome as at high salt
concentration or with small numbers of silanol groups the
elution order of gentamicin then and C^, which would
be expected by a consideration of the polarity of its
derivatives, is found. The Microbondapak C-18 column used
323for the gentamicin assays is a similar column to the 
Hypersil column used here, with 11% carbon loading and 
endcapping. Thus the 'normal' elution order as expected
283.
was observed with the EDTA salt used. The only exception to
333the predicted response was in a paper by Marples et al. 
where a Spherisorb column produced the 'normal' order whereas 
the reverse would be expected. The salt used was EDTA and 
at a high concentration,though not high enough to effect 
a cross-over of components. The only explanation for this is 
that either the column was more extensively endcapped because 
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